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Abstract 
Alzheimer’s disease (AD) is a common neurodegenerative disease that is characterised by the 
extracellular accumulation of plaques, comprised predominantly of the β-amyloid (Aβ) 
peptide. These Aβ peptides have demonstrated toxic effects on neurons under a variety of 
experimental conditions. Metallothioneins (MTs) are a family of low molecular weight, metal 
binding proteins that have demonstrated neuroprotective and neuroregenerative properties. 
Recently MTs have been shown in neuronal cultures to be protective against a toxic, copper-
bound form of Aβ (CuAβ). MTs have been proposed as a potential therapeutic for the 
treatment of AD, however, MT does not cross the blood brain barrier (BBB) to an appreciable 
degree, which limits its capacity as an AD therapeutic. More recently, synthetic peptides based 
on the MT sequence, termed emtins, have been developed. Emtins have not only reproduced 
some of the properties of MT but, importantly, one peptide has been demonstrated to cross 
the mouse BBB, indicating that emtins may represent a novel therapeutic for the treatment of 
AD. 
This thesis investigates the capacity of two emtins, EmtinB and EmtinAc, to protect cultured rat 
hippocampal neurons against CuAβ with the aim of determining the most effective peptide for 
ongoing studies. EmtinB was the more effective of the two emtins tested in this toxicity model. 
Furthermore, in a comparison of two EmtinB forms; a tetrameric, 4 -peptide form and a 
dimeric, 2-peptide form, the dimeric EmtinB peptide was shown to be considerably more 
protective than the tetrameric form. 
Three potential mechanisms by which EmtinB might protect cultured rat neurons against CuAβ 
were investigated: removal of copper from CuAβ to prevent formation of free radicals, direct 
scavenging of free radicals by EmtinB, and improved neuronal survival via activation of the LRP 
family of receptors. While no conclusion was reached on its primary mechanistic action, this 
thesis will show that EmtinB is able to bind metals such as copper and zinc, and can remove 
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copper from the CuAβ complex. Further investigations into mechanism show that EmtinB is 
also able to protect cultured rat neurons against hydrogen peroxide (which can be generated 
by CuAβ) and that EmtinB is unable to protect against CuAβ in the presence of an inhibitor of 
the LRP family of receptors suggesting that EmtinB may potentially be interacting with 
hippocampal neurons via the LRP family of receptors. 
The in vivo protective capacity of EmtinB was also investigated in this thesis using the 
APPswe/PS1Δ E9 mouse model of AD. In this model, EmtinB treatment was shown to improve 
cognitive outcomes, as measured by Y-maze, and also reduced astroglial activation, as 
measured by GFAP levels, but did not reduce levels of activated microglia. Although EmtinB 
treatment appeared to reduce plaque load, these changes were not statistically significant and 
soluble levels of Aβ remained unchanged. 
This thesis investigates the activity of emtin peptides to protect cultured hippocampal neurons 
against a toxic copper-bound form of Aβ and the ability of EmtinB to reduce cognitive deficits 
and alter pathological markers of AD in the APPswe/PS1ΔE9 mouse model of AD. Emtin 
peptides have demonstrated beneficial outcomes in both in vivo and in vitro models of AD, but 
as yet a single definitive mechanism cannot be ascribed.  
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Introduction 
1.1 Metallothionein 
Metallothioneins (MTs) are a family of low molecular weight proteins that are characterised by 
a high proportion of cysteine residues. Since the 1957 discovery of a metallothionein protein in 
equine kidney [1], there has been intense interest in the physical and biochemical properties 
of the MT family [2]. The ubiquitous expression of MTs in eukaryotes and expression of related 
proteins in some prokaryotic species [3, 4] suggests a pivotal biological role for the MT family 
of proteins yet, while studies have uncovered multiple functions of metallothionein, a primary 
biological function of MTs remains to be unambiguously determined.   
There are four main isoforms of MT that are expressed in mammalian species; 
metallothionein I (MT1), metallothionein II (MT2), metallothionein III (MT3) and 
metallothionein IV (MT4) [3]. Metallothionein 1 and 2 are expressed in almost all tissues and 
have similar expression profiles. The action and expression of the two are sufficiently similar 
that they are often treated as a single isoform and, for practical reasons, viewed as a single 
entity, referred to simply as MT1/2. MT3 and MT4 are MT isoforms that have a degree of 
tissue specificity. MT-3 is expressed mainly in the central nervous system, predominantly in 
neurons [5], but also in glia [6, 7] and in the reproductive system [8]. MT-4 is expressed 
exclusively in squamous epithelia [9]. 
The elusive function of MTs has been extensively researched in laboratory rodents, such as the 
mouse. The mouse metallothionein gene family consists of four members clustered on 
chromosome 8, each expressing one of the MT isoforms (MT1-MT4) [10-12]. In humans, 
however, metallothionein gene expression is more complex with around 18 genes in the MT 
gene family [13-16]. These genes encode multiple variants of MT and are found mostly on 
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chromosome 16 [13, 14]. While humans and mice have a single copy of MT2, MT3, and MT4 
genes, humans differ to mice in that they contain a large number of genes encoding MT1 
variants, seven of which are active in producing MT1 protein isoforms [15]. MT2 is coded for 
by a single active gene, MT2A, and is the most widely expressed of the metallothionein family 
in humans, constituting around 80% of MT in the body (reviewed in [17]). 
Early theories on the primary biological function of MTs revolve around their metal binding 
capacity. Metallothioneins bind a wide range of physiological metals, such as zinc and copper, 
as well as xenobiotic metals, such as cadmium and mercury.  Metallothioneins bind metals 
through the thiol groups (-SH groups) of their cysteine residues. Mammalian MTs contain 
61-68 amino acids and typically have 20 cysteine residues found at conserved positions [18] 
(see Figure 1). The conserved cysteine residues are distributed between two globular domains, 
the α-domain and β-domain, which bind 4 and 3 divalent metal ions, respectively, and form 
two distinct metal-thiolate structures [19] (see Figure 1.1). MT has a metal-binding capacity of 
up to 7 divalent metal ions, typically Zn(II), in an exclusively tetrahedral metal co-ordination, or 
up to 12 monovalent metal ions, such as Cu(I).  
1.2 Actions of metallothionein 
1.2.1 Sequestration and transfer of bio-metals to apo-proteins 
Bio-metals, such as copper and zinc, are essential micronutrients for plants and animals, 
however, these metals can also be toxic to living organisms. In response to this apparent 
paradox, plants and animals alike have developed mechanisms such as chelation and 
sequestration for managing these metals [20]. Chelation and sequestration of metals prevents 
unwanted actions of the metal ions while keeping them proximal and accessible within the 
cell. One theory of MT function suggests that MT could chelate metals and subsequently act as 
  
 
Figure 1.1 Human metallothionein 1-4 amino acid sequences and structure of human metallothionein 2 (cadmium bound)  
A) Aligned amino acid sequences of human metallothioneins MT1A, MT2, MT3 and MT4 [21]. Amino acid sequences of mammalian metallothioneins contain 
61-68 amino acids with 20 cysteines at conserved positions. Cysteines highlighted in yellow. B) NMR derived structure of human metallothionein 2A bound 
to 7 divalent cadmium ion (sequence established by [22] , image adapted from [23]).  Mammalian MTs have two distinct globular domains, the α-domain and 
the β-domain which bind 4 and 3 divalent metal ions, respectively. 
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a metal chaperone, therefore playing a role in the production of metalloproteins (reviewed in 
[4]). In vitro investigation of MT interaction with zinc shows that MTs are able to donate zinc to 
zinc-requiring apo-enzymes [24], receptors [25] and transcription factors [26], while a more 
recent in vivo study utilising 65Zn and metallothionein knockout (MTKO) mice showed that zinc-
bound MT can directly transfer zinc to the protein m-aconitase, supporting the theory that 
MTs act as zinc chaperones in vivo [27].  
While there is considerable evidence that MTs are capable of acting as a metal chaperone, this 
capacity does not appear to be an essential function of MTs. Bio-metals play an important role 
in catalytic, structural and regulatory functions and, as such, homeostasis is not just regulated 
by MTs but by a variety of proteins [28, 29]. Evidence for a non-essential role of MT’s in metal 
homeostasis comes from cultured yeast and mammalian cells in which MT has been ablated, 
with these cells able to grow and prosper to the same degree as cells expressing normal levels 
of MT (reviewed in [30]). Furthermore, in mammalian cells, zinc exchange between 
metalloproteins and extracellular zinc occurs in the absence of MT and the rate of this zinc 
transfer is minimally affected by restoring MT [4]. In addition to in vitro evidence, mice in 
which MT has been knocked out are physiologically and developmentally normal [31], 
strengthening the contention that MT does not play an essential role in metal transfer. While 
MT does not appear to be essential for development and survival, there is accumulating 
evidence that MT provides a benefit to an organism under circumstances of abnormal 
physiology such as heavy metal toxicity, oxidative stress or neurodegenerative disease. 
1.2.2 Heavy metal detoxification 
Many studies of metallothionein function have supported a role for MT in heavy metal 
detoxification. Early studies demonstrated that MTs are induced by heavy metals in vitro [32, 
33] and in vivo [34, 35], and metal binding studies have shown that, while zinc is the primary 
metal ion bound to the major MT isoforms under normal physiological conditions [36], zinc is 
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highly displaceable and MT binds to toxic heavy metals such as Cu and Cd with a much greater 
affinity (reviewed in [4, 37]). Accordingly, cells with decreased MT levels are susceptible to 
heavy metal toxicity and show increased sensitivity to copper (in single cell eukaryotes) and 
cadmium (in mice and mammalian cell-lines) while increased expression of MT protects 
against toxicity of these metals (reviewed in [4, 30]). Furthermore, in a study of metal toxicity 
using MT-null mice and wild-type controls, MT-null mice were more susceptible to cadmium, 
zinc and copper toxicity than the wild-type counterparts[38]. Taken together, these data 
suggest that MTs could play a significant role in protecting organisms against heavy metal 
toxicity, however, many authors believe that this capacity to scavenge toxic heavy metals, 
while advantageous, does not represent the primary physiological role of MTs [39] [4]. This 
view is based on the expression profile of MTs, their tissue distribution, and the fact that 
exposure to high levels of toxic heavy metals such as cadmium and mercury are, for mammals, 
a relatively recent phenomenon.  
1.2.3 Protection against oxidative stress 
The production of reactive oxygen species (ROS) is a normal occurrence in the body. ROS are 
continually produced in tissues by the mitochondria and can be additionally produced for 
beneficial purposes, such as an immune response, or as part of cell signalling systems [40]. The 
endogenous antioxidant defence system is responsible for counteracting the effects of ROS, 
and contains both enzymatic and non-enzymatic antioxidants [41]. Enzymatic antioxidants 
include catalase, which catalyses the breakdown of hydrogen peroxide (H2O2) to H2O and O2; 
superoxide dismutase (SOD), which catalyses the dismutation of the super anion (O2
-) to O2 or 
H2O2; and glutathione peroxidases, which reduce lipid hydroperoxides and also reduce H2O2; 
ceruloplasmin, a copper transport protein that has antioxidant capacity [42-44]. Non-
enzymatic antioxidants include reduced glutathione (GSH), which is able to donate a reducing 
equivalent (H+ or e-) to unstable molecules [45]. These antioxidants, along with other 
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endogenous and exogenous antioxidants, are responsible for maintaining an oxidative balance 
and oxidative stress is caused when ROS are produced in amounts that exceed the neutralising 
capacity of the antioxidant defence system [46].  
Evidence suggests that MTs might act to bolster the endogenous antioxidant defence system. 
MT is inducible in response to oxidative stress both in vitro and in vivo. In vitro, MT is induced 
in various cell culture models in response to hydrogen peroxide [47], ionizing radiation [48], 
and paraquat [49], all of which are known to promote the formation of free radicals. In animal 
models, oxidative stress induces metallothionein expression [50] and regulates MT gene 
expression [51]. MT upregulation has been observed in response to alkylating agents, which 
cause lipid peroxidation; in response to chemotherapy drugs such as cisplatin and bleomycin, 
which are believed to work through production of free radicals; after administration of radical 
forming organic solvents such as carbon tetrachloride (CCl4); and in response to free-radical 
inducing cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-6 (IL-6) (for a 
thorough review see [50]).  
Furthermore, susceptibility to oxidative stress is correlated to MT levels in cell culture models 
and in rodent models. For example, MTKO hepatocytes and embryonic stem cells, as well as 
MT-null cell lines, are more susceptible to oxidative stress [52-54] and cells overexpressing MT 
are more resistant to oxidative stress [55, 56]. In vivo, MTKO mice are more susceptible to a 
number of oxidative stressors while MT overexpressing mice have improved outcomes in a 
number of oxidative stress models  (reviewed in [2]).  
 Direct evidence for MT’s antioxidant capacity comes from in vitro studies in which 
metallothionein has variously been shown to dismutate superoxide [57, 58] and scavenge 
hydroxyl radicals ([57] [59]), 1,1-diphenyl-2-picrahydrazyl radicals [59], nitric oxide [60] and 
hydrogen peroxide [61]. Much like its metal binding capabilities, MT antioxidant activity 
appears to be dependent on cysteine residues [57]. Metallothionein is predominantly bound to 
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zinc under physiological conditions [62]. When MT is oxidised by ROS, cysteine sulfhydryl 
groups are oxidised to disulphides and zinc is lost from the cysteine [2](see Figure 1.2). 
Oxidised MT is either degraded or, in the presence of a selenium catalyst, can be reduced back 
into free-thiol form by glutathione [2, 62].  
MT’s capacity for reducing oxidative stress may play an important role in the central nervous 
system [63, 64], where both injury [65] and neurodegenerative diseases [64, 66] are associated 
with oxidative stress. Neuronal cells are particularly sensitive to oxidative stress [67]. In 
traumatic brain injury, much of the damage that occurs in the CNS following trauma is due to 
the secondary effects of glutamate excitotoxicity, Ca2+ overload, and oxidative stress [68]. Both 
necrotic and apoptotic cell death have been observed in mouse and rat models following 
traumatic CNS injury [69-71], and improved functional recovery is observed in response to 
inhibition [72] and scavenging [73] of ROS, suggesting that increased ROS production 
contributes to injury-mediated neuronal cell damage and neurological dysfunction [74]. 
Notably, MTKO mice show increased oxidative stress and apoptosis following brain injury 
compared with wild-type [75]. A further study shows MT overexpressing mice have reduced 
cell death and oxidative tissue damage after brain injury [76]. Addition of exogenous MT also 
improved outcomes after brain cryolesion in a rat model of brain injury, improving both wound 
healing and reactive axon growth [77], and reduced neuronal apoptosis and injury-induced 
oxidative stress after cryolesion in both normal and MTKO mice [76].Thus, the data suggest a 
protective role of MTs in the CNS under circumstances of increased oxidative stress, and this 
protective effect could be achieved by administration of exogenous MT. 
1.2.4 Neuroprotection and neuroregeneration 
While modulation of oxidative stress is clearly implicated as a mechanism of MT protection in 
the CNS, recent studies have suggested that MT could also be functioning through direct 
interaction with neurons or glial cells. 
  
 
Figure 1.2 Metallothionein oxidation in response to oxidative stressors 
After synthesis, the MT apo-protein (A) acquires metals, such as zinc, which bind to sulfhydryl groups of cysteine residues (B). Metallothionein can become 
oxidised in response to oxidative stressors, such as hydrogen peroxide (H2O2), which results in the formation of a disulphide bond between two sulfurs. 
Oxidised MT (C) is often degraded but, in the presence of selenium (Se), can also be reduced back to the free thiol form (A), by glutathione (GSH)/glutathione 
disulfide (GSSG). Adapted from [2, 37]. 
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In neurons, MT has been found to promote survival and regeneration when added 
exogenously. In culture, MT added directly to neuronal cultures promotes neurite outgrowth 
[77, 78], and reactive neurite sprouting after injury [77]. Exogenous MT application also 
promoted neuronal survival in hippocampal neurons after toxic insult with 6-hydroxydopamine 
[78] and in cerebellar granule neurons after potassium withdrawal [79]. In vivo, exogenous MT 
administered to brain regions damaged by needlestick injury promoted axonal growth into the 
lesion site [77], and MT administered to the eye after transection of the optic nerve 
dramatically improved axonal regeneration [80].  
In glia, exogenous MT has been shown to modulate the reactive nature of these supportive 
cells. Astrocytes become reactive after CNS insult or injury, inhibiting neuronal growth [81]. In 
cultured astrocytes, exogenous MT application altered the reactive phenotype, promoting a 
phenotype which was permissive to neuronal growth [82]. Similarly, microglial inflammatory 
response is also attenuated by MT both in vitro [83] and in vivo in traumatic brain injury 
models [84], and after treatment with neurotoxic quinolinic acid [83].  
MT was originally thought to function purely as an intracellular protein as it contains no signal 
motif for transport [85], however extracellular MT has been detected in the injured brain and 
cultured astrocytes have been shown to actively excrete metallothionein in response to zinc 
[80]. Importantly, recent evidence suggests MT binds to receptors on the surface of CNS cells 
such as astrocytes [86, 87], neurons [88-90] and microglia [91, 92]. 
Metallothionein has been found to bind members of the low density lipoprotein receptor 
(LDLR) family of receptors, low-density lipoprotein receptor-related proteins 1 (LRP1) and 2 
(LRP2). LRP1 and LRP2 are thought to play significant roles in the CNS where they are widely 
expressed in neurons and glia [85]. Family members of the LDLR type are structurally similar, 
single span transmembrane proteins, comprising an extracellular domain, a transmembrane 
domain, and an intracellular domain (See Figure 1.3). The extracellular domains of LDLR family 
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members are composed of repeats of distinct motifs; a ligand binding region, an epidermal 
growth factor (EGF)-precursor homology region, a region of O-linked sugars which is absent in 
LRP1 and LRP2 (See Figure 1.3) [86]. The cytosolic domain contains an NPxY motif which is 
important in the endocytic function of the LDLR family. The LDLR family were originally 
thought to function purely as endocytic receptors, internalising extracellular ligands for cellular 
use and degradation [87]. However, some members of this family, such as LRP1 and LRP2 can 
also act as signal transducers, activating intracellular signalling pathways via interaction with 
adaptor proteins such as disabled-1 (DAB1) and post-synaptic density-95 (PSD-95) [88].  
Both protective and regenerative actions of metallothionein have been shown to be mediated 
through LRP receptors [79, 80, 89, 90]. Fitzgerald et al. [90] showed that the capacity of MT2 to 
promote neurite outgrowth in cultured retinal ganglion cells could be blocked using anti-LRP 
antibodies and further investigation by Chung et al. [80] demonstrated that LRP-directed siRNA 
ablated the ability of MT2 to promote regenerative sprouting in cultured cortical neurons. 
Extending on this, Ambjorn et al. [79] used surface plasmon resonance to show MT2 was able 
to bind to both LRP1 and LRP2 on the surface of cultured cerebellar granule neurons, and that 
this binding was inhibited by receptor associated protein-1 (RAP), a competitive inhibitor of 
the LDLR family. In this study, MT was able to protect cerebellar granule neurons against 
apoptotic death caused by potassium deprivation and this MT-mediated cell survival was 
absent in the presence of the LRP inhibitor RAP, indicating that MT mediates survival through 
members of the LDLR family (see Figure 1.4). Further investigation showed that in cerebellar 
granule neurons, MT treatment activated the signalling molecule’s extracellular signal-
regulated kinase (ERK), protein kinase B/serine threonine kinase (PKB/AKT) and cAMP 
response binding protein (CREB). Both ERK, which is part of the mitogen activated protein 
kinases (MAPK) signalling pathway, and PKB/Akt, which belongs to the PI3K signalling pathway, 
have been implicated in anti-apoptotic intracellular signalling [91, 92], suggesting that MT  can 
activate at least two pathways which are able to directly regulate apoptosis [79]. 
                                                                                                                                 
 
 
Figure 1.3 LRP1 and LRP2 are members of the structurally similar low-density lipoprotein receptor (LDLR) family 
Low-density lipoprotein receptor-related protein 1 (LRP1) and 2 (LRP2) are members of the low-density lipoprotein receptor (LDLR) LDLR family. LRPs are so 
named because they contain structural domains found in the low density lipoprotein receptor (LDLR). This family of receptors comprise an extracellular 
domain (ECD), a transmembrane domain (TMD), and an intracellular domain (ICD). The extracellular domains of LDLRs consist of three distinct regions: 
cysteine rich ligand binding domains, EGF precursor-like domain and glycosylated region. These regions are found in the ECD of other LDLR family members 
in a varying number of repeats. The intracellular domain contains important NPXY motifs which mediate endocytosis. Figure adapted from [93] and [86]. 
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Figure 1.4 Metallothionein promotes neurite outgrowth and cell survival via interaction with LRP receptors 
Metallothionein has been shown to promote neurite outgrowth, regenerative neurite sprouting and cell survival via LRP receptors [80, 89, 90, 94]. LRPs are 
able to activate intracellular cascades and while the exact pathways remain to be elucidated, MT binding to LRP receptors has been shown to increase 
phosphorylation of Akt, CREB and ERK [94]. Receptor associated protein-1 (RAP) is an inhibitor of the LDL-family of receptors, including the LRP receptors. In 
the presence of RAP, MT is unable to promote cell survival or neurite outgrowth [94]. 
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Investigation into MT binding to LRP receptors has demonstrated that MT binding to LRP2 
could be out-competed with a small peptide similar to MT2 which contained a CKCK motif [79, 
89], suggesting that the CKCK motif may be important for LRP-mediated signalling. 
The accumulated evidence, that MT can be neuroprotective and neuroregenerative in vitro 
and in vivo, has given rise to speculation that aspects of MT biology may be useful in 
developing a treatment or therapeutic agent for Alzheimer’s disease. 
1.3 Metallothionein and Alzheimer’s disease 
1.3.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a common neurodegenerative disease and is characterised by the 
extracellular accumulation of plaques comprised predominantly of fragments of the β-amyloid 
peptide (Aβ). The Aβ peptide is generated through the proteolytic processing of the amyloid 
precursor protein (APP) (for reviews see [95, 96]). APP is a single-pass transmembrane protein 
comprised of a significant N-terminus ectodomain, an intramembrane domain, and a short 
intracellular domain [95, 96]. APP is highly expressed in the brain [95] and yet, despite 
numerous purported functions, the physiological function of APP in vivo remains unclear. 
There is some evidence that APP positively modulates synapse formation and maintenance 
[97], as well as learning and memory [98], and a potential trophic function has also been 
suggested since APP has been demonstrated to stimulate neurite outgrowth in cultured 
hippocampal neurons [99]. More recently, APP has been implicated in metal homeostasis, with 
evidence suggesting that APP acts by stabilising ferroportin, an iron transport protein, at the 
cell surface [100]. Notwithstanding these findings, there is currently no consensus on the 
physiological role of APP and its seminal function remains to be elucidated. 
Processing of APP occurs through proteolytic cleavage by α, β and γ secretases via two distinct 
processing pathways [95, 101] (see Figure 1.5). Both of the APP processing pathways use a 
                                                                                                                                Chapter 1 - Introduction                                                                                                                                 
Page | 32  
  
two-step sequential cleavage of APP, using either α or β-secretase to cleave within the N-
terminus ectodomain, followed by a second cleavage with γ-secretase in the transmembrane 
region; however only one pathway leads to the generation of amyloidogenic peptides [101]. 
Three non-toxic peptides are produced through APP cleavage with α and γ-secretases; APPsα, 
p3 and AICD - none of which are amyloidogenic [101]. Aβ peptides are derived from APP via 
the amyloidogenic processing pathway using β and γ-secretases. Cleavage by β-secretase in 
the ectodomain generates the APPsβ peptide [101]. Subsequent cleavage by γ-secretase 
liberates AICD protein and the amyloidogenic Aβ peptide[101]. Notably, alternate cleavage by 
β-secretase and γ-secretase gives rise to the variety of Aβ peptides observed in vivo, with Aβ 
peptides ranging in length from 39-42 amino acids [102] and of these, the Aβ1-40 and 1-42 
peptides are most common in the human brain [103]. Studies have now established that 
various biochemical forms of Aβ that specifically accumulate in the AD brain are toxic to 
neurons. While the cause of AD remains unknown, factors associated with its pathogenesis 
include oxidative stress, metal dyshomeostasis and neuronal cell loss.  
1.3.2 Oxidative stress in Alzheimer’s disease 
Oxidative stress is a key feature of the AD brain [104]. Studies have shown increased lipid 
peroxidation products, DNA and RNA oxidation products, and markers of protein oxidation, in 
AD brain (reviewed in [104, 105]).  
Aβ induces oxidative stress in vitro and in vivo (reviewed in [106]). Aβ peptide has been shown 
to generate free radicals in aqueous solution [107] and cause high levels of H2O2 and lipid 
peroxides in cells [108]. Exacerbating this increase in free radical production is the change in 
activity of endogenous antioxidant enzymes. Decreases in the activity of endogenous 
antioxidant enzymes SOD, catalase and glutathione peroxidase have been demonstrated in  
  
 
Figure 1.5 The processing pathways of amyloid precursor protein (APP) by secretase cleavage 
The APP protein is a single-pass transmembrane protein that contains the peptide sequence for β-Amyloid (Aβ). Processing of APP occurs via proteolytic 
cleavage of the APP protein by α, β, and γ secretases. Processing of APP occurs through two distinct pathways; the non-amyloidogenic pathway and the 
amyloidogenic pathway. Non-amyloidogenic processing of APP involves sequential cleavage of APP by α-secretase followed by cleavage in the transmembrane 
region of APP by γ secretase. This produces secreted APPα (APPsα), the p3 peptide and the APP intracellular domain (AICD). Amyloidogenic processing of APP 
occurs through a similar mechanism, with APP sequentially cleaved by β then γ secretases to produce secreted APPβ (APPsβ) the AICD and the Aβ peptide. 
As γ-secretase can cleave at either of two positions in the transmembrane domain, the resulting Aβ peptide can be comprised of either 40 or 42 amino acids, 
denoted Aβ1-40 and Aβ1-42 respectively. 
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various AD brain regions [109, 110]. Furthermore, decreased SOD and catalase is associated 
with neurofibrillary tangles and plaques in the AD brain [111]. 
Further studies have shown that not only does excess Aβ promote oxidative stress, but 
oxidative stress has been shown to increase Aβ production via alterations to secretases 
associated with APP processing (reviewed in [104]), suggesting that perhaps oxidative stress is 
maintained in the AD brain by a positive feedback system involving both oxidative stress and 
Aβ production [112].   
Interestingly, studies into antioxidant interventions in AD, using vitamin supplementation, 
have shown positive benefits (reviewed in [113]). Vitamin E administration reduced lipid 
peroxidation and Aβ levels in transgenic mice [70], and slowed disease progression in AD 
patients [114, 115], while vitamin B12 was shown to improve cognitive function in AD patients 
[116]. These studies suggest that oxidative stress plays a key role in AD progression and, 
furthermore, oxidative stress-directed therapies may prove viable for the treatment of AD. 
1.3.3 Metal dysregulation in Alzheimer’s disease 
A role for metals in amyloid toxicity has become increasingly supported in the literature. Metal 
ions such as Fe2+, Zn2+ and Cu2+ are found in senile plaques in vivo [117] and are thought to 
promote aggregation of Aβ and enhance toxicity (reviewed in [118, 119]). Of particular interest 
in Alzheimer’s pathology is the interaction of copper with Aβ. Copper ion levels are increased 
in the AD brain and are found co-ordinated directly to Aβ peptides in senile plaques (reviewed 
in [119]). Copper is a redox active metal and it has been shown that copper binding to Aβ both 
enhances the formation of Aβ aggregates and promotes generation of reactive oxygen species 
(ROS) [120, 121] via  Fenton chemistry [122].  
Recent studies have suggested that dysregulation of copper in the AD brain not only plays an 
important role in AD pathogenesis, but represents a novel therapeutic target [122-125]. In 
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support of this concept, early studies utilising 8-hydroxyquinone (8-OHQ) analogues, which are 
established copper chelating compounds, have demonstrated decreased Aβ deposition [126], 
as well as improved cognitive outcomes and lower levels of soluble Aβ [125] in the brains of 
transgenic mice. Similarly, treatment with 8-OHQ decreased cognitive decline and lowered 
plasma Aβ1-42 levels in AD patients [127, 128]. 
1.3.4 Neurodegeneration in Alzheimer’s disease 
A prominent characteristic of the AD is brain atrophy which results from neuronal loss in areas 
such as the cerebral cortex and hippocampus [129]. While the exact mechanism of cell death 
remains unknown [130], direct toxicity of Aβ peptide has been implicated.  
It is apparent that under certain conditions the Aβ peptide forms aggregates, leading to the 
production of a variety of soluble and insoluble protein assemblies, some of which have 
demonstrated neurotoxic properties. Despite over thirty years of research on amyloid protein 
and its variants, the answer to the fundamental question of which of the Aβ assemblies is the 
primary pathogenic form in vivo remains unanswered. Indeed, the intense investigation into 
Aβ toxicity has led to the discovery of previously undetected toxic Aβ aggregates and, 
subsequently, several Aβ species are now frontrunners in the toxicity debate. 
Historically, it was believed that the senile amyloid-containing plaques were the toxic assembly 
of Aβ responsible for neuropathology and degeneration in the Alzheimer’s brain [131]. More 
recently, however, this theory has fallen into disfavour as new evidence raises a number of 
points of contention.  Most central is the debate over how well amyloid plaque load 
corresponds with cognitive decline. Studies using AD patients and non-dementia control 
patients have generated evidence both for [132] and against [133] a significant correlation 
between Aβ deposition and cognitive deficit, leaving only a tenuous link between plaque 
formation and clinical symptoms of AD. Additionally, studies using transgenic animals have 
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been unable to demonstrate a clear link between plaque deposition and neuronal cell loss 
[134].  
Smaller fibrillar species of Aβ that are involved in the eventual deposition of amyloid into 
plaques were formerly favoured among researchers as the key toxic form of AB. These 
insoluble units of amyloid plaques were found to be toxic in vitro [135-137]and in vivo [138]. 
Additionally, Aβ1-42 is known to be the more fibrillogenic Aβ peptide [139], and increases in 
the ratio of Aβ1-42 to Aβ1-40 are linked to early onset familial AD [140]. However, insoluble 
Aβ levels correspond poorly with neurodegeneration and clinical pathology, and the more 
recent discovery of soluble toxic forms of Aβ has led to a revision of the amyloid hypothesis.  
Soluble oligomers are defined as any Aβ form that is detectable in an aqueous buffer after 
centrifugation [141] and are now argued to be the primary toxic form of Aβ in the AD brain 
[139, 142-145]. Soluble oligomers are demonstrated to be toxic in vitro [139, 143, 146, 147] 
and in vivo [138] and have been detected in brain plasma [148] and CSF [149]. Furthermore, 
not only do soluble oligomer levels correlate better to cognitive impairment than plaque 
deposition cited in [118, 150-152] but small oligomers have been found to be more toxic than 
their larger fibrillar counterparts [139, 141, 153, 154].  
In summary, key pathological aspects of AD are oxidative stress, metal dysregulation and 
neuronal degeneration. In contrast, MT has been proven to protect against oxidative stress in a 
number of models, is capable of binding metals implicated in AD pathogenesis and has 
demonstrated neuroprotective and neuroregenerative properties. Given the obvious overlap 
in Aβ pathology and MT action, MT has been suggested as a viable potential therapeutic for 
the treatment of AD. 
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1.3.5 Evidence for MT protection in AD 
MT exhibits a number of biological capabilities which could prove beneficial against AD 
pathology. As previously discussed, MT is involved in copper and zinc metabolism, has ROS 
scavenging capabilities, and improves regenerative sprouting of neurons after injury. The 
significance of MT in Alzheimer’s disease is suggested by a number of studies which show that 
MT is upregulated in animal models of AD [155, 156] and in humans [157]. Furthermore, MT 
has been found to protect cortical neurons from Aβ induced toxicity [78, 158] and prevent to 
formation of insoluble Aβ aggregates [159, 160].  
A recent example of in vitro MT neuroprotection in an AD-relevant model is the work of 
Meloni et al.  [160], who investigated the capacity of one metallothionein family member, 
MT3, to protect primary neurons in a cell culture model that incorporated Aβ peptide, AD-
associated metals, oxidative stress, and neuronal death. It was shown that copper-bound Aβ 
(CuAβ) is redox active and kills cells via the production of ROS, via Fenton-like chemistry [160].  
MT3, which carries endogenous zinc, was able to protect cultured primary neurons from CuAβ 
by mediating a metal swap to produce copper-bound MT3 and non-redox active ZnAβ. While 
this did suggest a role for metallothionein in AD therapy, MT3 is not a viable therapeutic 
molecule as, unlike MT1/2, MT3 inhibits the regenerative growth of neurons (reviewed in 
[161]). 
Chung et al.  [159] extended this work, investigating the capacity of the protective and 
regenerative MT family member, MT2, to protect against CuAβ-induced toxicity in cultured 
cortical neurons. In this study, MT2 was also able to protect neurons from CuAβ toxicity via the 
same copper-swap mechanism demonstrated in the work of Meloni’s et al. (Figure 1.6). These 
studies strengthen the evidence that MT could be a potential therapeutic for AD. 
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1.3.6 Issues with MT as an AD therapeutic 
One obstacle in the development of MT as a treatment for neurodegenerative illnesses of the 
CNS, is the difficulty involved in delivering the exogenous MT to its neuronal target. Despite 
generating interest as a potential therapeutic, to date there are no studies published reporting 
that peripherally administered metallothionein can cross the blood-brain barrier (BBB) to an 
appreciable degree [162]. As crossing the BBB is an essential requirement for any neuronal 
directed target, this limitation significantly impacts the potential of MT as a therapeutic in 
neurodegenerative disorders. However, the recent development of synthetic metallothionein 
analogues gives new direction for a possible therapeutic for the treatment of Alzheimer’s 
disease. 
 
1.4 Emtin Peptides – synthetic metallothionein analogues 
1.4.1 Synthetic peptides 
Peptides have emerged as one of the major classes of therapeutic molecules [163-165]. 
Peptides and peptide analogues have been developed to mimic naturally occurring molecules,  
such as hormones and growth factors, for drug delivery and immune prophylactics/diagnosis 
[163]. 
Peptides for therapeutic use are historically derived from natural peptides from plant, animal 
or human origins; from genetic or recombinant peptide libraries; or from peptides discovered 
from chemical libraries [163]. While these peptides have an advantage over small molecules 
and antibodies, they also have limitations which can inhibit their use as mainstream drugs, 
such as low potency, rapid renal clearance, and lack of stability in vivo due to protease 
degradation [163, 165]. To overcome these limitations, researchers have turned to the 
development of synthetic peptides. Synthetic peptides have become popular as ease of
  
Figure 1.6 Zinc-bound MT2 (Zn7MT2) undergoes a metal swap with copper-bound Aβ (CuAβ) to prevent Aβ-mediated free radical formation  
The Aβ1-40 and Aβ1-42 peptides can bind to copper ions, forming the redox active CuAβ. CuAβ produces free radicals via Fenton-like chemistry and has 
demonstrated toxicity in neuronal cell cultures [159, 160]. Zn7MT2 can undergo a metal swap with CuAβ to form ZnAβ, a less toxic form of Aβ [159, 160]. 
 
 
 
 
 
 
 
 
 
A) Production of free radicals by copper-bound Aβ
B) MT prevents free radical production by removing copper from CuAβ to produce zinc-bound Aβ
Biological reducing agent
Aβ1-40/42 CuAβ1-40/42 Free radical production
Metal swap between Zn7 MT and CuAB1-40/42
CuAβ1-40/42
Zn7MT2
ZnAβ1-40/42
Cu1Zn6MT2
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synthesis increases, enabling large scale synthesis and modification to the peptide sequence 
[163]. Importantly, peptide synthesis has evolved to enable production of multiple antigen 
proteins (MAPs), where synthetic peptides are tethered together using a core which is often 
lysine but alternatively, carbohydrate, calixarene, phosphorus or silicone based [166]. The 
tethering of multiple peptides to a core structure results in a branched, globular peptide, 
termed a dendrimer, which has multiple reactive end groups at the surface, with the aim of 
promoting synergistic enhancement of selected functions [166]. 
Dendrimers were first developed by Fritz Vögtle in 1978 (reviewed in [167]). Synthetic 
methods of producing dendrimers were improved using a novel convergent synthetic 
approach introduced by Hawker and Fréchet in 1990 [168], resulting in a rapid expansion of 
the synthetic peptide literature [169]. Peptide dendrimers are broadly defined as any 
compound containing peptides as branching elements, and can vary in complexity producing a 
range of molecules ranging from very low to very high molecular weight [170]. Dendrimers 
have many biomedical applications, such as protein mimics, drug delivery vehicles and, more 
recently, have also been used as gene transfection reagents [170, 171]. 
For dendrimers to be successful for medical applications they must fulfil several important 
criteria of biological importance [166]. The dendrimers should be non-toxic, non-immunogenic 
(if not required for vaccine), able to cross bio-barriers such as intestine, BBB, cell membranes, 
and be able to stay in circulation for the required time needed to have a clinical effect [166, 
172]. 
The pharmacological properties of peptide dendrimers inform the therapeutic potential of 
these molecules. In general, synthetic peptides are less immunogenic than proteins or 
antibodies [173, 174] and, as small molecular weight substances are established to have low 
immunogenicity [175], low molecular mass dendrimers are less immunogenic than high 
molecular mass dendrimers [170]. A study by Francis et al. 1991 [176] investigated the 
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immunogenicity of dimers, tetramers and octapeptide dendrimers, finding that dimeric 
peptides were significantly more immunogenic than monomers, and that tetramers are 5-10 
fold greater than dimers. In some cases, such as immunochallenge, immunogenicity is 
desirable [166] and immunogenicity would be a positive attribute. Thus, dendrimeric peptides 
may be immunogenic or non-immunogenic depending on the specific properties of the 
dendrimer and this can be modulated by manipulating the size of the dendrimer.  
Peptide dendrimers have been shown to be more resistant to proteases, and therefore more 
stable, than monomeric peptides. An in vitro study showed that tetra-branched peptide 
dendrimers were detectable in human plasma and serum after 24 hours incubation, while 
monomeric peptides were degraded within two hours [177]. An in vitro study of monomeric, 
dimeric, trimeric and tetrameric peptides administered intraperitoneally to mice showed 
monomeric peptides were degraded quickly in plasma with around 50% loss in two hours, 
while multivalent constructs were more stable with minimal degradation in the first 12-24 
hours [105]. 
The toxicity of synthetic peptide dendrimers is determined by the characteristic of each 
dendrimer. While some dendrimers exhibit toxicity (for a review see [166]) (notably cationic 
dendrimers which destabilise the cell membrane [178]) many peptide dendrimers have been 
found to have no or low toxicity [178-181]. Dendrimeric peptides also have a high level of 
efficacy (reviewed in [163]) explainable by an increase in avidity. Avidity describes the binding 
strength of a molecule with multiple binding sites. Multivalent molecules have increased 
avidity as a result of cooperative interactivity where the dissociation of a ligand from its 
receptor is less favoured [182].  
Additionally, the small size of peptide dendrimers increases the possibility that these 
molecules can be effectively delivered to tissue. Indeed, some dendrimers have been shown to 
cross biological barriers such as the intestine [183] and blood-brain barrier [184].  Thus, 
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synthetic peptides have shown potential as non-toxic, high efficacy biological barrier 
permeating, high stability, peptide mimetics.  
1.4.2 The emtin peptides 
The laboratory of Berezin and Bock, at the University of Copenhagen, has produced synthetic 
peptides based on the amino acid sequence of human MT2 [94]. Four such peptides have been 
produced, with each peptide being 14 amino acids in length and corresponding to either the C-
terminus or N-terminus amino acid sequences of the α-domain or β-domain [185] (Figure 1.7).  
These peptides are termed ‘emtins’ and their nomenclature is based on the MT domain and 
terminus that each individual emtin is modelled upon. Thus, the emtins corresponding to the 
C-terminus and N-terminus of the α-domain are termed EmtinAc and EmtinAn respectively 
and, similarly, the emtins corresponding to the C-terminus and N-terminus of the β-domain are 
termed EmtinB and EmtinBn respectively (See Figure 1.7) [185]. EmtinB nomenclature is 
slightly different to the other peptides, as EmtinB was the first emtin to be developed and the 
terminus was not specified in the naming. The emtin peptide sequences are not identical to 
their MT2 template. MT has a high number of cysteine residues and, to prevent unwanted 
bridge formation between cysteines in the peptides during synthesis, the amino acid sequence 
has been altered slightly from native MT2 sequence by substituting some of the cysteine 
residues for serine residues [94, 185] (See Figure 1.7).  
These synthetic protein analogues can be produced as monomers, dimers linked by a single 
lysine, or dendrimeric tetramers linked by a three lysine backbone (see Figure 1.7) [186]. 
Experiments by the Berezin and Bock laboratory using the emtin peptides have been carried 
out with the tetrameric forms [94, 184, 185], likely because earlier work with other dendrimers 
showed that tetramers are most effective in producing the mimetic effect [186]. 
The emtin family of metallothionein-derived peptides was developed with the aim of 
producing an MT-mimetic peptide. As discussed previously, MT2 is noted for having 
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neuroprotective, neuritogenic and anti-apoptotic properties which underpin positive effects in 
the CNS after injury and during illness, and these properties form the basis for its speculative 
potential as a CNS therapeutic. For emtins to exhibit validity as a potential therapeutic in 
neurodegenerative disorders it must first be shown that they can mimic these properties of 
MT2 and early evidence suggests that at least some of the emtins exhibit metallothionein-like 
properties in vitro [94, 185]. 
Ambjorn et al. [94] investigated the properties of the tetrameric form of the peptide modelled 
on the c-terminus of the β-domain, EmtinB. EmtinB, when administered in vitro to primary 
cultures cerebellar granule neurons, was found to stimulate neurite outgrowth with an efficacy 
equivalent to that of MT, and to promote cell survival with greater efficacy than MT [94]. 
EmtinB administration resulted in increased activation of ERK and PKB/Akt (which are involved 
in neurite outgrowth and cell survival) two kinases which are known to be activated by MT 
[94]. It was further demonstrated that EmtinB was acting through the LRP family of receptors, 
which are putative receptors for metallothionein [80, 90, 94]. Thus it appears that EmtinB is an 
MT-mimetic peptide capable of reproducing at least some of the biological effects 
demonstrated by MT in vitro [184].  
Asmussen et al. [185] extended this work by investigating Emtins Ac, An, and Bn, and their 
capacity to achieve the same MT-mimetic results. EmtinBn exhibited no capacity for neurite 
extension, however EmtinAc and EmtinAn were both found to promote neurite extension and 
cell survival. Intriguingly, while both EmtinAc and EmtinAn were both found to activate ERK 
and PKB/Akt, only Emtin Ac was found to act through the LRP family of receptors [185]. Thus, 
while EmtinB, EmtinAc and EmtinAn all promote neurite extension and survival, only EmtinB 
and EmtinAc act through LRP receptors  (the putative MT receptor) suggesting that, of the four 
produced peptides, EmtinB and EmtinAc are most similar in action to the parent protein MT2.
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Figure 1.7 Sequence of emtin peptides compared with human MT2 sequence and 
schematic of emtin dimer and tetramer structure on lysine backbone 
A) Emtins are short 14-15AA peptides based on the α-domain or β-domain of the human 
MT2 sequence. Amino acid sequences for EmtinB, EmtinBn, EmtinAc and EmtinAn are 
aligned with the human MT2 sequence and denoted in black, green, pink, and blue 
respectively. Amino acid sequences do not exactly match the sequence for MT2; some 
cysteine residues present in MT2 have been substituted for serine in emtin sequences to 
prevent aggregation of the peptides. Substituted serine residues are highlighted in bold 
(adapted from [185]). B) Emtin peptides have been produced in both dimeric and tetrameric 
form. Dimeric emtin peptides are produced by tethering two of the same peptide sequence 
together using a single lysine backbone. Tetrameric emtins are produced using four peptides 
tethered to a 3 lysine backbone (adapted from [186]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDPNCSCAAGDSST
EmtinBn 1-14 
Dimer
Tetramer
β-domain α-domain
SAGSCKCKESKSTS
EmtinB 15-28
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B
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More recently it has been demonstrated, using an animal model of epilepsy, that EmtinB has a 
significant neuroprotective effect in vivo. MTKO mice are more susceptible to seizures induced 
by kainic acid than their wild-type counterparts [184]. Kainic acid induction of seizures is a 
model currently used for screening potential anti-epileptic drugs. EmtinB was found to not 
only attenuate kainic acid-induced seizures, but to ameliorate kainic acid-induced 
neuropathology in the hippocampi of treated mice [184]. Arguably the most fascinating finding 
from this work was that, despite being administered subcutaneously, EmtinB was able to affect 
the target neurons in the hippocampal region of the brain. Analysis of the CSF of treated and 
non-treated mice demonstrated that Emtin B is able to cross the blood-brain barrier [184]. The 
ability of other Emtins to cross the blood-brain barrier is yet to be established; however, given 
that the emtins are all of very similar size and construction, there is a high likelihood that other 
emtins could share this attribute.  
Taken together, the evidence indicates that EmtinAc and EmtinB are good candidates for 
MT-mimetic peptides as they most closely recapitulate the properties of MT. EmtinAc and 
EmtinB exhibit both neuroprotective and neuroregenerative properties and, additionally, 
EmtinB readily crosses the blood-brain barrier, fulfilling a crucial requirement of a neuronal 
therapeutic (See Table 1.1).  
Table 1.1 Metallothionein-like properties of the emtin peptides 
Protein/peptide Neurite 
outgrowth 
Neuronal 
survival 
Bind LRP 
receptors 
Bind 
copper 
Cross 
BBB 
MT2 Yes  [77, 79] Yes [79] Yes [79] Yes [187] No 
EmtinB Yes [79] Yes [79] Yes [79] ? Yes 
EmtinBn No [185] Yes [185] Yes [185] ? ? 
EmtinAc Yes [185] Yes [185] Yes [185] ? ? 
EmtinAn Yes [185] Yes [185] No [185] ? ? 
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1.5 Thesis aims  
The metal binding, radical scavenging and neuroprotective properties of metallothionein have 
identified MTs as a potential therapy for the treatment of Alzheimer’s disease. However, the 
inability of MT to cross the BBB makes it an unlikely candidate for CNS-directed therapy. Some 
emtin peptides, in particular EmtinAc and EmtinB, have been able to reproduce some of the 
neuroprotective and neuritogenic actions of MT, and one of the peptides, EmtinB, has been 
shown to cross the BBB. We hypothesise that emtin peptides can act as MT-mimetics and 
rescue cultured neurons from CuAβ-mediated toxicity and, furthermore, this neuroprotective 
capacity will improve cognitive outcomes and pathological markers of AD in vivo in the 
APPswe/PS1ΔE9 mouse model of AD.  
Accordingly, this thesis will evaluate the potential of EmtinAc and EmtinB to recapitulate the 
neuroprotective effects of MT when applied to a culture model relevant to Alzheimer’s 
disease, and to modulate cognitive and neuropathological outcomes when administered to an 
animal model of Alzheimer’s disease. 
Aim 1: Determine the capacity of EmtinAc and EmtinB to protect primary cultured 
hippocampal neurons in the established CuAβ model of neuronal Aβ insult. 
Aim 2: Determine the mechanism of emtin protection in the CuAβ model of neuronal Aβ 
insult. 
Aim 3: Investigate the effect of emtins on pathological traits in the APPswe/PS1ΔE9 model of 
AD. 
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Chapter 2 – Materials and Methods 
2.1 media, buffers and solutions       
2.1.1 Subsequent media 
Neurobasal media (Gibco, USA) supplemented with 2% (v/v) B27 (Gibco) and 0.1% (v/v) 
gentamycin solution (Gibco, USA) and 0.5mM L-glutamine (Gibco, USA). Stored at 4°C.  
2.1.2 Initial media 
Subsequent media with 10% fetal bovine serum (Gibco, USA). Stored at 4°C.  
2.1.3 Ascorbate (0.03M solution)  
A 0.03M solution of ascorbate was prepared by dissolving 0.05g of sodium ascorbate in 10mL 
of distilled water. 1μL of 0.03M ascorbate was added to each 100µL reaction tube to achieve a 
final concentration of 300µM.   
2.1.4 Hank’s Buffered Salt Solution (HBSS) 
HBSS solution was prepared by adding 0.35g of NaHCO3 and 1 bottle (9.8g) of Hanks’ Buffered 
Salts Solution (HBSS; Gibco, USA) in 950mL in MilliQ water. The pH was adjusted to 7.2 before 
adjusting the volume to 1L. HBSS was filter sterilised into a sterile bottle and stored at 4°C.
       
2.1.5 Phosphate Buffered Saline (PBS; 0.01M) 
 PBS was prepared by combining 10mL of 31.2% NaH2PO4·2H2O solution, 40mL of 28.4% 
Na2HPO4 solution and 100mL of 9% NaCl. The solution was made to a volume of 1L by adding 
850mL of MilliQ water and the pH was adjusted to 7.2. PBS was filter sterilised and stored at 
4°C.  
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2.1.5.1 NaH2PO4.2H2O solution (31.2%) 
31.2g of NaH2PO4.2H2O in1L of MilliQ water. Stored at room temperature. 
2.1.5.2 Na2HPO4 solution (28.4%)  
28.4g of Na2HPO4 in 1L in MilliQ. Stored at room temperature. 
2.1.5.3 NaCl solution (9%) 
90g of NaCl in 1L MilliQ. Stored at room temperature. 
2.1.6 Phosphate Buffered Saline with 0.05% Tween20 (PBS-T; 0.01M) 
PBS (method 2.1.5) with 0.05% tween-20. Store at 4°C. 
2.1.7 Tris Buffered Saline 10x stock (10 x TBS) 
Tris base was prepared by dissolving 60.5g of Tris base and 87.6g of NaCl in 950mL of MilliQ 
water. The pH was adjusted to 7.5 and made to a final volume of 1L with MilliQ water. Stored 
at 4°C. 
2.1.8 Tris Buffered Saline with 1% Tween20 (1 x TBS-T)  
To make a working solution of TBS, 100mL of 10x TBS stock solution was added to 900mL of 
MilliQ water. To make TBS-T, 1mL of Tween-20 was added and mixed thoroughly. Stored at 
4°C. 
2.1.9 Trypsin (2.5%) 
Stock 2.5% trypsin (Gibco, USA) was stored in 500µL aliquots at -20°C. Stock was diluted to 
0.1% for use.           
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2.1.10 Tris buffer  
Tris buffer was prepared by dissolving 0.315g of Tris-HCl and 0.584g of NaCl in 95mL of water. 
The pH was adjusted to 7.4 and the solution made to a volume of 1L with distilled water. 
Stored at 4°C.  
2.1.11 Nuclear Yellow stock solution  
10mg of nuclear yellow dye (Invitrogen, Thermofisher Scientific, MA, USA) was dissolved in 
1mL of MilliQ water to give a 10mg/mL concentrated stock solution (stored at 4°C). A working 
solution of 1g/mL was prepared by dilution in PBS.      
2.1.12 EmtinB preparation for cell culture experiments 
EmtinB (Neoloch, Hellerup, Denmark) was prepared at 10mg/mL in sterile MilliQ water. This 
was diluted in warm subsequent media to the required concentration.   
2.1.13 Ethylenediaminetetraacetic acid (EDTA; 100mM) 
EDTA solution was prepared by dissolving 37.5mg of Na2EDTA·2H2O in 1mL of sterile MilliQ 
water. The pH was adjusted to 8 and the solution stored at 4°C. 
2.1.14 Paraformaldehyde (PFA; 4%)  
40g paraformaldehyde was dissolved in 500mL of MilliQ water at 60°C.  A solution of 10M 
sodium hydroxide was added drop-wise until the PFA solution became clear. The PFA solution 
was then added to 500mL 2X PBS (2x PBS is prepared using the method for 1x PBS described in 
2.1.5 made to a total volume of 500mL instead of 1L). Stored at 4°C. 
2.1.15 Preparation of 200µM copper-bound Aβ 
1mg of Aβ1-40 was dissolved in 1.15mL of sterile distilled water to give a concentration of 
200µM. A 20mM solution of copper chloride was prepared in sterile MilliQ and 1µL was added 
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for every 100µL of Aβ required. The mixture was incubated at room temperature for 30 
minutes (no shaking required). 
2.1.16 Preparation of a 1mg/mL sample of EmtinB in PBS 
A 10mg/mL stock of EmtinB (Neoloch, Hellerup, Denmark) was prepared by reconstituting 
10mg of EmtinB dimer. To make a 1mg/mL EmtinB sample, 100µL of the 10mg/mL stock was 
added to 900µL of sterile PBS. 
2.1.17 Zinc saturated solution (67mM) 
A saturated (approximately 67mM) solution of ZnCl2 was prepared by dissolving 0.0913g of 
ZnCl2 in 10mL of sterile PBS. Stored at 4°C. 
2.1.18 Copper saturated solution (67mM) 
A saturated (approximately 67mM) solution of CuCl2 was prepared by dissolving 0.1142g of 
CuCl2·2H20 in 10mL of sterile PBS. Stored at 4°C. 
2.1.19 CuCl2 for copper swap (20mM) 
20mM CuCl2 was prepared by dissolving 0.034g of CuCl2 in 10mL of MilliQ water. Stored at 4°C. 
2.1.20 Aβ1-42 for copper swap (30.4µM) 
1mg of Aβ1-42 was resuspended in 7.284mL of tris buffer. To get a final concentration of 
25µM, 82.2µL of 30.4µM Aβ1-42 was added to each 100µL reaction. Stored at -20°C. 
2.1.21 Hydrogen peroxide stock solution (100mM) 
10.2µL of 30% H2O2 (9.8M) was made to 1mL with sterile MilliQ water to give a concentration 
or 100mM. This was diluted in warmed Neurobasal media to give an in-media concentration of 
100µM. 
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2.1.22 Receptor Associated Protein (RAP) stock solution 
RAP (250µg; Progen Biotechnik, Heidelberg, Germany), was dissolved in sterile MilliQ at 10µM. 
RAP was diluted to 1µM in warmed subsequent media for use. Stored at -20°C. 
2.1.23 Reconstitution of siRNA 
siRNA directed at LRP1 (ON-TARGETplus Rat Lrp1 (299858) siRNA; Dharmacon, CO, USA), LRP2  
(ON-TARGETplus Rat Lrp2 (29216); Dharmacon, CO, USA), and a non-targeting control siRNA 
(Non-targeting siRNA #2 ; Dharmacon, CO, USA) were reconstituted in RNase free water 
(Dharmacon, CO, USA) to a concentration of 5µM according to manufacturer’s instructions. In 
brief, siRNA was re-suspended in 1mL of water and pipetted gently before incubation in an 
orbital mixer for 30 minutes at room temperature. The siRNA was then centrifuged briefly to 
collect all liquid. RNA was stored in 10µL aliquots at -20°C. 
2.1.24 Coomassie brilliant blue 
Coomassie brilliant blue stain was prepared by dissolving 0.5g of Coomassie brilliant blue 
(Sigma, USA) in a solution of 45% water, 45% methanol and 10% acetic acid. The resulting 
solution was stirred for 4 hours before filtering through filter paper (Whatman 18.5cm 
diameter, qualitative; Sigma, USA). Coomassie stain was stored at room temperature. 
2.1.25 Coomassie destain solution 
Coomassie detain solution was prepared by combing 10% glacial acetic acid, 10% methanol 
and 80% MilliQ water. Stored at room temperature. 
2.1.26 HEPES (10mM) 
HEPES solution was prepared by dissolving 1.1915g of HEPES (Sigma, USA) in 500mL 0.01M 
PBS. The pH was adjusted to 7.2 and the solution was filter sterilised into a sterile bottle. 
Stored at 4°C.       
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2.1.27 Laemlli 4 x sample buffer (reducing) 
5mL of 1M Tris-HCl pH 6.8, was combined with 2mL of 20% SDS, 2mL of glycerol, 2mL of 
-mercaptoethanol and 0.02% bromophenol blue. Stored at -20°C. 
2.1.28 Western Blot Running buffer 
NuPAGE MES SDS running buffer (NP0002; 20x; Invitrogen, Thermofisher Scientific, MA, USA) 
was diluted 1:20 in MilliQ water. 
2.1.29 Western Blot Transfer buffer 
Transfer buffer was prepared by dissolving 11.5 grams of Glycine and 2.4 grams of Tris base in 
600mL of MilliQ water. 160mL of methanol was added to give a final volume of 800mL. Stored 
at room temperature. 
2.1.30 Western Blot Blocking solution   
5g of Aptamil gold infant formula milk powder (Woolworths, TAS. AUS) was dissolved in 100mL 
of TBS-T (method 2.1.8). 
2.1.31 Immuno diluent  
0.3% TritonX in PBS (method 2.1.5).       
2.1.32 Immuno wash solution 
0.25% TritonX in PBS (method 2.1.5). 
2.1.33 RIPA Lysis buffer  
RIPA lysis buffer was prepared by combining 50mM Tris-HCl (0.394g), 150mM NaCl (0.4383g), 
1mM EDTA (0.0186g), 1% triton (0.5mL), 1% Sodium deoxycholate (0.5g), and 0.1% SDS in 
50mL of MilliQ water. The pH was adjusted to 7.4. To prevent protein degradation, 1% 
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protease inhibitor cocktail (Thermofisher scientific, MA, USA) was added immediately prior to 
use. 
2.2 Methods 
All procedures carried out on animals were approved by the University of Tasmania Animal 
Ethics Committee and were carried out in accordance with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes (2004). Rat tissue was obtained from 
Sprague-Dawley rats and mouse tissue was obtained from APPswe/PS1ΔE9 double transgenic 
mice or control wild-type C57 black 6 (B6) mice. All cultures were grown in an incubator at 
37°C with 5% CO2. 
2.2.1 Hippocampal neuron culture 
Hippocampal neurons were cultured from E17/18 rat embryos. Embryos were removed from 
the uterus of mothers euthanized by CO2 asphyxiation, removed from the embryonic sacs and 
decapitated. Heads were placed on ice while awaiting dissection. Embryonic brains were 
removed using tweezers to cut along the midline of the embryo skull and applying lateral 
pressure to the head to force the brain out of the cranium. The brain was then placed into 
HBSS and dissected under microscope. Firstly, the cerebellum was dissected out and discarded. 
The brain was then cut along the corpus callosum to separate the hemispheres. The thalamus 
and hypothalamus were removed from each hemisphere, revealing the hippocampus. The 
meninges were peeled back and removed to expose the hippocampus, which was then 
dissected out. The hippocampal tissue was transferred to 5mL of ice-cold HBSS. When all 
brains were thus dissected, 200µL of 2.5% trypsin (Sigma, USA) was added and the tube 
inverted gently to mix before incubating at 37C for 5 minutes in a water bath. The HBSS/0.1% 
trypsin mixture was removed and 1mL of initial plating media was added to the trypsinised 
tissue. The tissue was gently triturated using a 1mL pipette to form a cell suspension. This cell 
suspension was filtered through gauze to give a single cell suspension. 
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Trypan blue (Sigma, USA) was used to perform a cell count. Cells were plated at 1x105 cells per 
well and maintained in an incubator at 37C with 5% CO2.  
Cells were changed from initial medium to subsequent medium after 24 hours and media 
relaced every 2-4 days thereafter.         
2.2.2 Trifluoroacetic acid (TFA) and trifluoroethanol (TFE) 
monomerisation of Aβ 
1mg of Aβ1-42 peptide resuspended in 1mL of TFA followed by evaporation of TFA under a 
stream of nitrogen. The peptide was then washed three times in TFE (1mL) using the same 
evaporation method as for TFA. Monomerised peptide was stored at -20°C.  
2.2.3 Gel Coomassie staining 
Gels were incubated in Coomassie brilliant blue (method 2.1.24 Coomassie brilliant blue) 
overnight with gentle shaking on an orbital mixer at room temperature. Gels were then 
transferred to destain solution (method 2.1.25) and incubated with gentle shaking on an 
orbital mixer at room temperature until the bands became clear. Gels were imaged on a 
Carestream image station 4000MM Pro (Carestream Molecular imaging, CT, USA) using 
Carestream MI SE software (v4.5.2). 
2.2.4 AlamarBlue® assay 
AlamarBlue assay was carried out as per the manufacturer’s instructions:  a 10% solution of 
alamarBlue (Invitrogen, Thermofisher scientific, MA, USA) was prepared in warmed 
subsequent media. The experimental media was removed from wells and 300µL of the 10% 
alamarBlue in media solution was added to cells. After 1.5 hours incubation under cell culture 
conditions, 50µL of the media was removed from each well and transferred to a clear bottom 
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96-well plate. The blank used was 10% alamarBlue in subsequent media, incubated under the 
same conditions for an equal amount of time. 
The fluorescence of the media was read using a SpectraMax M2 plate reader (Molecular 
Devices) and SoftMax Pro computer program (v 4.8). Samples were blank subtracted before 
analysis.   
2.2.5 Protein extraction from primary cultured neurons 
To produce lysates for protein analysis, cells (which were plated at 1 x 105 cells per well) were 
washed twice with ice-cold PBS, and 100µL of RIPA buffer (method 2.1.33) was added to each 
well.  
Cells were incubated in RIPA buffer on ice, with shaking for 15 minutes. Cells were then 
collected and mixed by vortex for ten seconds followed by incubation on ice for a further 15 
minutes. Cells were centrifuged at 10,000rpm at 4°C for 10 minutes and the supernatant 
collected. 
2.2.6 Immunocytochemistry (ICC) on neuronal cultures 
Hippocampal neurons were fixed in 4% PFA prior to immunostaining. All primary antibodies 
were incubated in immuno diluent (method 2.1.31) for 1 hour at room temperature or 
overnight at 4°C. Secondary antibodies were incubated in PBS for 1 hour at room temperature. 
Cells were washed 3 times for ten minutes after each antibody incubation using immuno wash 
solution (method 2.1.32) Antibodies used are described in Table 2.1. 
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Table 2.1 Antibodies used in ICC of neuronal cells. 
Target Antibody Concentration 
LRP1 Rabbit anti-LRP1 (L2170, Sigma, MO, USA) 1:1000  
Tau Rabbit anti-Tau (A0024, Dako, NSW, AUS) 1:2500 
GFAP Rabbit anti-GFAP (20334, Dako, NSW, AUS) 1:2500  
Rabbit antibody Goat anti-rabbit Alexa 594-conjugated 
(Molecular probes, OR, USA) 
1:1000 
Mouse antibody Goat anti-mouse Alexa 488-conjugated 
(Molecular probes, OR, USA) 
1:1000 
 
2.2.7 BCA protein assay 
Quantitation of protein was carried out using the Pierce BCA Protein Assay Kit (#23225; 
Thermofisher scientific, MA, USA) according to the manufacturer’s instructions. Briefly, in a 96 
well plate either 10 or 25µL of sample was combined with 200µL of Working Reagent (a 
solution comprising 1 part kit reagent A to 50 parts kit reagent B). A standard curve was 
prepared on the same plate using an appropriate protein standard. Samples and standards 
were incubated for 30 minutes at 37°C before the absorbance was recorded at 562nm on a 
SpectraMax M2 plate reader (Molecular Devices) and SoftMax Pro computer program (v 4.8). 
2.2.7.1 BCA analysis of protein in neuronal cell extracts 
Analysis of protein in neuronal cell extracts in RIPA buffer was carried out according to 2.2.7 
with the following specific detail. In brief, 10µL of each sample was added to a 96 well plate 
along with the following standards: 0, 25, 125, 250, 500, 750, 1000, 1500 and 2000µg/mL 
Bovine serum albumin (BSA) diluted in RIPA buffer (method 2.1.33). Sample concentrations 
were determined using the BCA standard curve equation of the line. 
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2.2.7.2 BCA analysis of protein in column fractions  
Analysis of protein in the column fractions was carried out using a BCA Protein Assay. The BCA 
assay was carried out according to 2.2.7. In brief, 25µL of each column fraction was added to a 
96 well plate along with the following standards: 0, 0.031, 0.062, 0.125, 0.25, and 0.5. 1.0, and 
2.0mg/mL of Apo-EmtinB. Sample concentrations were determined using the EmtinB standard 
curve equation of the line calculated from the standard curve constructed on each plate. 
2.2.7.3 BCA analysis of extracts from whole brain hemispheres and 
hippocampal enriched samples 
Analysis of protein in brain extracts in RIPA buffer was carried out according to 2.2.7 with the 
following specific detail. Samples were diluted 1:10 to reduce protein concentration before 
10µL of each sample was added to a 96 well plate along with the following standards: 0, 25, 
125, 250, 500, 750, 1000, 1500 and 2000µg/mL Bovine serum albumin (BSA) diluted in RIPA 
buffer (method 2.1.33). Sample concentrations were determined using the BCA standard curve 
equation of the line calculated from the standard curve constructed on each plate. 
2.2.8 Preparation of 5mg/mL biotinylated EmtinB 
Biotinylation of EmtinB was carried out using the ImmunoProbe Biotinylation kit (Sigma-
Aldrich, MA, USA) as per the manufacturer’s instructions. In brief, EmtinB dimer was dissolved 
in sterile MilliQ water at an approximate concentration of 10mg/mL. Equal volumes (500µL) of 
10mg/mL EmtinB and BAC-sulfo biotin ester in 6% DMSO/94% PBS were combined together 
and incubated on ice for 2 hours with gentle shaking.  
The provided column was equilibrated with 6 x 5mL of PBS (method 2.1.5) before the reaction 
mixture was applied. Biotinylated EmtinB was eluted from the column in 10 x 1mL fractions 
and quantified using BCA assay. Biotinylation of EmtinB was confirmed by dot blot. 
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2.2.9 Mouse subcutaneous injection and gavage protocol 
Animals were sedated with isofluorane before they were injected or gavaged with the 
appropriate volume of 5mg/kg biotinylated EmtinB peptide. Previous work using injection of 
EmtinB [184] and oral administration of peptides [188] suggested that protein should be 
detectable in serum approximately 45 minutes after administration. Based on these papers the 
mice were sedated 45 minutes post administration for sample collection. Based on this work, 
the mice were terminally anaesthetised with a lethal dose of pentabarbitone, >100mg/kg given 
intraperitoneally, 45 minutes after administration of EmtinB.  
When mice had reached a plane of full surgical anaesthesia, as assessed by loss of pedal reflex, 
blood was extracted via  intra-cardiac puncture using 1mL syringe and 22G needle coated with 
EDTA (0.5M, pH 8.0; method 2.1.13) and put into an EDTA coated eppendorf for plasma 
collection (approximately 2µL of EDTA per 100µL of blood). The EDTA/blood mixture was kept 
chilled at 4° C while the rest of the procedure and tissue collection was performed then 
centrifuged at 4°C for 15 minutes at 200g (5000rpm) and the supernatant was collected.  
2.2.10 Protein extraction from EmtinB injected and control 
APPswe/PS1ΔE9 brains  
Proteins from frozen brain samples were extracted in RIPA buffer with protease inhibitor. 
Cortical and whole hemisphere samples were ground under liquid nitrogen in a mortar and 
pestle. A small amount of the ground brain was then transferred to a chilled Eppendorf tube 
and 300µL of RIPA buffer (method 2.1.33) added. Tubes were homogenized using a T10 basic 
ultra-turrax (IKA, Selangor, Malaysia) on setting 3 for short bursts until thoroughly mixed. The 
mixtures were then centrifuged at 4°C for 15 minutes at 13,000rpm. The supernatant was 
collected and the pellet discarded. 
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2.2.11 Western blot analysis and quantitation 
Western blot gels were run at 200 volts for 20-30 minutes using western blot running buffer 
(method 2.1.28). Transfer of proteins to a membrane used western blot transfer buffer 
(method 2.1.29). For visualisation of protein bands, blots were incubated in chemiluminescent 
substrate (EMD Millipore, MA, USA) for five minutes before imaging using a Carestream image 
station 4000MM Pro (Carestream Molecular imaging, CT, USA) using Carestream MI SE 
software (v4.5.2). 
2.2.11.1 Western blot analysis of mouse serum samples from injected 
and gavaged mice 
Western blots were carried out using The Novex® NuPAGE® SDS-PAGE Gel System 
(Thermofisher scientific, MA, USA). Protein samples were run on Nupage gels using Nupage 
MES SDS running buffer (Invitrogen Thermofisher scientific, MA, USA) 
Samples were prepared by mixing 50% serum with 50% Laemlli reducing sample buffer 
(method 2.1.27). A control sample of biotinylated EmtinB dimer was prepares using 50ng in 
50% MilliQ/50% Laemlli reducing sample buffer. Gels were run on a NuPAGE 4-12% bis-tris gel 
(Invitrogen, Thermofisher scientific, MA, USA) and transferred to nitrocellulose membrane 
(Thermofisher scientific, MA, USA) at 30 volts for 1 hour. Blots were blocked western blot 
blocking solution (method  2.1.30) overnight at 4°C before incubating in avidin-HRP 
(Invitrogen, Thermofisher scientific, MA, USA) for four hours at room temperature. 
2.2.11.2 Western blot analysis of mouse brains from injected and 
gavaged mice  
Cortical and whole hemisphere samples were analysed by western blot for the presence of 
biotinylated EmtinB. Protein extract from cortex and whole hemisphere brain samples were 
analysed for protein content by BCA assay. Equal total protein amounts of hemisphere samples 
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(127µg) and cortex samples (30µg) were prepared in a 10µL volume, and then 1.5µL of 
NuPAGE reducing agent (Invitrogen, Thermofisher scientific, MA, USA) and 3.5µL of LDS 
sample buffer (Invitrogen, Thermofisher scientific, MA, USA) were added. The samples were 
heated at 80°C for 15 minutes before running on a NuPAGE 4-12% bis-tris gel (Invitrogen, 
Thermofisher scientific, MA, USA). Blots were transferred to polyvinylidene fluoride (PVDF) 
membrane at 20 volts for 1 hour then blocked in western blot blocking solution (method  
2.1.30) overnight at 4°C.Blots were incubated in avidin-HRP (Invitrogen, Thermofisher 
scientific, MA, USA) for four hours at room temperature. 
2.2.11.3 Western blot analysis of EmtinB trial brains 
Whole hemisphere and hippocampal extracts were analysed by western blot. RIPA extracts 
were analysed for protein content by BCA assay and equal total protein amounts of 
hemisphere samples (20µg) and hippocampal samples (12µg) were prepared in a 6.5µL 
volume, then 1µL of NuPAGE reducing agent (Invitrogen, Thermofisher scientific, MA, USA)  
and 2.5µL of NuPAGE LDS sample buffer (Invitrogen, Thermofisher scientific, MA, USA) were 
added. Samples were heated at 80°C for 15 minutes before running on a NUPAGE 4-12% bis-
tris gels (Invitrogen, Thermofisher scientific, MA, USA) and transferring to a PVDF membrane. 
The membrane was blocked in western blot blocking solution (method 2.1.30) for one hour at 
room temperature.  
2.2.11.4 Antibodies for western blotting 
Primary antibodies were incubated in western blot blocking solution (method 2.1.30) 
overnight at 4°C and then washed 3 x 10 minutes in PBS-T (method 2.1.6) at room 
temperature. Secondary goat anti-mouse (P0447) and goat anti-rabbit (P0448) antibodies were 
purchased from Dako (Glostrup, Denmark), and were incubated in 5% milk formula 
(Woolworths, Tas) powder for two hours at room temperature, then washed in PBS-T three 
times for ten minutes. For antibody details see Table 2.2.  
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Table 2.2 Primary and secondary antibodies used in western blotting 
Target Primary antibody Concentration Secondary antibody Concentration 
EmtinB dimer  
(biotinylated) 
Streptavidin-HRP conjugate (SNN1004, Invitrogen, 
Thermofisher scientific, MA, USA). 
1:1000 None None 
APP Mouse anti-APP (MAB348, EMD Millipore, MA, USA) 1:1000 Anti-mouse HRP 1:10000 
LRP1 Rabbit anti-LRP1 (L2170, Sigma, USA) 1:1000 Anti-rabbit HRP 1:10000 
IBA1 Rabbit anti-IBA1 (01919741, Wako, VA, USA) 1:500 Anti-rabbit HRP 1:10000 
GFAP Rabbit anti-GFAP (20334, Dako, Glostrup, Denmark) 1:1000 Anti-rabbit HRP 1:10000 
Synaptophysin Rabbit anti-Synaptophysin (9272, EMD Millipore, MA, USA) 1:2000 Anti-rabbit HRP 1:7000 
PSD95 Mouse anti-PSD95 (75-028, NeuroMab, CA, USA) 1:1000 Anti-mouse HRP 1:7000 
(III)-tubulin Mouse anti-(III)-tubulin (G7121, Promega, WI, USA) 1:2000 Anti-mouse HRP 1:20000 
-actin Mouse anti--actin (A2228, Sigma, USA) 1:2500 Anti-mouse HRP 1:20000 
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2.2.11.5 Quantitation of western blots 
Image files (.tiff format) were imported into ImageJ (NIH, MD, USA) and analysed using the 
following protocol: 
1. Flip image so that the first sample on the gel is on the left hand side of the image. 
2. Ensure the image shows white bands on a black background. 
3. Convert the image to 8 bit greyscale. 
4. Subtract the background using a rolling ball radius of 50 pixels. 
5. Set the scale to pixels. 
6. Set the measurements to area and integrated density 
7. Using the ROI manager, place a box around each band and add it to the list of items to 
be analysed. 
8. Measure the integrated density of each band.  
The integrated density of each band was obtained and normalised to the control samples on 
each gel. Each band was then normalised to the actin control. All samples were then 
represented as a percentage of the SSV control. 
Significance was determined using a one-way ANOVA with Tukey Post-test and PRISM software 
(GraphPad Prism, version 6, La Jolla, CA, USA) for analysis of trial brains, while a t-test was 
used for comparison between B6 control mice and APPswe/PS1ΔE9 mice.  
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Chapter 3 – Emtins protect against CuAβ mediated toxicity in 
primary rat hippocampal neurons   
3.1 Introduction  
Oxidative stress is a key feature of the AD brain. While the source of excess free radicals is still 
under debate, there is some evidence that free radical generating, redox active metals are 
involved. Consistent with this idea, redox active metals, such as copper, are enriched in 
amyloid plaques in the AD brain [189]. Investigation into copper involvement in AD, using in 
vitro studies, has shown that Aβ peptides bind copper with high affinity and, under culture 
conditions, copper-bound Aβ (CuAβ) produces reactive oxygen species which are toxic to 
neurons [108, 121, 160]. Two members of the metallothionein family of proteins,  MT2 and 
MT3 have been shown to be protective against toxic CuAβ species in cultured neurons, and 
this has led to speculation that MTs could represent a potential therapeutic for the treatment 
of AD [159, 160]. One of the key requirements of a potential AD therapeutic is the ability to 
reach targets within the brain by crossing the protective blood-brain barrier and consequently 
the pharmacokinetics of MT has been of great interest to researchers. While MTs have 
demonstrated promising neuroprotective capabilities in cell culture models, recent in vivo 
work looking at subcutaneous injection of MT into mice concluded that systemic 
administration of MT does not result in any detectable level of MT crossing the blood-brain 
barrier and entering the CNS [162], and thus the therapeutic value of MT is limited. 
More recently, synthetic peptides, termed emtins, have been produced that are based upon 
the short AA sequences of the MT2 protein. Emtins have demonstrated some capacity to act as 
MT-mimetics; emtins bind to the same family of receptors of MT2, promote neurite 
outgrowth, and improve neuronal survival (see Table 1.1). Unlike MT, there is evidence that 
these synthetic peptides are able to cross the blood-brain barrier. Biotinylated EmtinB peptide, 
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in tetrameric form, has been detected in CSF of C57BL/6J mice by western blot 30 minutes 
after intraperitoneal injection [184]. Given that the emtin peptides can reproduce some of the 
neuroprotective effects of MT, the capacity for EmtinB to cross the blood-brain barrier raises 
the potential therapeutic value of emtin peptides as candidate AD therapeutics. However, it is 
not currently known if emtins are able to protect neurons in an AD relevant model of neuronal 
toxicity, such as CuAβ-induced toxicity.  
Of the four emtin peptides produced, EmtinB and EmtinAc are the most MT-mimetic (see 
Table 1.1). EmtinB and EmtinAc bind LRP receptors, improve neuronal survival and promote 
neurite outgrowth. This chapter will investigate the potential of EmtinB and EmtinAc tetramers 
and dimers (see Figure 1.7) to protect cultured hippocampal neurons from CuAβ-induced 
toxicity. 
3.2 Methods  
3.2.1 Hippocampal neuron culture 
Hippocampal neurons were cultured as described in Chapter 2 with the following specific 
detail: 1) between 5 and 8 E17/18 Sprague-Dawley rat embryos were used per culture 2) cells 
were grown in 24-well plates at a cell density of 1x105 cells per well, 3) cells were maintained 
in subsequent media for 7 days. In previous work, immortalised cells [160] and primary rat 
cortical neurons at 3 days in vitro (DIV) were utilised [159]. In this study, hippocampal neurons 
were treated at 7DIV. In primary neuronal cultures, synapses are just beginning to form at 3 
DIV [190] and at 7DIV, neurons are more mature [190, 191]. After 7 DIV, neurons in culture 
begin to undergo neuronal pruning [192] and, for this reason, treating neurons after 7 DIV was 
avoided to prevent introducing variability from natural cell loss.  
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3.2.2 Treatment of hippocampal neurons with CuAβ, Emtins and MT2 
Hippocampal neurons were grown to 7DIV to produce a network of neurons. Vehicle and 
treatments were administered on day 7 in subsequent media containing 300µM ascorbate. 
The redox cycling of CuAβ is catalysed by cellular reductants such as ascorbate [160]. 
Ascorbate was added at a final concentration of 300µM as this approximates the ascorbate 
concentration found in the CSF and extracellular space within the brain [160]. In experiments 
using CuAβ1-40 as the toxic insult, cells received media containing either 10µM CuAβ-only, or 
10µM CuAβ with the addition of MT2, EmtinAc or EmtinB at a concentration of 10 or 25µM. 
The concentration of emtins used in vitro has been selected based on producing an experiment 
where there were equal ratios of CuAβ and EmtinB/metallothionein. EmtinB concentrations 
were based on previous metallothionein and CuAβ experiments where copper swap 
mechanism was the main mechanism of action and this worked effectively as equimolar 
concentrations. The concentration of Aβ was selected based on published studies [159, 160] 
and previous work within the lab using metallothionein as a therapeutic against CuAβ toxicity. 
Control cells received the ascorbate enriched media containing sterile MilliQ water vehicle. In 
CuAβ1-42 treated cells, cells received either media containing 25µM CuAβ or 10µM CuAβ with 
the addition of tetrameric EmtinB (25µM) or dimeric EmtinB (20, 25 or 100µM). After 
treatment, hippocampal neuron cultures were incubated at 37°C with 5% CO2 for 24 hours, 
after which cell viability was assessed using alamarBlue assay. Cells were visualised by fixing 
cells in 4% PFA and immunostaining for tau protein. In this thesis, graphs with a single column 
per treatment represent a single experiment carried out in a 24-well plate using mixed 
neurons from 5-8 embryonic Sprague-Dawley rat pups. Graphs with multiple columns per 
treatment represent repeat experiments from different culture days using the same 
experimental design, and patterned columns denote a single experimental culture. 
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3.2.3 Microscopy 
Photographs were taken using a 20x objective on an Olympus BX50 microscope using a 
Photomatrix Cool Snap HQ2 camera. 
3.2.3 Statistical analysis 
Analyses were carried out using GraphPad PRISM version 4 (La Jolla, CA, USA). All plates were 
analysed individually using One-way ANOVA with Tukey post-test. 
3.3 Results  
3.3.1 Tetrameric emtins attenuate CuAβ1-40 toxicity in hippocampal 
neurons 
The capacity for tetrameric EmtinAc to protect neurons against CuAβ-induced toxicity was 
tested in an in vitro CuAβ toxicity model using 7DIV primary rat hippocampal neurons. 
Treatment of neurons with 10µM CuAβ1-40 alone resulted in a significant decrease in 
neuronal viability compared to control neurons (Figure 3.1). To determine if the synthetic 
peptide, EmtinAc, has any efficacy as a protective agent against CuAβ-induced cell loss, 7DIV 
neurons were treated with CuAβ1-40 in combination with either 10µM or 25µM EmtinAc.  
While 25µM EmtinAc was able to significantly protect the hippocampal neurons from the 
CuAβ-induced toxicity (Figure 3.1), 10µM EmtinAc was not able to attenuate CuAβ-mediated 
toxicity.  
EmtinB tetramer was also tested in the CuAβ toxicity model using 7DIV hippocampal neurons. 
Consistent with results from the EmtinAc peptide, EmtinB was shown to significantly rescue 
cell viability at 25µM compared to treatment with CuAβ1-40 alone (Figure 3.2).  Interestingly, 
10µM EmtinB also improved cell viability compared with neurons treated only with CuAβ1-40 
(Figure 3.2), showing protective capacity at lower concentration compared to EmtinAc. This  
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Figure 3.1 EmtinAc protects against CuAβ1-40 induced toxicity in hippocampal neurons 
Addition of CuAβ1-40 at 10µM (n=6) significantly decreased the viability of cultured 
hippocampal neurons relative to control cells treated with MilliQ water vehicle (n=6). Tetrameric 
EmtinAc at 10µM (n=6) did not significantly rescue cultured hippocampal neurons from 10µM 
CuAβ1-40 mediated toxicity. However, EmtinAc at 25µM (n=6) did significantly rescue the 
viability of CuAβ1-40 treated cells. One-way ANOVA with Tukey post-test. # = significantly 
different to control neuron viability (p<0.05). ** = p<0.01. All data are means and SEM.  
# 
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Figure 3.2 EmtinB protects against CuAβ1-40 induced toxicity in hippocampal neurons 
CuAβ1-40 (10µM, n=6) significantly reduces neuronal viability of cultured hippocampal neurons 
compared with vehicle-treated controls (n=6). At 10µM, tetrameric EmtinB (n=6) significantly 
improves the viability of CuAβ1-40 treated neurons. 25µM EmtinB (n=6) also improves the 
viability of CuAβ1-40 treated neurons compared to CuAβ1-40  treated cells, and is more effective 
at improving neuronal viability of CuAβ1-40 treated cells than 10µM EmtinB. One-way ANOVA 
with Tukey post-test. # = significantly different to control neuron viability (p<0.05), * = p<0.05, 
** = p<0.01, *** = p<0.001. All data are means and SEM.  
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suggests that EmtinB is more effective in the protection of neurons in the CuAβ model. 
Accordingly, future experiments in this thesis will focus on the capabilities of EmtinB as a 
potential therapeutic for AD. 
3.3.2 Tetrameric EmtinB protects cultured neurons from CuAβ1-40 
toxicity with the same efficacy as MT2 
The potential of EmtinB to act as a therapeutic lies not only in its ability to be MT-mimetic, but 
also in its ability to act with similar efficacy to MT. To test the relative efficacy of EmtinB and 
MT2, a direct comparison of protective capacity was carried out using the CuAβ model of 
amyloid toxicity. 
Consistent with previous experiments (see Figure 3.2), co-administration of 10µM EmtinB 
tetramer and 10µM CuAβ to hippocampal neurons significantly increased cell viability 
compared with CuAβ only treatment (Figure 3.3). Similarly, co-administration of 10µM MT2 
and 10µM CuAβ produced a significant increase in cell viability compared with the CuAβ alone 
treatment. A comparison of MT2 and EmtinB efficacy in this experiment showed there was no 
statistical difference between MT2-induced increases in cell viability and EmtinB-induced 
increases in cell viability (p>0.05).  
3.3.3 CuAβ1-40 and CuAβ1-42 have comparable toxicity in hippocampal 
neurons 
Initial testing of EmtinB neuroprotective capacity (see 3.3.1 and 3.3.2) utilised the more easily 
obtainable Aβ1-40 at 10µM. A concentration of 10µM is relatively mild for synthetic Aβ which, 
in other publications [159, 160], has been used at much higher concentrations to promote 
toxicity. Using a higher concentration of Aβ than the 10µM currently employed would likely 
produce a more severe insult and have a greater impact on the viability of the neuron cultures, 
therefore allowing the protective capabilities of EmtinB peptides to be more rigorously tested.    
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Figure 3.3 EmtinB and Zn7MT2 protect against CuAβ1-40 toxicity with equal efficacy 
Viability of hippocampal neurons was significantly decreased by treatment with 10µM CuAβ1-40 
(n=4) compared with vehicle treated control neurons (n=4). Both 10µM EmtinB (n=4) and 10µM 
Zn7MT2A (n=4) significantly improved the viability of CuAβ1-40 treated neurons and were 
equally efficacious in protecting neurons against CuAβ1-40 toxicity, with no significant 
difference in neuronal viability between Zn7MT2 and tetrameric EmtinB treated cells.  One-way 
ANOVA with Tukey post-test. # = significantly different to control neuron viability (p<0.05). 
* = p<0.05, ** = p<0.01. All data are means and SEM.  
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To this end, a higher concentration of CuAβ was used in further studies to achieve a more 
robust toxicity. Additionally, the type of Aβ used was changed from the Aβ1-40 to the Aβ1-42 
fragment. This was to determine the efficacy of EmtinB against this more aggregation-prone 
and, reportedly, more toxic fragment. Furthermore, the Aβ1-42 fragment is a more 
appropriate in vitro Aβ investigative target for EmtinB neuroprotection studies, as future 
experiments will extend to animal trials using the APPswe/PS1ΔE9 mouse model of AD which 
overexpress the Aβ1-42 fragment. To determine an appropriate toxicity to use, and to 
investigate the relative toxicities of the Aβ1-40 and 1-42 fragments, a small concentration 
curve was constructed on 7DIV hippocampal neurons using 10, 25 and 40µM CuAβ1-40 and 
CuAβ1-42. In this experiment, the CuAβ1-40 and 1-42 fragments have comparable toxicity, 
with no statistical difference (p>0.05) between Aβ1-40 and Aβ1-42 at each concentration 
(Figure 3.4). From this experiment a concentration of 25µM CuAβ1-42 was selected for future 
experiments as it shows a strong toxicity, but is not sufficiently toxic to kill all of the cells.  
3.3.4 TFA/TFE monomerisation of Aβ1-42 produces no toxic residues. 
A unique problem encountered when using synthetically produced Aβ1-42 peptide is the 
notorious variability in its toxicity, a property which makes it unpredictable and limits its 
effectiveness as a research tool [193].  In our laboratory it has been observed that Aβ1-42 re-
suspension is variable, with the Aβ1-42 suspensions varying in opacity by visual inspection. 
Given the aggregation-prone nature specific to the Aβ1-42 fragment, and the fact that this 
variability in toxicity and in clarity has not been observed in this lab when using the Aβ1-40 
fragment, we deduce that the variability in Aβ1-42 toxicity is potentially caused by the peptide 
fragment already having aggregated prior to re-suspension. In an attempt to limit variability 
between experimental replicates, and to ensure a more reproducible toxic effect using the 
Aβ1-42 peptide fragment, each vial of Aβ1-42 peptide was thus monomerised by a process  
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Figure 3.4 CuAβ1-40 and CuAβ1-42 have comparable toxicity in cultured hippocampal neurons 
CuAβ1-40 and CuAβ1-42 were applied to hippocampal neurons at 10µM, 25µM and 40µM for 
24 hours and subsequent cell viability assessed using alamarBlue assay. No significant difference 
in cell viability was apparent between the two peptides at any concentration investigated. One-
way ANOVA with Tukey post-test. All data are means and SEM.  
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which uses the solvents trifluoroacetic acid (TFA) and trifluoroethanol (TFE) (see method 
2.2.2). Both TFA and TFE are toxic to living organisms, thus it is essential to ensure, prior to 
using the peptide in cell culture, that no toxic residues remain after the monomerisation 
process. To confirm the absence of toxic residues, a TFA blank was prepared. The TFA blank 
underwent the same chemical process as monomerised Aβ, in the absence of the Aβ peptide. 
This TFA blank was resuspended in an identical manner to the Aβ1-42 peptide and tested for 
toxicity using 7DIV hippocampal neurons. TFA/TFE treatment produced no toxic side effects for 
cultured hippocampal neurons, with no change in cell viability for blank treated cells compared 
to control cells treated with sterile MilliQ vehicle (Figure 3.5), whilst the TFA/TFE monomerised 
CuAβ1-42 (25µM) showed a significant decrease in cell viability relative to both control and 
TFA/TFE blank treated neurons (Figure 3.5). 
3.3.5 EmtinB dimers and tetramers have no effect on the viability of 
untreated primary cultured hippocampal neurons. 
Prior to determining the protective effect of EmtinB peptides in the CuAβ1-42 toxicity model, it 
was necessary to determine if EmtinB alters the viability of neurons under basal conditions. 
EmtinB dimer (25-100µM) and tetramer (25µM) were administered to 7DIV hippocampal 
neurons for 24 hours and subsequent cell viability assessed by alamarBlue assay. Neither 
EmtinB dimer nor EmtinB tetramer altered the viability of the cultured neurons relative to the 
untreated control neurons (Figure 3.6), suggesting that the increase in cell viability observed in 
the CuAβ treated neurons is a protective effect against CuAβ toxicity. 
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Figure 3.5 TFA monomerised CuAβ1-42, but not the TFA blank, is toxic to cultured hippocampal 
neurons 
TFA monomerised CuAβ1-42(n=5) reconstituted in MilliQ water at 25µM induces significant 
neuronal cell death in 7DIV cultured hippocampal neurons compared with vehicle control 
neurons (n=4). The TFA Blank, prepared in the absence of Aβ and resuspended in MilliQ water, 
exhibits no toxicity in the cultured neurons (n=4) compared with vehicle control cells. One-way 
ANOVA with Tukey post-test. # = significantly different to control neuron viability (p<0.05), **** 
= p<0.0001. All data are means and SEM. 
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Figure 3.6 EmtinB dimers and tetramers have no effect on the viability of cells under basal 
conditions 
EmtinB tetramer at 25µM (n= 3) had no effect on hippocampal cell viability compared with 
vehicle control neurons (n=3). Additionally, neither 25µM (n=4) nor 100µM (n=3) EmtinB dimer 
altered neuronal viability compared with control neurons. One-way ANOVA with Tukey post-
test. All data are means and SEM.  
Chapter 3 – Results: Emtin efficacy in vitro 
  
Page | 79  
 
3.3.6 EmtinB tetramers are protective against CuAβ1-42 toxicity in 
primary cultured hippocampal neurons. 
The ability of EmtinB tetramer to protect hippocampal neurons against CuAβ1-42 toxicity at a 
25µM concentration was investigated in three separate experiments. In all three experiments, 
25µM CuAβ1-42 reduced cell viability compared to vehicle control cells (Figure 3.7). Tetrameric 
EmtinB significantly rescued neuronal viability of CuAβ1-42 treated neurons compared to 
CuAβ1-42-only treated neurons (Figure 3.7).   
3.3.7 EmtinB is significantly more protective in dimeric form compared to 
tetrameric form 
While previous studies by Ambjorn [94], Asmussen [185] and Sonn [184] have investigated the 
properties of the tetrameric forms of the emtin peptides, less is known about the dimeric 
forms of the peptide. The protective capacity of the EmtinB dimeric peptides was established 
in the CuAβ model of toxicity herein. In two experiments 25µM CuAβ1-42 induced toxicity 
significantly reduced neuronal viability of hippocampal neurons relative to vehicle control 
neurons (Figure 3.8). In both experiments, EmtinB dimer (25µM) completely abrogated CuAβ1-
42 induced neuronal toxicity (Figure 3.8).  
In a direct comparison of dimer and tetramer, EmtinB tetramer (25µM) significantly increased 
cell viability of CuAβ1-42 treated cells compared to CuAβ1-42-only treated neurons 
(Figure 3.9). EmtinB dimer was significantly more effective in protecting against CuAβ induced 
toxicity compared with tetramer (Figure 3.9), and subsequently only EmtinB dimer was 
selected for further investigation. 
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Figure 3.7 EmtinB tetramer protects hippocampal neurons against CuAβ1-42 
25µM CuAβ1-42 reduced cell viability of cultured hippocampal neurons after a 24 hour 
treatment. Tetrameric EmtinB (25µM) improves the viability of 25µM CuAβ1-42 treated 
hippocampal neurons compared to CuAβ1-42 treatment alone. Each culture was analysed by 
one-way ANOVA with Tukey post-test. Comparisons denoted # or $ were made within cultures 
and no comparisons were made between cultures. # = significantly different to control neuron 
viability (p<0.05), $ significantly different from CuAβ. All data are means and SEM. 
 
  
 
Figure 3.8 EmtinB dimer significantly protects against CuAβ toxicity in hippocampal neurons  
Hippocampal neurons were treated with 25μM CuAβ alone or concurrently with 25μM EmtinB dimer for 24 hours and cell viability was assessed using 
alamarBlue assay. PFA fixed neurons were immunostained with tau. CuAβ treatment significantly decreased cell viability (A) and resulted in cell loss (B) 
compared with vehicle control cells. Dimeric EmtinB rescued cell viability (A) and prevented neuronal loss (B). Cultures were analysed by one-way ANOVA 
with Tukey post-test. Comparisons were made within experiments only; no comparisons were made between cultures. # = significantly different from control, 
$ significantly different from CuAβ (p<0.05). 20x magnification. Scale bar = 50μm.   
AB
Control CuAβ CuAβ + EmtinB dimer
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Figure 3.9 EmtinB dimer is more effective than tetramer against CuAβ1-42 toxicity in 
hippocampal neurons  
CuAβ1-42 treatment (n=5) significantly reduces neuronal viability of hippocampal neurons 
compared with vehicle control neurons (n=4). Both dimeric (n=5) and tetrameric (n=5) EmtinB 
forms improved cell viability compared to neurons treated with CuAβ1-42 alone. Dimeric EmtinB 
improved cell viability significantly more than the tetrameric EmtinB. # = significantly different 
to control neuron viability, (p<0.05) **** = p<0.0001. One-way ANOVA with Tukey post-test. All 
data are means and SEM.  
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3.3.8 EmtinB dimer effect is concentration dependent 
To determine if EmtinB dimer protection against CuAβ-mediated toxicity is concentration 
dependant, hippocampal neurons were treated with 25µM CuAβ1-42 or with 25µM CuAβ1-42 
concurrently with EmtinB dimer (20 or 100µM). 
In all experiments 25µM CuAβ1-42 reduced cell viability after 24 hours incubation on primary 
hippocampal neurons (Figure 3.10). At 20µM EmtinB dimer was able to significantly increase 
the viability of hippocampal neurons relative to 25µM CuAβ1-42  treated neurons, although 
the effect size was small (Figure 3.10). Addition of 100µM EmtinB with CuAβ1-42 significantly 
increased cell viability relative to CuAβ1-42-only treated neurons, and neurons that were 
treated with CuAβ1-42 and 20µM EmtinB (Figure 3.10). 
3.3.9 High EmtinB concentrations are less effective at protecting cultured 
neurons from CuAβ1-42 toxicity  
To determine an optimal dosing concentration for EmtinB dimer, a concentration curve was 
constructed using EmtinB dimer at 25, 75 and 125µM on 7DIV hippocampal neurons.  
CuAβ1-42 (25µM) significantly reduced neuronal viability as measured by alamarBlue assay. 
Addition of 25µM and 75µM EmtinB significantly improved neuronal viability relative to 
CuAβ1-42 treated cells compared with CuAβ1-42-only treated neurons (Figure 3.11). At these 
concentrations, neurons were restored to full viability as compared to vehicle control neurons. 
125µM EmtinB also significantly improved cell viability relative to CuAβ1-42-only treated cells; 
however, unlike 25µM and 75µM EmtinB dimer, cells treated with 125µM EmtinB did have 
significantly lower viability compared with control cells (Figure 3.11).  
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Figure 3.10 EmtinB protection against CuAβ1-42 toxicity is concentration dependent  
Hippocampal neurons were treated with either 25µM CuAβ1-42 or 25µM CuAβ1-42 
simultaneously with EmtinB dimer (20 or 100µM, as denoted). CuAβ1-42 significantly reduced 
cell viability compared to vehicle control cells. 20µM EmtinB dimer significantly improved 
neuronal viability of CuAβ1-42 treated cells, as did treatment with 100µM EmtinB dimer. 100µM 
dimeric EmtinB treatment was significantly more efficient at improving neuronal viability 
compared with 20µM dimeric EmtinB. One-way ANOVA with Tukey post-test. #significantly 
different to control neuron viability, $ significantly different to CuAβ, € significantly different to 
20µM EmtinB treatment (p<0.05). All data are means and SEM.  
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Figure 3.11 EmtinB protection against CuAβ1-42 toxicity is reduced at high EmtinB 
concentration 
CuAβ1-42 (n=4) significantly reduced neuronal viability compared with vehicle treated control 
cells (n=4). EmtinB dimer fully protected hippocampal neurons for CuAβ toxicity at 25µM (n=4) 
and 75µM (n=4). While EmtinB at 125µM (n=4) was able to protect cultured neurons from 
CuAβ1-42toxicity, 125µM EmtinB was significantly less protective than 25µM EmtinB. One-way 
ANOVA with Tukey post-test. #significantly different to control neuron viability (p<0.05),  
** = p<0.01, *** = p<0.01, **** = p<0.0001. All data are means and SEM.  
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3.3.10 EmtinB dimer is only effective when added concurrently with 
CuAβ1-42 
As with any potential therapeutic for the treatment of neurodegenerative diseases, 
intervention at the earliest possible stage is desirable. This allows for prevention of damage to 
fragile neurons, which are not able to be regenerated after insult. To determine if EmtinB can 
be used as a pre-treatment to protect neurons against CuAβ toxicity, 7DIV primary cultured 
hippocampal neurons were pre-treated with 25µM EmtinB for either one day or one hour (as 
specified) prior to administration of CuAβ1-42 (Figure 3.12). Neither one hour nor one day pre-
treatment with EmtinB produced an increase in cell viability relative to CuAβ1-42-only treated 
cells. EmtinB added concurrently with CuAβ1-42 was able to improve cell viability, suggesting 
that whatever mechanism EmtinB is acting through, it requires EmtinB to be present at the 
time of insult. 
3.4 Discussion and conclusions 
Previous work by Meloni [160] and Chung [159] has established the protective capacity of MT3 
and MT2, respectively, in the CuAβ model of neurotoxicity. This chapter sought to determine 
which, if any, of the emtin peptides demonstrate a similar capacity to protect neurons against 
CuAβ-mediated toxicity. Both EmtinB and EmtinAc were found to protect cultured neurons 
against CuAβ, with EmtinB tetramer the more efficacious of the two peptides studied. MT2 
and EmtinB tetramer had comparable efficacy against CuAβ, while EmtinB dimer was robustly 
more effective at protecting against CuAβ than EmtinB tetramer. EmtinB dimer appears 
concentration dependent, with higher concentrations improving cell viability to a greater 
extent than lower concentrations, however this trend was only observed at concentrations less 
than 100µM, with higher concentration EmtinB showing reduced efficacy. Notably, EmtinB was 
only effective against CuAβ toxicity when administered at the same time as the CuAβ. Pre- 
Chapter 3 – Results: Emtin efficacy in vitro 
  
Page | 88  
 
 
 
Figure 3.12 EmtinB is protective against CuAβ1-42 toxicity only when it is administered 
concurrently 
Hippocampal neurons treated with 25µM CuAβ1-42 (n=5) had significantly lower cell viability 
after 24 hours treatment compared with vehicle treated control cells (n=4). The cell viability of 
CuAβ1-42 treated neurons was significantly improved by 25µM dimeric EmtinB (n=5) when 
added simultaneously with CuAβ1-42 but EmtinB did significantly improve neuronal viability 
when added 1 day prior to CuAβ1-42 (n=5) or 1 hour prior to CuAβ (n=5). Each culture was 
analysed by one-way ANOVA with Tukey post-test. # = significantly different to control neuron 
viability (p<0.05). **** = p<0.0001. All data are means and SEM. 
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treatment of hippocampal neurons with EmtinB prior to CuAβ administration has no effect on 
CuAβ toxicity.   
3.4.1 The EmtinB/CuAβ model 
A comparison of CuAβ1-40 and CuAβ1-42 showed that there was little difference in the toxicity 
of the two copper-bound peptides and, as such, both CuAβ1-40 and CuAβ1-42 were utilised in 
this work. The Aβ1-42 peptide is difficult to prepare [194] and has variable toxicity [193, 195]. 
In an attempt mitigate the variability exhibited by synthetic Aβ1-42, each batch of peptide was 
monomerised before use, using TFA/TFE monomerisation. To ensure that these chemicals left 
no toxic residue after monomerisation, TFA/TFE blanks were tested on hippocampal neuron 
cultures, showing that the toxicity that arises from the addition of the CuAβ is generated 
exclusively by the CuAβ. Thus, the effect of the emtin peptides results fully from an effect 
against CuAβ-mediated toxicity. 
To demonstrate that the increase in cell viability produced by EmtinB in CuAβ treated neurons 
is a result of neuroprotection and not a stimulation of cell metabolism, the effect of EmtinB on 
cell viability under basal conditions (unstressed cells) was investigated. Addition of EmtinB 
tetramer (25µM) or dimer (25-100µM) had no effect on hippocampal cell viability, indicating 
that improvement in viability on addition of EmtinB is a direct effect of neuroprotection 
against CuAβ toxicity. The observation that EmtinB has no effect on the function of cells under 
basal conditions but is beneficial under stress is reminiscent of MT action. MT appears non-
essential for normal growth and reproduction, as exemplified by the normal function of cells 
and organisms that lack MT [30, 31], but confers an advantage under conditions of stress such 
as oxidative stress or metal toxicity [4, 52, 53]. 
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3.4.2 Comparison of emtin efficacies 
Both EmtinB tetramer and EmtinAc tetramer demonstrated a capacity to protect against CuAβ- 
induced toxicity in cultured hippocampal neurons. Tetrameric EmtinB was able to protect 
hippocampal neurons against CuAβ at lower concentration than EmtinAc, suggesting that the 
EmtinB peptide is the more effective peptide in this context. Interestingly, the protective 
capacity of tetrameric EmtinB was similar to the protective capacity of MT2.  
Previous emtin studies by Ambjorn [79], Asmussen [185] and Sonn [184] have utilised the 
tetrameric form of EmtinB, most likely because evidence from previous studies, using other 
peptides, has shown that tetramers have a higher affinity for the target protein than trimeric, 
dimeric or monomeric peptide assemblies [196, 197]. In this experimental work, the EmtinB 
dimer shows a much greater capacity than the tetramer to protect neurons against 
CuAβ-mediated toxicity. 
It is unclear why EmtinB is more efficacious than EmtinAc, or why dimeric EmtinB is more 
efficacious than tetrameric EmtinB. One possibility is that the efficacy of these peptides relates 
to the aggregate state of the peptide; some peptides may have a higher propensity to 
aggregate than others. For example, EmtinAc may have a greater propensity than EmtinB to 
aggregate under experimental conditions and, similarly, the tetrameric form may be more 
likely to aggregate than the dimer, with aggregation rendering the peptide unable to carry out 
the function required. In fact, we have observed in the process of this study that EmtinB dimer 
does self-aggregate into higher MW SDS-resistant forms under freeze-thaw conditions (data 
not shown). If or how aggregation affects the capacity of emtins to act in its neuroprotective 
role remains to be determined. 
More likely, the reason behind the difference in peptide efficacy is linked to emtin mechanism 
of action. There are three main candidates for emtin mechanism of action; based upon the 
capabilities of the parent protein MT2 (discussed in Chapter 1), emtins could potentially be 
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involved in free radical scavenging, Cu/Zn metal swap, or activating signalling cascades via LRP 
receptors. 
Previous investigation into MT protection against CuAβ-mediated toxicity showed that MTs 
can perform a metal swap with CuAβ to prevent toxic ROS production [159, 160]. It is possible 
that the EmtinB peptide acts in a similar manner, by removal and redox silencing of the copper 
from CuAβ.  While it is currently unknown what, if any, binding capacity EmtinB has for either 
zinc or copper, given that the emtin sequences have been altered to remove some cysteine 
residues, it is possible that EmtinB no longer has the capacity to bind metals, or has altered 
metal binding properties. The metal binding capabilities of the EmtinB peptide will be 
investigated in Chapter 4. 
MT2 has also demonstrated strong free radical scavenging capabilities. The capacity of MT2 to 
scavenge free-radicals is a result of the high cysteine content of the protein. MT2 was unable 
to protect against H2O2 toxicity when tested in cultured cortical neurons, suggesting that in the 
CuAβ model of toxicity, MT2 action is not via scavenging of ROS.  Additionally, as many 
cysteine residues are substituted for serine in the emtin peptides, it is unlikely that EmtinB is 
acting as a free radical scavenger in this model. To confirm this, the capacity of EmtinB to 
protect against H2O2 toxicity will be further explored in Chapter 4.  
MT2 has also been shown to interact with the LRP family of receptors, resulting in signal 
transduction through MAPK signalling pathways. In accordance with this, work by Ambjorn 
et al. [94] suggests that EmtinB’s neuroprotective activity is mediated through LRP receptors 
via a sequence specific motif. However, in a scenario involving signal transduction and 
activation of neuroprotective pathways, it would be expected that pre-treatment of cells with 
emtin might be protective against CuAβ yet neither pre-treatment of one day nor one hour 
prevented CuAβ toxicity (see Figure 3.12). Interestingly, Aβ is also believed to be a ligand for 
LRP-receptors.  Hence, it is possible that MT/emtin may interfere with Aβ-LRP interactions; this 
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too will be explored in Chapter 4, through the use of molecular approaches that interfere with 
LRP receptors. 
Regardless of what mechanism emtins work through, it is clear that the EmtinB peptide is 
better able to protect cultured hippocampal neurons than EmtinAc, and in turn that dimeric 
EmtinB is more efficacious than tetrameric EmtinB. While it would be informative to explore 
these differences further, restriction on time and resources required further investigations to 
focus on only one of these peptides; EmtinB dimer had greatest efficacy and the EmtinB 
tetramer has reported BBB penetrance, thus dimeric EmtinB was selected for further 
investigation. 
3.4.3 Concentration determination 
Investigations using low (20µM) and high (100µM) dimeric EmtinB concentrations showed that 
EmtinB is concentration dependent, with high concentration EmtinB improving the viability of 
CuAβ1-42-treated cells to 100% of non-insulted control. To further clarify the effective 
concentration range, EmtinB effect on CuAβ toxicity was investigated across a 25-125µM 
range. Once again, EmtinB improved the viability of CuAβ1-42-treated cells in concentration- 
dependent manner until 100% of control viability was reached. These data suggest that full 
protection against CuAβ1-42 can be achieved within a concentration range of 25-100µM. 
Interestingly, at concentrations above 100µM, the ability of EmtinB to protect cells from 
CuAβ1-42 appeared to be reduced, with CuAβ1-42 treated cells showing lower viability in the 
presence of high concentrations of EmtinB compared with concentrations within the 25-50µM 
range. Although the data requires repetition for a robust analysis, it suggests that at high 
concentration either EmtinB cannot carry out its required function, or that the EmtinB itself 
has a direct negative effect on the hippocampal neurons.  
It is possible that, at 125µM, the concentration of emtin peptide overwhelms the ubiquitin 
proteasome system (UPS)/autophagy system of the neurons. Overwhelmingly high peptide 
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concentration within a cell causes compromised proteasome activity, which has been shown to 
result in neurodegeneration [198].   
Additionally, while smaller MW synthetic peptides have been shown to be less cytotoxic than 
larger MW synthetic peptides, as previously discussed, EmtinB appears to be able to aggregate 
under some conditions. Theoretically, then, if the EmtinB is aggregating at high concentration, 
this may be creating high MW peptide aggregates and thus promotes toxicity. 
Any cytotoxicity of the dendrimers could also potentially be explained by the interactions 
between negatively charged cell membranes and the positively charged dendrimer surface, 
which enables dendrimers to adhere to and damage the cell membrane, causing cell lysis 
[166]. While the net charge of EmtinB has not been tested experimentally, the estimated net 
charge of the EmtinB dimer at pH7 is +4.7, using a peptide property calculator, and thus 
cationic toxicity is possible.   
Alternatively, EmtinB may not be negatively affecting cells, but rather may just be exhibiting 
reduced efficacy at high concentration. Drugs often exhibit a sigmoidal dose-response curve 
[199]. A dose response curve is the relationship between drug dose and biological response to 
that treatment. With a sigmoidal dose response, the dose curve is S-shaped, where low drug 
concentration elicits a very small response, a range of intermediate concentrations promotes 
responses that form the linear part of the s-curve and a maximal response and plateau is 
achieved at high concentration [199]. Some molecules, however, exhibit a bell-shaped 
concentration-response curve, rather than the traditional sigmoidal dose-curve. Recent work 
by Owen et al. [199] examined the dose response curves of three anti-cancer drugs which are 
known to aggregate and form colloids. These three drugs produced traditional sigmoidal dose-
response curves when maintained in their monomeric state, however when allowed to 
generate colloids all three drugs produced bell-shaped dose-response curves [199]. The 
authors postulate that the formation of colloids prevents the passage of the drug across the 
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cell membrane, thus preventing its action [199]. While this represents a possible explanation 
for the suspected lower activity of EmtinB at high concentration, the data available does not 
allow for a definitive description of the EmtinB dimer concentration-response curve and 
further investigation is required to elucidate these hypotheses.  
Thus taken together, the data suggest that high concentrations of EmtinB could potentially be 
detrimental to hippocampal neurons and that, in vitro at least, concentrations between 25µM 
and 100µM offer an optimal effect. 
3.4.4 Conclusion 
This work has validated that EmtinB and EmtinAc are neuroprotective against CuAβ, and that 
the EmtinB dimer is a suitable candidate for further in vitro investigation. The mechanism of its 
protection, in comparison to the known effects of native MT2, will be explored in Chapter 4. 
Furthermore, as EmtinB has been reported to readily cross the BBB (while native MT2 does 
not) Chapter 5 will evaluate the neuroprotective potential of EmtinB in APPswe/PS1ΔE9 mice.  
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Chapter 4 – EmtinB mechanism of neuroprotection against 
copper-Aβ 
4.1 Introduction 
As demonstrated in Chapter 3, the investigated MT-based, synthetic emtin peptides protect 
cultured hippocampal neurons from toxicity induced by CuAβ1-40 and CuAβ1-42. This chapter 
will explore the potential mechanisms by which emtins might be exerting their protective 
effect.  
Aβ toxicity has been shown to be mediated by H2O2 in culture [108]. While the mechanism of 
H2O2 generation was unspecified in the work by Behl  [108], there is mounting evidence that 
redox active metals, such as iron and copper, can interact with Aβ peptides to produce H2O2. 
CuAβ has been shown to generate H2O2 in cell-free preparations [121, 200], and the toxic 
effect of CuAβ in cell culture is blocked by catalase, an enzyme that breaks down H2O2 [121]. 
More recently, Meloni et al. [160] found that CuAβ exerts its neurotoxic effect through the 
production of ROS. These data suggest that one mechanism of CuAβ toxicity is through the 
production of H2O2 and subsequent free radical production.  
As discussed in Chapter 1, MT2 exhibits number of properties which could protect neurons 
against CuAβ neurotoxicity. For example, MT2 has been shown under various circumstances to 
protect against free radicals produced in the Fenton reaction [59], act through LRP receptors 
to activate anti-apoptotic pathways, and to undergo a metal swap with CuAβ to prevent CuAβ 
toxicity. On this basis, given that EmtinB is MT2 mimetic, it could also act through any of these 
mechanisms to achieve neuroprotection against CuAβ toxicity in cultured hippocampal 
neurons.  
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This chapter will explore the potential of EmtinB to: 
1. Participate in a metal swap with CuAβ,  
2. Protect against H2O2-induced toxicity, and 
3. Act through LRP receptors to mediate neuronal protection.  
4.2 Methods 
4.2.1. Metal binding and metal swap methods 
4.2.1.1 ICP-MS analysis of zinc and copper associated with dimeric 
EmtinB  
For analysis, 1mL samples in PBS were diluted 10x in ultrapure water (>18MOhm) with nitric 
acid and indium (as internal standard) added to a final concentration of 1% and 100ppb, 
respectively. Standards were prepared using 10% PBS in ultrapure water (>18MOhm) with 
nitric acid and indium as per the sample preparation. Raw data was blank-subtracted and 
dilution-factor adjusted before analysis. 
Samples were prepared and then analysed using an Element 2™ ICP-MS and raw data compiled 
by Dr Ashley Townsend (Deputy Director of the Central Science Laboratory (CSL) Sandy Bay 
campus, University of Tasmania).   
4.2.1.2 Zinc and copper binding by dimeric EmtinB  
To determine if EmtinB dimer has any intrinsic copper or zinc bound to it after synthesis, a 
1mg/mL solution of EmtinB dimer in PBS was analysed via ICP-MS.  
To produce the copper and zinc solutions for this experiment, saturated solutions of CuCl2 and 
ZnCl2 were prepared in PBS at an estimated concentration of 670mM to add to EmtinB. To 
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determine the actual concentration of metals added to the EmtinB dimer, samples were 
prepared by adding the same volume of saturated solution to PBS alone. ICP-MS analysis of 
these samples empirically confirmed the concentration of Cu and Zn added to EmtinB was 
640.6µM and 662.76µM, respectively. 
To determine the capacity of EmtinB to bind to copper and zinc, 1mg/mL (335µM) EmtinB was 
incubated in the presence of CuCl2 or ZnCl2 at an approximate protein to metal ratio of 1:2. A 
1mL reaction mixture containing 100µL of EmtinB dimer stock (10mg/mL in PBS), 10µL of 
saturated CuCl2 or ZnCl2, and 990µL of sterile PBS was prepared. The reaction mixture was 
incubated at room temperature for 30 minutes to allow binding of metals to the EmtinB dimer. 
Unbound metals were removed from the EmtinB/metal mixtures using PD-10 columns 
(GE Healthcare, UK). Control columns containing copper or zinc but no EmtinB were also 
prepared and passed through a PD-10 column.  
Protein content of collected fractions was determined by BCA assay and visualised using 
SDS-PAGE and subsequent Coomassie stain, while copper and zinc content was determined  
by ICP-MS. 
4.2.1.3 Free metal separation by PD-10 column  
PD-10 columns were used as per manufacturer instructions. In brief, columns were 
equilibrated using 30mL of PBS before applying the samples (1mL). As the required sample 
volume for these columns is 2.5mL, after the 1mL of sample entered the column, a further 
1.5mL of PBS was added to the column. All flow through for this step was discarded. The 
samples were then eluted from the column in ten 1mL fractions, which were collected in pre-
chilled Eppendorf tubes. The sample-containing Eppendorf tubes were returned to ice 
immediately after sample collection. 
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4.2.1.4 Visualisation of protein in column fractions using SDS-PAGE and 
Coomassie stain  
To visualise protein content in the collected column fractions, 10µL of each fraction was mixed 
with 2.5µL of NuPAGE LDS sample buffer (Invitrogen, Thermofisher scientific, MA, USA) and 
1µL of NuPAGE reducing agent (Invitrogen, Thermofisher scientific, MA, USA) and heated to 
80°C for 10 minutes before running on a NuPAGE 4-12% bis-tris gradient gel (Invitrogen, 
Thermofisher scientific, MA, USA). 
Gels were stained overnight in Coomassie brilliant blue and then destained in Coomassie 
destain solution until protein bands were clear (after around 6 hours). 
Stained gels were imaged using a Carestream image station 4000MM Pro (Carestream 
Molecular imaging, CT, USA) using Carestream MI SE software (v4.5.2). 
4.2.1.5 EmtinB in the aggregation assay  
The ability of EmtinB to participate in a metal swap with CuAβ1-42 was investigated using an 
aggregation assay developed by Meloni et al. [160]. For this aggregation, 25µM Aβ1-42 was 
incubated with 25µM CuCl2 (in tris buffer) and 300µM ascorbate in the presence of Apo-
EmtinB, Cu-EmtinB, Zn-EmtinB. Control samples were prepared with copper chloride, 
ascorbate, Aβ1-42 and PBS vehicle. All samples were 100µL reaction volumes and were 
incubated at 37°C for 72 hours at 300rpm shaking. 
Samples were made to 1.9mL with tris buffer and balanced in pairs to 0.000g before 
centrifuging at 21,000G in a Sorvall ultracentrifuge (Thermofisher scientific, MA, USA) in a 70.1 
TI rotor for one hour at 4°C. After centrifugation, the supernatant was discarded and the 
remaining pellets were resuspended in 20µL of NuPAGE LDS sample buffer (Invitrogen, 
Thermofisher scientific, MA, USA) containing 10% NuPAGE reducing agent (Invitrogen, 
Thermofisher scientific, MA, USA). 
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Samples were heated at 80°C for ten minutes, and then run on a NuPAGE 4-12% gradient gel 
(Invitrogen, Thermofisher scientific, MA, USA) for 15 minutes at 200 volts. Protein bands were 
visualised using Coomassie brilliant blue stain. 
4.2.1.6 Preparation of metal bound EmtinB dimer  
Metal-bound EmtinB was produced by incubating EmtinB with copper or zinc chloride. 100µL 
of EmtinB dimer stock (10mg/mL in PBS) was added to 10µL of saturated CuCl2 or ZnCl2 and 
990µL of sterile PBS. The reaction mixture was incubated at room temperature for 30 minutes 
to allow binding of metals to the EmtinB dimer. Unbound metals were removed from the 
EmtinB/metal mixtures using PD-10 columns (GE healthcare, UK). Concentration of EmtinB was 
measured using BCA assay and the required concentration added to the 100µL reaction 
volume to achieve 25µM EmtinB. 
4.2.2 EmtinB protection against H2O2-mediated toxicity 
The capacity of EmtinB to protect against H2O2 was investigated in 7DIV hippocampal cultured 
neurons. Cell cultures were prepared as per method 3.2.1. At 7 DIV subsequent media was 
removed and replaced with Neurobasal media (subsequent, less B-27 supplement) containing 
100µM H2O2 and 25µM EmtinB.  Cells were left to incubate for 24 hours at 5% CO2 and 37°C 
and cell viability assessed using an alamarBlue assay. 
4.2.3 EmtinB protection via LRP-mediated mechanism 
4.2.3.1 Inhibition of EmtinB action by RAP 
EmtinB has been shown to act through LRP receptors to promote neuronal survival in 
cerebellar granule neurons [94]. To determine if EmtinB mechanism of action is mediated via 
the LRP family of receptors, the receptor-associated protein (RAP), a specific inhibitor of LRP-
ligand binding, was used to block the potential interaction of EmtinB and LRP receptors. 
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RAP was added to 7DIV neurons and incubated for 30 minutes at 37°C and 5% CO2. After this 
incubation, EmtinB and CuAβ were added at 25µM. 
4.2.3.2 Knockdown of LRP1 and LRP2 using siRNA 
Primary cultured hippocampal neurons were transfected using siRNA (GE Dharmacon, 
Thermofisher scientific, MA, USA) and Dharmafect transfection reagent-1 (GE Dharamcon, 
Thermofisher scientific, MA, USA). All protocols were carried out as per the manufacturer’s 
instructions. In brief, siRNA was incubated at the desired concentration in subsequent media 
for five minutes at room temperature. Dharmafect transfection reagent was concurrently 
incubated in subsequent media at the desired concentration for five minutes. The transfection 
reagent and siRNA solutions were then mixed and incubated for a further 20 minutes at room 
temperature before adding the appropriate amount of subsequent media, pre-warmed to 
37°C. The siRNA and transfection reagent media were added to primary cultured neurons and 
these cultures were maintained at 37°C with 5% CO2 until cells were collected.  
According to manufacturer’s instruction, the recommended range for siRNA concentration is 
5-50nM and the recommended range for Dharmafect transfection reagent is 0.05% to 0.5%. As 
an initial pass the concentrations selected for transfection were 25nM siRNA and 0.25% 
Dharmafect transfection reagent. To determine effective temporal conditions for knockdown, 
cells were transfected with siRNA for LRP1 and LRP2 at 6DIV for 24 or 5DIV for 48 hours, with 
cells collected for protein analysis at 7DIV. Control cells were transfected with non-targeting 
siRNA for 48 hours.  
Subsequent experiments using 0.5% transfection reagent resulted in a loss of cell viability (data 
not shown) and, as such, 0.25% Dharmafect was used in all experiments. 
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4.2.3.3 siRNA knockdown of LRP1 and LRP2 in CuAβ model of toxicity 
For all experiments, except Figure 4.22, siRNA was added concurrently at 25nM with the 0.25% 
Dharmafect. For experiment Figure 4.22 siRNA for LRP1 and LRP2 were added concurrently at 
50nM and 0.25% Dharmafect. 
4.2.3.4 Western blotting for LRP1  
Western blotting was carried out as per the protocol described in general methods. 
Specifically, samples were run on NuPAGE 4-12% gradient gels (Invitrogen, Thermofisher 
scientific, MA, USA) at 200 volts for 20 minutes then blotted to nitrocellulose at 20 volts for 
one hour. Samples were blocked in western blot blocking solution (method 2.1.30) for 30 
minutes prior to primary antibody incubation. Primary LRP1 (1:1000, Rabbit anti-LRP1, L2170, 
Sigma, MO, USA) antibody was incubated in western blot blocking solution for 2 hours at RT or 
overnight at 4°C. Secondary antibody was Anti-Rabbit-HRP (Dako, Glostrup, Denmark) 
incubated at 1:1000 in western blot blocking solution for 1 hour at room temperature.   
4.2.3.5 Immunocytochemistry 
For immunocytochemistry, cells were fixed in 4% PFA for 15 minutes then washed three times 
in PBS-T (method 2.1.6) for ten minutes. Cells were incubated in primary LRP1 or LRP2 
antibody at 1:1000 in immuno diluent for one hour at room temperature or overnight at 4°C. 
Cells were washed three times for ten minutes each wash to remove primary antibody, then 
secondary anti-rabbit-594 antibody was incubated for one hour at room temperature in 
immuno diluent. Cells were washed a further three times for ten minutes before mounting in 
permafluor mountant (Dako, Glostrup, Denmark). Cells were allowed to dry overnight before 
imaging. 
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4.2.3.6 Microscopy 
Photographs were obtained using 40x and 60x objectives on an Olympus BX50 microscope 
using a Photomatrix Cool Snap HQ2 camera. 
4.3 Results 
4.3.1 Evaluation of EmtinB metal-binding properties 
Having established that EmtinB is a potent protective agent against CuAβ induced 
neurotoxicity in primary cultured hippocampal neurons (Chapter 3), the following experiments 
will attempt to determine whether this protective action is occurring through the same metal-
swap mechanism reported for MT2 and MT3 [159, 160]. In these studies, zinc bound MT2 
[159] and MT3 [160] were able to protect cultured neurons by swapping their endogenously 
bound zinc with the copper bound to Aβ. In the study by Chung et al. [159], it was 
demonstrated that MT could only undergo a metal swap with CuAβ when MT was in its zinc-
bound state (Zn7MT2). Attempts using other MT2 species, such as CuMT2 and apo-MT were 
unsuccessful, as was a carboxymethylated form (CM-MT), which is unable to bind metals. 
Notably, in the emtin studies detailed in Chapter 3, the peptides were not prepared in the 
presence of metals and the peptides are reported as being unmetallated in the literature [94], 
suggesting that emtin peptides have no endogenous metals to participate in a metal swap with 
CuAβ. Furthermore, the capacity of emtins to bind metals is unreported in the literature. To 
determine if the emtin mechanism of action in the CuAβ model of toxicity is, like MT, via a 
metal swap mechanism, it is important that the inherent, post synthetic metalation state of 
the EmtinB dimer and its capacity to bind copper and zinc, be conclusively established. As 
preliminary work showed EmtinB dimer to be the most efficacious, the EmtinB dimer will be 
the subject in this investigation. 
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4.3.1.1 EmtinB is not bound to copper or zinc when added to cell cultures 
EmtinB dimer was analysed via ICP-MS to determine the inherent copper and zinc 
concentration of the peptide prior to its addition to tissue culture experiments. ICP-MS 
analysis of EmtinB prepared in PBS at 1mg/mL showed no appreciable levels of either copper 
or zinc in the solution (Figure 4.1).  
4.3.1.2 EmtinB dimer can bind free copper and zinc 
To determine if the EmtinB dimer is capable of binding copper and zinc, free copper or free 
zinc was incubated with EmtinB, and the unbound metals removed using a desalting column. 
For this analysis, the column eluent was collected in ten 1mL fractions. Fractions were also 
collected from a control column where only free copper or free zinc was applied to the 
column. Fractions were analysed for protein content by BCA Assay and SDS-PAGE, and ICP-MS 
was used to determine copper and zinc content. 
Evaluation of copper-binding capacity of EmtinB  
As no antibody is currently available for the detection of EmtinB, detection of this peptide was 
carried out using BCA assay to quantify protein concentration and SDS-PAGE with Coomassie 
stain to confirm EmtinB presence by size comparison. Protein was present in column fractions 
1, 2 and 3 of the EmtinB/copper column, with the highest concentration of protein found in 
fraction 2 (Figure 4.2A; blue). In contrast, no protein was detected in the fractions from the 
copper-only control column (Figure 4.2A; orange).  
Analysis of EmtinB in EmtinB/copper column fractions using SDS-PAGE and subsequent 
Coomassie stain confirms the presence of protein in fractions 1 and 2. Protein was not 
detectable in fraction 3 by Coomassie stain, likely reflecting the lower sensitivity of protein 
staining with Coomassie compared with BCA/Spectroscopy detection techniques. Interestingly,  
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Figure 4.1 Dimeric EmtinB peptide contains no intrinsically bound copper or zinc   
EmtinB dimer was reconstituted in sterile PBS at 1mg/mL (335µM). Analysis for copper and zinc 
content was carried out by ICP-MS and showed that the 335µM EmtinB solution contained 
almost no copper (-0.04µM) or zinc (0.43µM). 
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Figure 4.2 EmtinB is detectable in fractions 1-3 of the EmtinB/Cu column but not in 
copper-only control column fractions  
EmtinB dimer (335μM) was co-incubated with a saturated (≈670µM) CuCl2 for 30 minutes. 
Unbound copper was separated from EmtinB dimer on a PD-10 column. Ten 1mL fractions 
(F1-F10) were collected and analysed for protein content using a BCA assay (A) and SDS-
PAGE/Coomassie stain (B). A) Protein was detected in fractions 1-3 of the EmtinB/Cu column. 
Fractions from a copper-only column contain no protein. B) A control sample of apo-EmtinB 
dimer is visualised at around 10kDa when resolved by SDS-PAGE. EmtinB was detectable in 
fractions 1 and 2 of the EmtinB/Cu column however, after incubation with copper, EmtinB in 
the column fractions had an apparent molecular weight of around 20kDa, twice the 
molecular weight of the freshly prepared EmtinB. 
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freshly prepared EmtinB migrated at approximately 10kDa on the gel, while EmtinB eluted 
from the copper-containing solution appeared to migrate at about 20kDa (Figure 4.2B).  
Copper content was investigated using ICP-MS. In the copper-only control column, no copper 
was detectable within the first 10 column fractions (Figure 4.3; orange) in accordance with the 
expectation that free copper ions are retained within the column beads. In column fractions 
collected from the EmtinB/Cu column, copper was detected in column fraction 1, 2, 3, with the 
highest concentrations in fraction 2 (Figure 4.3; blue).  
A direct comparison of protein and copper content from the EmtinB/copper column fractions 
shows that EmtinB and copper are found in the same fractions in the same molar quantities, 
suggesting that EmtinB has bound to the copper in a 1:1 ratio (Figure 4.4) 
Zinc-binding properties of EmtinB  
BCA analysis of the protein content in fractions from the EmtinB/zinc column showed that the 
EmtinB protein was present in fractions 1 to 3, with the highest concentration found in fraction 
2 (Figure 4.5A). This pattern is consistent with findings from the EmtinB with copper column, 
suggesting that EmtinB elutes within fractions 1-3 of the PD-10 column under these conditions. 
Analysis of the EmtinB/zinc column fraction by SDS-PAGE and Coomassie stain confirmed the 
presence of EmtinB in fractions 1-3 (Figure 4.5B). 
ICP-MS analysis showed that no zinc was detectable in the first 3 column fractions of the 
zinc-only control column (Figure 4.6), suggesting that free zinc does not elute in this buffer in 
the first three column fractions. However, zinc was found to be present in the later fractions, a 
finding consistent with the expected performance of the column. In column fractions collected 
from the EmtinB/Zn column, zinc was detected in column fraction 1, 2, 3, with the highest 
concentration in fraction 2 (Figure 4.6), suggesting that zinc is eluting together with EmtinB. 
The molar ratio of EmtinB peptide to zinc suggests a 1:1 binding ratio (Figure 4.7).   
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Figure 4.3 Copper is detectable in column fractions from copper incubated with EmtinB but 
not fractions from the copper-only column   
EmtinB (335µM) was incubated with copper chloride (640µM) for 30 minutes and applied to a 
PD10 purification column to separate unbound copper from EmtinB protein. Ten 1mL fractions 
(F1-F10) were eluted and analysed for copper content using ICP-MS. ICP-MS analysis of the 
fractions show a marked increase in copper concentration in fractions 1-3 of the EmtinB/copper 
column. In control fractions from a copper-only column, where no EmtinB is present, fractions 
show no increase in copper concentration. 
Chapter 4 – Results: Mechanism of EmtinB action 
Page | 109  
 
 
 
 
 
Figure 4.4 Copper concentration correlates with EmtinB presence or absence 
EmtinB (335µM) and copper were co-incubated for 30 minutes and any unbound copper was 
then removed using a PD10 purification column. Analysis of the ten 1mL fractions (F1-F10) 
collected from the column show protein present in fractions 1,2, and 3, with the highest 
concentration in fraction 2 (see Figure 4.2). The pattern of appearance is identical for copper 
concentration, with the highest concentration of copper in fraction 2 with lower amounts in 
fractions 1 and 3 (see Figure 4.3). A direct comparison of copper and EmtinB content in these 
fractions indicates that EmtinB and copper appear in the same fractions (F1-3) and are present 
in equal concentrations. 
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Figure 4.5 Protein is present in fractions 1-3 of the EmtinB/zinc column but not in zinc-only 
column fractions  
EmtinB (335µM) was incubated with zinc chloride (660µM) for 30 minutes and applied to a 
PD10 purification column to separate free zinc from EmtinB protein. Ten 1mL fractions were 
collected and analysed for protein content using BCA assay (A) and SDS-PAGE/Coomassie 
stain (B). A) Fractions from the zinc-only column show no protein present in any fraction, 
while protein was present in fractions 1-3 of the EmtinB/zinc column. B)  Apo-EmtinB dimer 
was resolved at around 10kDa. EmtinB incubated with zinc was present in fractions 1, 2, and 
3, and migrated at the same molecular weight as apo-EmtinB. 
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Figure 4.6 Zinc is present in fractions 1-3 from EmtinB/zinc column but is absent in fractions 1-
3 of the zinc-only control column   
EmtinB (335µM) was incubated with zinc chloride (660µM) for 30 minutes and applied to a PD10 
purification column to separate unbound zinc from EmtinB protein. ICP-MS analysis for zinc 
shows zinc present predominantly in fractions 1-3 of the EmtinB/zinc column, with lower 
amounts detected in fractions 4-10. By comparison, fractions from the zinc-only control column 
show no zinc in fractions 1-3, but have similar levels to the EmtinB/zinc column in fractions 4-
10, suggesting that free unbound zinc begins to be eluted around fraction 4-5. 
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Figure 4.7 EmtinB and zinc co-elute in fractions 1-3 of the EmtinB/zinc column 
EmtinB and zinc were co-incubated for 30 minutes before passing through a PD-10 column to 
remove unbound zinc. Ten 1mL fractions from this column were analysed for protein and zinc. 
Protein was found to be present in fractions 1, 2 and 3, with the highest concentration in 
fraction 2 (see Figure 4.6). Fractions 1-3 were also found to have the highest concentration of 
zinc (see Figure 4.7). A direct comparison of zinc and EmtinB in these fractions shows that EmtinB 
and zinc appear in the same fractions (1-3), and do so in a 1:1 ratio. 
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4.3.1.3 Metal bound EmtinB can undergo a metal swap with CuAβ 
Having established that EmtinB can bind both copper and zinc in a 1:1 ratio, the capacity of 
dimeric EmtinB to undergo a metal swap with CuAβ was evaluated in the context of preventing 
the formation of toxic copper-bound aggregates of Aβ. This experiment used the methods 
developed by Meloni et al. [160] in their investigation of MT3 neuroprotection against CuAβ, 
and used in subsequent work by Chung et al. [159] on MT2in a similar investigation. When 
copper is bound to Aβ, the resulting CuAβ complex forms an SDS-insoluble aggregate that does 
not resolve on an SDS-PAGE gel. However, the analogous ZnAβ aggregate is SDS soluble and 
can be observed using this method. Accordingly, Meloni [160] and Chung [159] have 
independently shown that when ZnMT undergoes a metal-swap with CuAβ, the SDS soluble 
ZnAβ aggregate is formed.  
To determine whether EmtinB can prevent the formation of an insoluble CuAβ aggregate, 
25µM EmtinB was incubated in Apo, zinc-bound or copper-bound form with 25µM CuAβ1-42 
for 72 hours. Following centrifugation to collect Aβ aggregates, the samples were resolved by 
SDS-PAGE and visualised using Coomassie stain. 
No SDS-soluble Aβ was observed in samples of CuAβ alone (Figure 4.8). Similarly, no SDS-
soluble Aβ was observed when CuAβ was incubated with Apo-EmtinB. Interestingly, when 
CuAβ was incubated with either Zn-bound or Cu-bound EmtinB, an SDS soluble Aβ aggregate 
was produced (Figure 4.8).   
4.3.1.4 EmtinB does not readily bind metals under cell culture conditions.  
While it was determined that metal bound EmtinB can prevent the formation of CuAβ 
aggregates in Chapter 3, EmtinB peptides, which were introduced into culture in metal free 
form, were found to protect against CuAβ. A possible explanation for this observation is that  
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Figure 4.8 EmtinB can undergo a metal swap with CuAβ, but only when bound to a metal 
The capacity of EmtinB to undergo a metal swap with CuAβ was evaluated using the 
aggregation assay developed by Meloni et al. [160], wherein copper-bound Aβ forms an SDS-
insoluble aggregate that is not resolvable by SDS-PAGE while zinc-bound Aβ forms an SDS-
soluble aggregate detected by SDS-PAGE, and subsequent Coomassie stain. CuAβ was 
aggregated at 37°C for 72 hours alone or in the presence of Apo, Zinc-bound or copper-bound 
EmtinB. The resulting aggregate was collected by ultracentrifugation and analysed by SDS-
PAGE/Coomassie stain. Consistent with expectations, CuAβ alone produced no soluble 
aggregate. Incubation of CuAβ with apo-EmtinB also produced no soluble aggregate, 
however, incubation of CuAβ with zinc-bound EmtinB produced an SDS soluble aggregate, 
indicating that zinc-bound EmtinB is able to undergo a metal swap with CuAβ. Incubation of 
CuAβ with CuEmtinB also appeared to produce an SDS-soluble Aβ aggregate, although 
potentially to a lesser degree than the ZnEmtinB.   
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EmtinB peptides become metallated by scavenging zinc or copper present in the cell culture 
environment.  
To investigate this, EmtinB was incubated in subsequent media and separated from free 
metals using a PD-10 column. Protein was present in fractions 1-3 of both the EmtinB/media 
column and the control media-only, as assessed by BCA analysis (Figure 4.9), consistent with 
protein being present in tissue culture media even in the absence EmtinB. However, higher 
protein levels observed in EmtinB/media columns compared with media-only columns suggest 
that EmtinB was present in these fractions. The presence of EmtinB was confirmed by SDS-
PAGE analysis, with media-associated proteins found at high molecular weight and a band, 
most likely EmtinB observed around 10kDa (Figure 4.10A, B). EmtinB was not observable in 
fractions 1 and 3, as would be expected based on biochemical protein analysis (Figure 4.10B), 
however as mentioned previously, Coomassie stain detection of proteins appears less sensitive 
than detection by BCA assay.  
ICP-MS analysis of copper and zinc levels in subsequent media found very low levels of both 
copper (0.02µM) and zinc (1.28µM), suggesting that there is very little metal available for 
EmtinB to scavenge (Table 4.1). Accordingly, low levels of both copper (0.27µM) and zinc 
(0.86µM) were found in EmtinB/media column fractions, which were similar to Cu (0.35µM) 
and Zn (0.62µM) levels in media-only fractions (Table 4.1).  
To compare EmtinB concentration to metal content, EmtinB dimer concentrations in the 
fractions were analysed by BCA assay. The EmtinB concentration of the fractions was 
calculated to be around 106µM based on an EmtinB dimer standard curve and assumed to be 
zero for the media-only control (Table 4.1). By comparison, zinc and copper concentrations 
were less than 1µM in both media-only control and EmtinB/media fractions (Figure 4.11). Thus 
it appears that the presence of EmtinB in the column fractions is not associated with an 
increase in copper or zinc concentration and therefore the EmtinB dimer is not scavenging 
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Figure 4.9 Protein concentration is higher in fractions from media with EmtinB added than 
fractions from media-only 
Neurobasal media was incubated for two hours in the presence or absence of 335µM EmtinB 
dimer, before removal of free metal ions on a PD-10 column. Ten 1mL fractions (F1-F10) were 
collected and their protein content analysed by BCA assay. Protein was detected in fractions 1-
3 of the EmtinB/media column, and was also detected in these same fractions (F1-F3) of the 
control media-only column. While protein was detected in fractions from both EmtinB/media 
and control columns, more protein was detectable in the EmtinB-containing column, suggesting 
EmtinB is present in these fractions.  
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Figure 4.10 EmtinB presence is confirmed by SDS-PAGE after incubation in media 
Column fractions, from a media-only control column (A) and an EmtinB/media column (B), 
which were previously analysed by BCA Assay (Figure 4.9), were analysed for protein content 
using SDS-PAGE and subsequent Coomassie stain to confirm the presence or absence of 
EmtinB. High molecular weight protein bands are observed in fractions 1, 2 and 3 of both the 
media-only control column, and the EmtinB/media column, confirming that protein is 
present in media prior to EmtinB administration. EmtinB dimer was detected at around 
10kDa in fraction 2 of the EmtinB/media column, which is comparable with the migration of 
apo-EmtinB dimer. 
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Column [Cu] [Zn] Estimated [EmtinB] 
Media-only 0.35 
 
0.62 
 
0µM 
EmtinB/Media 0.27 
 
0.86 
 
106µM 
Media (no column) 0.02 1.28 0µM 
 
 
Table 4.1 Copper and zinc are not enriched in EmtinB-containing fractions after incubation 
with media  
EmtinB dimer was incubated in Neurobasal media at 1mg/mL (335µM) for two hours before 
fractionating on a PD-10 column. Fractions 1 and 2, containing the highest protein content, 
were pooled and analysed for copper and zinc content by ICP-MS. A media sample not passed 
through a PD-10 column was also analysed to ascertain copper and zinc content prior to 
column fractionation. EmtinB content in these samples was estimated using BCA assay results 
for all fractions. Copper and zinc levels were below 1µM for both the media-only control 
fractions, and the EmtinB/media samples. EmtinB concentrations were estimated to be 0 and 
106µM, respectively, suggesting that EmtinB is not scavenging metals from the media. Analysis 
of media with no EmtinB present, and prior to column fractionation, shows that very little 
copper (0.02µM) and zinc (1.28µM) are available for scavenging.  
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Figure 4.11 EmtinB does not scavenge copper or zinc from Neurobasal media 
 EmtinB dimer was incubated in Neurobasal media at 1mg/mL (335µM) for two hours before 
fractionating on a PD-10 column. Fractions 1 and 2, containing the highest protein content, were 
pooled and analysed for copper and zinc content by ICP-MS. A media sample not passed through 
a PD-10 column was also analysed to give copper and zinc content prior to column fractionation. 
EmtinB content in these samples was estimated using BCA assay results for all fractions. Copper 
and zinc levels were below 1µM for both the media-only control fractions and the EmtinB/media 
samples. EmtinB concentrations were estimated to be 0 and 106µM respectively, suggesting 
that EmtinB is not scavenging metals from the media.   
                                                                                  Chapter 4 – Results: Mechanism of EmtinB action 
Page | 123  
 
significant amounts of either metal from the media used in these experiments. 
4.3.1.5 EmtinB does not scavenge metals from tissue culture media 
conditioned by cortical neurons. 
EmtinB was unable to scavenge metals from subsequent media, however ICP-MS analysis 
showed that unconditioned media has very little free metal. If EmtinB is scavenging metals to 
use in a copper swap mechanism with CuAβ, it must be scavenging them from metals derived 
from the cultured hippocampal neurons. To aid in the detection of EmtinB and metals, 
previous experiments have used high concentrations of EmtinB (1mg/mL; 335µM). This 
experiment aimed to determine if EmtinB could scavenge metals secreted from cells, and thus 
used 25µM EmtinB, a concentration found to be protective against CuAβ (see Chapter 3). 
Neurobasal media was conditioned for 24 hours on 7DIV cultured cortical neurons to 
potentially enrich the media in cell-secreted metals. The conditioned media was then 
incubated for a further 24 hours in the presence or absence of EmtinB before separating the 
protein from unbound metals on a desalting column. Unfractionated conditioned media 
samples were reserved for ICP-MS analysis to give a total metal content prior to fractionation. 
In this instance only the most concentrated fractions (fractions 1-3) were selected for BCA 
analysis as these fractions will contain the highest EmtinB content. BCA analysis of these 
fractions show protein in both EmtinB/conditioned media column fractions, and in conditioned 
media-only column fractions (Figure 4.12), which is consistent with previous findings of protein 
in media-only (See Figure 4.9). On average, total protein concentration was slightly higher in 
EmtinB/conditioned media fractions compared to conditioned media-only fractions (see Figure 
4.13). Subtracting average protein content of media-only fractions from the average protein 
content of EmtinB/conditioned media fractions gives an average difference of 105µg, which is 
roughly comparable in scale to the 75µg of EmtinB added in. Given that the slightly higher  
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Figure 4.12 Protein is detectable in fractions 1-3 of EmtinB/conditioned media columns and 
conditioned media-only columns  
Subsequent media was conditioned on 7DIV cortical neurons for 24 hours before EmtinB dimer 
was added at 25µM. EmtinB was incubated at 37°C with the conditioned media for a further 24 
hours (n=4). Control conditioned media, with no EmtinB added, was incubated identically 
(n=4). After incubation, samples were fractionated on a PD-10 column and ten 1mL fractions 
collected.  Fractions 1, 2 and 3 from each column were analysed for protein content by BCA 
assay. Protein was detected in fractions 1, 2 and 3 of both conditioned media-only and 
EmtinB/conditioned media columns. The pattern of elution was the same for both conditions, 
and similar concentrations were observed for both columns.  
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Figure 4.13 Protein is detectable in fractions 1-3 of EmtinB/conditioned media columns and 
conditioned media-only columns 
 Subsequent media was conditioned on 7DIV cortical neurons for 24 hours before EmtinB 
dimer was added at 25µM. EmtinB was incubated at 37°C with the conditioned media for a 
further 24 hours (n=4). Control conditioned media, with no EmtinB added, was incubated 
identically (n=4). After incubation, samples were fractionated on a PD-10 column and ten 1mL 
fractions collected. The protein-containing fractions from these columns, fractions 1, 2 and 3, 
were analysed for protein content by BCA assay. Average total protein was calculated for each 
PD-10 column and was slightly higher (0.105mg/mL) for EmtinB/conditioned media columns 
than conditioned media-only columns. 
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average concentration of protein in EmtinB/conditioned media columns roughly corresponds 
to the concentration of EmtinB added into the media, and that all previous experiments with 
these columns show EmtinB eluting in Fractions 1-3, it is likely that the EmtinB has passed 
through the columns and into the appropriate fractions.  Fraction 2, the most concentrated 
fraction, was used for ICP-MS analysis of copper and zinc. Copper and zinc levels were not 
significantly different between EmtinB/conditioned media and conditioned media-only (Figure 
4.14), suggesting that EmtinB dimers are not scavenging metals from conditioned media.  
The accumulated evidence suggests that EmtinB is able to undergo a metal swap with CuAβ 
but only under conditions where it was previously bound to another metal. For the metal swap 
mechanism to occur in culture, EmtinB must be able to scavenge metals from the cell culture 
model, yet no evidence has been found that suggests this is occurring in these experiments.  
While no definitive conclusion can yet be drawn from this work, the data do suggest that 
EmtinB could be working through a mechanism other than the metal-swap with CuAβ. 
4.3.2 EmtinB protection against H2O2 toxicity 
To investigate the ability of EmtinB to block H2O2-induced toxicity, EmtinB and 100µM H2O2 
were applied concurrently to 7DIV cultured neurons for 24 hours and subsequent cell viability 
assessed by alamarBlue assay. It was found that 25µM hydrogen peroxide, a standard 
concentration used in published studies, decreased cell viability compared with control 
neurons (Figure 4.15). EmtinB significantly ablated hydrogen peroxide toxicity, increasing cell 
viability of H2O2 treated neurons (Figure 4.15).  
At a higher H2O2 concentration of 100µM, which is highly neurotoxic, EmtinB had minimal 
protective effect (Figure 4.16). 
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Figure 4.14 Copper and zinc are not significantly increased in EmtinB-containing fractions after 
incubation in conditioned media  
EmtinB was incubated in conditioned media for 24 hours at 37°C (n=4). Control conditioned 
media, with no EmtinB added was incubated identically (n=4). Samples were fractionated on a 
PD-10 column and ten 1mL fractions collected. The fraction containing the most protein, 
fraction 2, was analysed by ICP-MS for copper and zinc. There was no significant difference in 
zinc content (t-test P=0.132) or copper content (t-test P=0.1904) between EmtinB/conditioned 
media fractions and conditioned media-only control fractions.  
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Figure 4.15 EmtinB has significant protective effect against H2O2 toxicity in cultured 
hippocampal neurons 
 Hippocampal neurons were treated with 25µM H2O2, either alone or concurrently with dimeric 
EmtinB (50µM). Cell viability was assessed after 24 hours using alamarBlue assay. Treatment 
with H2O2 alone (n=8) caused a decrease in cell viability compared with vehicle treated control 
neurons (n=8). Addition of 50µM EmtinB (n=8) to H2O2 treated cells resulted in a significant 
protective effect against H2O2-mediated toxicity. One-way ANOVA with Tukey post-test.  
# = significantly different to control neuron viability (p<0.05), *** = p<0.001. All data are means 
and SEM. 
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Figure 4.16 EmtinB has a small but significant protective effect against H2O2 toxicity in cultured 
hippocampal neurons 
Hippocampal neurons were treated with 100µM H2O2, either alone or concurrently with dimeric 
EmtinB (50µM). Cell viability was assessed after 24 hours using alamarBlue assay. Treatment 
with H2O2 alone (n=16) caused a severe and significant decrease in cell viability compared with 
vehicle treated control neurons (n=16). When EmtinB (n=16) was co-administered with H2O2, 
EmtinB improved the viability of H2O2 treated cells by a small but significant margin. One-way 
ANOVA with Tukey post-test. # = significantly different to control neuron viability (p<0.05), 
**** = p<0.0001. All data are means and SEM. 
                                                                                  Chapter 4 – Results: Mechanism of EmtinB action 
Page | 130  
 
4.3.3 LRP-mediated EmtinB protection against CuAβ1-42 
While the metal-swap mechanism and protection against H2O2 represent two possible 
mechanisms of EmtinB action, a further possibility is that EmtinB is working through LRP 
receptors to promote neuronal survival. Both MT2 and EmtinB have demonstrated an ability to 
act through LRP receptors to promote survival of cerebellar granule neurons against shock 
induced K+ withdrawal [94]. To determine if the protective action of EmtinB against CuAβ is 
mediated through the LRP family of receptors, the protective actions of EmtinB were tested in 
the presence of RAP, a commonly employed LRP ligand used as a competitive inhibitor to block 
LRP receptors, and siRNA directed specifically and LRP1 and LRP2. 
4.3.3.1 RAP abrogates EmtinB neuroprotective action in the CuAβ model 
of toxicity 
The capacity for EmtinB to protect cultured hippocampal neurons against CuAβ1-40 was tested 
in the presence or absence of 1µM RAP. Both EmtinB tetramers (Figure 4.17) and dimers 
(Figure 4.18) were able to significantly protect against CuAβ toxicity, increasing cell viability 
compared to CuAβ treated cells. In the presence of RAP, EmtinB was unable to effect this 
change and cell viability for this treatment was not significantly different from CuAβ alone 
(Figures 4.17 and 4.18). This suggests that inhibition of LRP receptors prevents EmtinB action. 
Importantly, RAP alone had no effect on the viability of CuAβ treated cells, suggesting that 
blocking EmtinB binding to LRP receptors prevents EmtinB action. 
4.3.3.2 LRP1 and LRP2 knockdown using siRNA 
MT2 has been shown to interact with LRP1 and LRP2 [89, 90, 94, 201]. Given that emtins are 
based on MT2 sequence, LRP1 and LRP2 represent logical investigative targets for the 
mechanism of EmtinB action. Ambjorn et al. [94] established that EmtinB is able to bind to 
LRP1 and LRP2 on the surface of neurons using an in vitro binding assay. To evaluate whether  
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Figure 4.17 Tetrameric EmtinB cannot protect against CuAβ1-40 toxicity in the presence of RAP  
EmtinB capacity to protect hippocampal neurons against CuAβ was investigated in the presence 
of RAP, an inhibitor of the LRP family of receptors. For inhibition of LRP, neurons were pre-
incubated with RAP for 30 minutes prior to addition of EmtinB and CuAβ. CuAβ1-40 added to 
cultured hippocampal neurons (n=6) caused a significant decrease in neuronal viability 
compared to vehicle treated neurons (n=3). 25µM tetrameric EmtinB (n=6) significantly 
improved the viability of CuAβ1-40 treated cells compared with cell treated with CuAβ1-40 alone 
(n=6); however, this protective capacity was completely abrogated in the presence of RAP (n=6). 
One-way ANOVA with Tukey post-test. # = significantly different to control neuron viability 
(p<0.05), * = p< 0.05, ** = p<0.01. All data are means and SEM. 
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Figure 4.18 Dimeric EmtinB cannot protect against CuAβ1-42 toxicity in the presence of RAP 
EmtinB protection against CuAβ1-42 was investigated in the presence of the LRP family agonist, 
RAP. Hippocampal neurons were pre-incubated with RAP (1µM) for 30 minutes prior to addition 
of EmtinB and CuAβ1-42. 25µM CuAβ1-42 (n=5) caused a significant decrease in neuronal 
viability compared with vehicle control treated neurons (n=4). 50µM EmtinB (n=4) improved the 
viability of 25µM CuAβ1-42-treated cells compared with neurons treated with CuAβ1-42 alone. 
In the presence of RAP (n=4), EmtinB was unable to protect neurons from CuAβ1-42 toxicity. 
RAP treatment in the absence of EmtinB (n=4) had no effect on the toxicity of CuAβ. One-way 
ANOVA with Tukey post-test. # = significantly different to control neuron viability (p<0.05), 
**** = p<0.0001. All data are means and SEM. 
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EmtinB acts specifically through these receptors to protect neurons against CuAβ-mediated 
toxicity, siRNA was used to knockdown expression of LRP1 and LRP2.  
To ensure that the siRNA knockdown had no effect on cell viability, an alamarBlue assay was 
carried out prior to the collection of treated neurons. Treatment of cultured neurons with 
siRNA (LRP1, LRP2, or non-targeting) for either 24 or 48 hours did not alter cell viability 
compared to untreated control neurons (Figure 4.19), showing that these conditions are not 
detrimental to cultured hippocampal neurons. 
Levels of LRP1 in treated neurons were investigated using both western blotting and 
immunocytochemistry (ICC). Analysis of treated cells by western blot showed an observable 
decrease in LRP1 levels in cells treated with siRNA for 24 or 48 hours compared with both 
untreated cells and cells treated with non-targeting siRNA (Figure 4.20 A). This depletion of 
LRP1 levels was confirmed by immuno-labelling (Figure 4.20 B). As expected, the prolonged 
siRNA treatment (48 hours) resulted in a greater degree of LRP1 knockdown.  
Unfortunately, basal LRP2 was not detectable by either western blot or ICC in cultured 
hippocampal neurons, which are known to express LRP2 [85]. Two different antibodies were 
used, including one reported in prior publications. Accordingly, it was not possible for this 
study to evaluate the effect of the siRNA on LRP2 levels. However, this siRNA has been used in 
other studies carried out by Dr Lila Landowski (School of Medicine, UTAS).  In this work, 
Landowski at al. [202] used a growth-cone turning assay to demonstrate that LRP2 siRNA 
induced a functional knockdown in neurons derived from dorsal root ganglia [203], see  
Figure A1, Appendix A. For the purposes of this work, it will be assumed that the LRP2 siRNA 
was equally successful at knocking down LRP2. 
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Figure 4.19 Knockdown of LRP1 and LRP2 using 25nM siRNA has no effect on cell viability 
Hippocampal neurons were maintained in culture to 5DIV and 6DIV before administration of 
25µM siRNA for 48 or 24 hours, respectively. Neurons treated with LRP1 or LRP2 siRNA showed 
no difference in cell viability compared with control untreated neurons after 24 or 48 hours 
incubation.  Similarly, treatment of neurons with non-targeting siRNA for 48 hours did not cause 
any difference in cell viability compared with either control neurons or neurons treated with 
targeted siRNA for LRP1 or LRP2. One-way ANOVA with Tukey post-test. All data are means and 
standard error of the mean (SEM). 
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Figure 4.20 LRP1 levels are successfully decreased using 25µM LRP1 siRNA  
A) Hippocampal neurons were treated with 25µM LRP1 or non-targeting siRNA for 24 or 48 
hours. LRP1 levels were analysed using western blot (A) and immunocytochemistry (B). A) 
Western blot shows a marked decrease in LRP1 protein in cells treated for 24 or 48 hours 
with LRP1 siRNA. No decrease in LRP1 protein is observed after 48hrs treatment with non-
targeting siRNA. B) LRP1 siRNA treated cells showing a considerable decrease in LRP1 positive 
staining in 24hr treated (Figure B-iii) and 48hr treated (Figure B-ii) hippocampal neurons 
compared with non-targeting siRNA treatment (Figure B-i). Figure B-ii shows untreated cells 
with no primary antibody to illustrate levels of non-specific staining. Scale bar is 25μm.   
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4.3.3.4 Effect of combined LRP1 and LRP2 knockdown on EmtinB 
protection of neurons 
Earlier results showing the successful blocking of EmtinB protective action by RAP (see Figures 
4.17 and 4.18), suggesting the involvement of the LRP family of receptors in EmtinB 
mechanism of protection against CuAβ. To determine if LRP1 and LRP2 are involved in EmtinB-
mediated neuronal protection, primary cultured hippocampal neurons were treated with 
siRNA to both LRP1 and LRP2 for 48 hours. Control cells were left untreated. Control and siRNA 
knockdown cells were treated with vehicle control, 25µM CuAβ1-42, or 25µM CuAβ1-42 co-
administered with 25µM EmtinB dimer (Figure 4.21), or 50µM EmtinB dimer (Figure 4.22). In 
both experiments, knockdown of siRNA has no effect on EmtinB efficacy with EmtinB dimer 
exerting the same protective effect against CuAβ1-42 regardless of whether the cells had been 
treated with siRNA or not (Figure 4.21, Figure 4.22). 
4.3.3.5 Effect of LRP1 and LRP2 knockdown on EmtinB interaction with 
cultured hippocampal neurons 
Given that MT2 has previously been shown to interact with cultured neurons via an LRP-
mediated mechanism [80, 90, 94, 204], EmtinB interaction with hippocampal neurons was 
investigated using ICC. Biotinylated dimeric EmtinB was administered to neurons at 25µM and 
incubated for 30 minutes or 3 hours. For control cells, no EmtinB was added. Biotinylated 
EmtinB was detected using ICC directed at the biotin tag. EmtinB was identified in the culture 
by its punctate appearance (Figure 4.23, Bii and Biii), which was not observable in the control 
cells (Figure 4.23, Aii).  EmtinB was observed to be associated with cells 30 minutes after 
administration (Figure 4.23, Biii), although whether EmtinB puncta are at the surface bound to 
the membrane or internalised in vesicles was not established. Furthermore, EmtinB was 
observable in the cytosol of neurons after 3 hours incubation (Figure 4.23, Cii and Ciii), 
suggesting that EmtinB is rapidly internalised by neurons via an as yet unknown mechanism   
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Figure 4.21 Knockdown of LRP1 and LRP2 has no effect on EmtinB protection against CuAβ1-42 
Cultured hippocampal neurons either received 25nM siRNA to both LRP1 and LRP2 for 48 hours 
(LRP-) or were left untreated as control neurons (LRP+). At 7DIV control LRP+ and LRP-siRNA-
treated neurons were treated with; vehicle control, 25µM CuAβ1-42, or 25µM CuAβ1-42 in 
conjunction with 25µM dimeric EmtinB. CuAβ1-42 caused reduced neuronal viability in both 
control LRP+ and LRP- neurons compared with vehicle control neurons. 25µM dimeric EmtinB 
improved cell viability relative to CuAβ1-42-only treatment in both LRP+ and LRP- neurons cells. 
One-way ANOVA with Tukey post-test. # = significantly different to control neuron viability 
(p<0.05), **** = p<0.0001. All data are means and SEM.
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Figure 4.22 LRP1/LRP2 knockdown using 25nM siRNA does not abrogate EmtinB protection 
against CuAβ1-42 toxicity  
EmtinB action against CuAβ1-42 was tested in both siRNA treated neurons and control 
neurons. Hippocampal neurons were either left untreated (LRP+) or treated with 25nM LRP1 
and LRP2 siRNA for 48 hours (LRP-) before application of; vehicle control, 25µM CuAβ1-42, 
or 25µM CuAβ1-42 co-administered with 50µM EmtinB. CuAβ1-42 reduced neuron viability 
relative to vehicle control neurons and there was no significant difference in CuAβ-42 toxicity 
between LRP- siRNA treated and LRP+ control cells. EmtinB improved the viability of CuAβ1-
42 cell relative to CuAβ alone however there was no difference in EmtinB ability to protect 
against CuAβ1-42 in LRP- siRNA treated neurons compared with control LRP+ control 
neurons. One-way ANOVA with Tukey post-test. # = significantly different to control neuron 
viability (p<0.05), *** = p<0.001. All data are means and SEM. 
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Figure 4.23 EmtinB is taken up into cells within 3 hours of administration  
EmtinB, labelled with biotin, was administered to 7DIV cultured hippocampal neurons and fixed at 30 minutes and three hours. To determine basal 
fluorescence of hippocampal neurons, untreated cells were fixed at 30 minutes. Fixed neurons were immunostained for the cytoskeletal protein tau (green) 
and for biotinylated EmtinB (red). Untreated neurons (Ai) have minimal autofluorescence in the red channel (Aii , Aiii), while at 30 minutes post treatment 
(Bi) the biotinylated EmtinB is visible in punctate staining either at the cell surface or within the cell (Bii, Biii; highlighted by arrow). At three hours post EmtinB 
administration (Ci), diffuse EmtinB staining is observed in the cytoplasm (Cii, Ciii; highlighted by arrow). Scale bar is 25µm. 
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This mechanism could potentially still be a receptor-related mechanism or perhaps, as the 
protein is cationic (+5.7 at pH7), could be a mechanism based on the selective uptake of 
cationic molecule via interaction with the negatively charged cell membrane [205].  To 
determine if siRNA knockdown of LRP1 and LRP2 affected EmtinB internalisation, neurons 
were treated with 25nM siRNA to both LRP1 and LRP2 for 48 hours. Control cells were left 
untreated.  Biotinylated dimeric EmtinB (25µM) was added to neurons for 30 minutes or three 
hours before fixing in 4% paraformaldehyde and EmtinB visualised using ICC. EmtinB puncta 
were associated with neurons in both siRNA treated and control cells (Figure 4.24ii, i) with no 
observable difference. Similarly, after three hours incubation, EmtinB was evident in the 
cytosol of neurons which had been siRNA treated (Figure 4.24iv) and also in the cytosol of 
control cells (Figure 4.24iii), suggesting that siRNA knockdown of LRP1/2 has no effect on 
uptake of EmtinB into hippocampal neurons or that, in these experiments, despite siRNA 
knockdown, there is still sufficient LRP1 and/or LRP2 expressed to enable internalisation of 
EmtinB.  
As the 25nM siRNA treatment did not prevent EmtinB action, the siRNA knockdown was 
repeated using the maximum siRNA concentration recommended in the manufacturer’s 
instructions; 50nM. Consistent with previous work, CuAβ1-42 produced a decrease in cell 
viability relative to vehicle control neurons in both untreated and siRNA treated cells 
(Figure 4.25A). EmtinB (50µM) improved the neuronal viability of CuAβ1-42 treated neurons 
relative to cell treated with CuAβ alone (Figure 4.25A). This increase was observed equally in 
both untreated and siRNA treated cells, suggesting that LRP1/2 are not integral to EmtinB 
mechanism of action. Western blot analysis for LRP1, in control and 50nm siRNA-treated cells, 
showed a marked decrease in LRP1 levels in the 50nm siRNA treated cells compared with 
untreated control neurons (Figure 4.25B), indicating that the LRP1 is significantly decreased in 
these cells with no impact on EmtinB protective capacity. 
  
Figure 4.24 siRNA knockdown of LRP1 and LRP2 has no effect on EmtinB uptake into neurons   
EmtinB, labelled with biotin, was administered to control and LRP1/2 siRNA treated cultured hippocampal neurons. Cells were fixed after 30 minutes and 
three hours and hippocampal neurons were immunostained for Tau (green) and biotinylated EmtinB (red). Nuclei were stained with nuclear yellow (cyan). 
30 minutes after EmtinB administration, both control and siRNA treated cells had observable puncta (i, ii; highlighted by arrows). At three hours post 
administration, both control and siRNA treated cells show more diffuse EmtinB staining in the cytosol (iii, iv; highlighted by arrows) suggesting successful 
EmtinB uptake. Scale bar is 25µm. 
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Figure 4.25 EmtinB efficacy is not diminished by siRNA knockdown of LRP1 and LRP2 
High concentration (50nM) siRNA was used to produce a substantial reduction in LRP1 and 
LRP2 in 7DIV hippocampal neurons. A) Incubation of siRNA-treated and control cells with 
25μM CuAβ1-42 significantly reduced neuronal viability relative to vehicle control cells. Co-
incubation of the CuAβ1-42 with 50μM dimeric EmtinB improved cell viability compared with 
CuAβ1-42 alone, and this recovery was equally apparent in control and siRNA treated 
neurons. One-way ANOVA with Tukey post-test. # = significantly different to control (p<0.05), 
*** =p<0.001. B) Western blot of control and siRNA treated cells shows considerable 
knockdown of LRP1 in siRNA treated neurons.  
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4.4 Discussion and conclusions 
This chapter investigated the capacity of EmtinB to protect against CuAβ via three main 
mechanisms; metal swap with CuAβ, protection against reactive oxygen species, and 
protection via an LRP-mediated mechanism. It was established in this work that EmtinB was 
not able to undergo a metal swap with CuAβ1-42 in its metal-free form (apo), but could 
prevent the formation of insoluble CuAβ1-42 when metal-bound. Apo-EmtinB was able to 
protect hippocampal neurons against H2O2-induced toxicity and, additionally, LRP receptors 
were implicated in mediating EmtinB protection against CuAβ since the LRP competitive 
inhibitor, RAP, blocked EmtinB action. However, experiments using siRNA ablation of LRP1 and 
LRP2 failed to provide further evidence for the role of these receptors. These findings 
collectively provide mechanistic insight into the protective capacity of emtins.   
4.4.1 EmtinB metal swap 
The capacity for EmtinB to bind key biological metals such as, copper and zinc, has not 
previously been described. MT2 is capable of binding seven zinc ions, or around 12 copper 
ions, and this is mediated through highly conserved cysteine residues (cys, C), which constitute 
a large proportion (around 30%) of all amino acid residues. In the MT2 protein, each zinc ion 
(Zn2+) is coordinated in a tetrahedral geometry by four cysteine residues, while copper is 
bound as Cu+ in a trigonal geometry via three cysteine residues [206]. In emtins, a majority of 
these cysteine residues have been replaced by serine to prevent self-aggregation of the 
peptide [185] and, consequently, for EmtinB, there are only two cysteine residues in each 
peptide chain available for metal binding (see Figure 1.7). Based on this decrease in cysteine 
residues available for metal binding, EmtinB likely has a lower metal-binding capacity than 
native MT2.   
Consistent with this hypothesis, this study found that dimeric EmtinB can bind copper or zinc 
at a 1:1 ratio in vitro. This is in accordance with the presence of 4 cysteine residues, which 
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presumably supports a single metal binding site. Based upon these data, copper-bound, 
zinc-bound and metal free dimeric EmtinB were evaluated for their capacity to prevent CuAβ1-
42 forming an SDS-insoluble aggregate. While apo-EmtinB was unable to prevent CuAβ1-42 
from forming an insoluble aggregate, zinc-bound EmtinB did prevent the formation of an SDS-
insoluble CuAβ1-42 aggregate, suggesting that Zn-EmtinB can undergo a metal swap with CuAβ 
while Apo-EmtinB cannot. Although the current work did not formally prove the existence of a 
metal swap between EmtinB and CuAβ1-42 in vivo, this is consistent with our previous studies 
with MT2, where zinc-bound MT2 was able to undergo a metal swap with CuAβ to promote 
the formation of SDS-soluble ZnAβ instead of the SDS-insoluble CuAβ aggregate, while apoMT2 
and carboxymethylated MT2 were unable to participate in such a mechanism [159]. 
One interesting discrepancy is the action of Cu-EmtinB, which also prevented the formation of 
an SDS-insoluble CuAβ aggregate. In contrast to this, native copper-bound MT2 is unable to 
prevent the formation of insoluble CuAβ aggregates. It is not clear how Cu-EmtinB mediates 
this change in CuAβ, however the answer may lie in the copper binding capacity of EmtinB and 
the specific conformation of Cu-EmtinB.  
The metal-binding capacity of MT2 is limited seven divalent metal ions, such as Zn2+. However, 
MT can bind a larger complement of monovalent metal ions, with studies showing that MT 
binds around 12 (and up to 15) copper ions [207]. These copper ions are bound by bridging 
sulphur atoms in two clusters, an S11Cu6 cluster in the β-domain, and an S9Cu6 cluster in the α-
domain [207]. This indicates that the four cysteine residues present in dimeric EmtinB could 
potentially support at least two copper ions. Furthermore, EmtinB was found to dimerise when 
bound to copper (Figure 4.2), unlike apo and Zn-EmtinB, which maintain a monomeric 
structure (Figure 4.5). It is possible that this conformational difference may alter the metal 
binding capacity of EmtinB, and/or alter the affinity of EmtinB for copper, such that it can bind 
additional copper and subsequently remove copper from CuAβ. Interestingly, there is some 
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evidence for this as EmtinB was found to bind metals at a higher than 1:1 ratio when incubated 
with both copper and zinc at the same time (data not shown). This phenomenon remains to be 
fully tested and would be an interesting theory to explore in future studies.   
Notably, in Chapter 3 studies it was found that EmtinB, when prepared and applied in apo 
form, was protective against CuAβ1-42 toxicity. Given that only metal-bound EmtinB can 
prevent the formation of SDS-insoluble CuAβ aggregates, the ability of EmtinB to “scavenge” 
metals from media was evaluated. There was no evidence of metal scavenging by EmtinB from 
either basal cell culture medium or neuron-conditioned culture medium.  
While EmtinB is clearly not bound to metals after incubation in media or conditioned media, 
this may be due to a lack of available copper and zinc in this media. Basal media (Table 4.1) 
and conditioned media (data not shown), were analysed for copper and zinc by ICP-MS but the 
results were not definitive. In basal media samples, copper levels appeared higher in media 
after column fractionation than before, suggesting that copper detection is impeded in whole 
media. This indicates a potential non-spectral interference created by a factor in the media, 
which is not present after fractionation of the media on a PD-10 column. This interference 
might prevent the accurate detection of copper in media samples. This issue may not affect 
zinc detection, as zinc levels in whole media are higher than total zinc detected in fractions. As 
we do not have an independent method of determining zinc levels in media, it is possible that 
zinc detection is also being depressed, however, the concentration of zinc in whole media 
determined by ICP-MS analysis is consistent with the concentration reported by the 
manufacturer (0.674µM; Technical resources, Thermofisher scientific, MA, USA).  
Ostensibly, these results would indicate that EmtinB is not acting via a metal swap mechanism 
in cell culture experiments, however the data do not exclude the possibility that apo-EmtinB 
might bind metals when applied to cultured neurons. In adult brain, zinc concentration is 
approximately 200µM  [208, 209] with about 90% of this existing as metalloproteins [210]. 
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Extracellular zinc concentrations in adult brain are estimated to be around 1µM, suggesting 
that free zinc is not highly available [211]. However, there are some areas of the brain where 
ionic zinc has been detected in relatively high amounts [210]. Historically, ionic zinc has been 
detected in the brain using Timm’s sulfide-silver staining method, a method which is not able 
to detect zinc which has been complexed by sequestration proteins [210, 212]. Using this 
histochemical stain reveals large amounts of chelatable zinc in the cerebral cortex and limbic 
region of the brain, including the hippocampus, and this zinc is localised in the presynaptic 
vesicles of neurons [210]. These neurons are termed zincergic neurons and there is evidence 
that zincergic neurons release sequestered zinc from presynaptic terminals in a calcium and 
impulse-dependent manner [209]. 
Zincergic neurons are a subset of glutamatergic neurons and three glutamatergic pathways are 
evident in the hippocampus. Neurons projecting from the entorhinal cortex to the 
hippocampus via the perforant path, dentate granular neurons projecting to the CA3 
pyramidal neurons via mossy fibres, and CA3 pyramidal neurons projecting to the CA1 
pyramidal neurons via the Schaffer collaterals, are all positive for zinc via Timm’s method 
[209]. Of these pathways, zinc is most prominent in the synaptic boutons of the mossy fibres 
[209, 210]. Stimulation of these fibres prompts the release of zinc from pre-synaptic vesicles, 
resulting zinc release into the synaptic cleft, with estimated concentration ranging as high as 
300µM [210]. While this concentration estimate is contentious, with other studies reporting 
zinc-concentration estimates from nil to 100µM [213, 214] most studies appear to be on 
agreement that chelatable zinc is produced at the synaptic cleft of zincergic neurons. Given the 
presence of zincergic neurons in the hippocampus, one possibility in relation to this 
investigation is that EmtinB is scavenging free zinc from zincergic neurons in the hippocampal 
neuron cultures, which have been demonstrated to contain glutamatergic neurons [215].  
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With high local concentrations of synaptic zinc in culture, EmtinB could potentially scavenge 
zinc released at the synaptic cleft, however there is no evidence to prove or disprove this in 
the current work.  Furthermore, this concept is difficult to investigate as EmtinB is rapidly 
taken up in culture (see Figure 4.25), making isolating the EmtinB for further analysis without 
disrupting the protein-metal bond challenging. To investigate this theory, one could use 
biotinylated EmtinB and incubate this with hippocampal neurons. Cells could then be 
homogenised via trituration and EmtinB removed from the lysate by affinity purification using 
the biotin tag, and resulting metal content measured by ICP-MS.   
In conclusion, EmtinB can undergo a metal swap with CuAβ and can prevent the formation of 
an SDS-insoluble CuAβ aggregate, but this study has been unable to find evidence that this is 
occurring in the cell culture model of CuAβ toxicity. As such, the metal swap mechanism 
cannot be confirmed as the EmtinB mechanism of action. 
4.4.2 EmtinB protection against H2O2 toxicity  
CuAβ has been demonstrated to produce H2O2 and then subsequent downstream radicals by 
Fenton and Harber-Weiss reactions [64, 216-218]. Catalase, the enzyme that catalyses the 
decomposition of H2O2, has been shown to decrease the toxicity of CuAβ in culture, suggesting 
that intervention to prevent H2O2-induced toxicity and the subsequent production of free 
radicals could be a viable mechanism of protection against CuAβ [121].  
In this work, dimeric EmtinB was shown to protect cultured hippocampal neurons against 
H2O2-mediated toxicity, however it is not known if this occurs through direct scavenging 
activity. Notably, EmtinB protection against H2O2 is inconsistent with past work with MT2. 
While MT2 has a demonstrated an ability to scavenge free radicals [57], it was unable to 
protect cultured cortical neurons against H2O2 toxicity [219]. Furthermore, MT2-protective 
action against free radicals is mediated by the conserved cysteine residues in the MT2 
sequence that form the disulphide bonds responsible for radical quenching. In EmtinB, a 
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majority of these cysteine residues have been substituted for serine, and it would therefore be 
predicted that EmtinB is likely to demonstrate lessened oxidant scavenging capacity than 
native MT. These factors call into question whether this protective action of EmtinB is via free 
radical scavenging or some other mechanism. To elucidate this, future studies should 
undertake to investigate whether EmtinB is capable of scavenging radicals downstream of 
H2O2 thought to mediate the toxic effect of H2O2 - for example hydroxyl radicals. 
In conclusion, while EmtinB clearly works to protect cultured cells against H2O2, whether this 
protective effect is a result of free radical scavenging or some other mechanism remains to be 
elucidated.  
4.4.2 LRP-mediated EmtinB protection   
Emtins and MT2 have been shown to act through cell surface receptors, LRP1 and LRP2, to 
activate both MAPK and PI3K pathways, and this activation was associated with neuronal 
survival after insult [94]. It is therefore possible that EmtinB mechanism of action in culture 
against CuAβ is a not a result of EmtinB interacting directly with CuAβ, but a result of EmtinB 
acting on neurons to promote neuronal survival via LRP receptors.  
Initial investigations into LRP involvement in EmtinB protective action utilised the 39kD 
receptor associated protein (RAP), a specific inhibitor of the low density lipoprotein receptor 
(LDLR) family [220], of which LRP1 and LRP2 are members. In this work, RAP prevented EmtinB 
action against CuAβ toxicity in cultured neurons (see Figures 4.19 and 4.20). While RAP has 
also been reported to interact with, and bind to, both Aβ40 and Aβ42 peptides [221], in this 
study RAP treatment alone had no effect on the toxicity of CuAβ, suggesting that RAP-
mediated decrease in CuAβ toxicity results from an interaction of EmtinB with a member of 
the LDLR family of receptors.  
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Subsequent investigation into this mechanism using siRNA knock-down of LRPs 1 and 2 
showed that combined knockdown of LRP1 and LRP2 had no effect on EmtinB action (see 
Figures 4.23 - 4-27).  
The results of this investigation raise two main possibilities. Firstly, the knockdown of LRP1 and 
LRP2 may not be sufficient to impede EmtinB action. While LRP1 appeared to be significantly 
reduced when analysed by western blot, LRP2 knockdown could not be established. Future 
studies could address this by using qPCR to quantify LRP2 knockdown rather than protein 
detection techniques, and, additionally, by using a functional test for LRP knockdown, such as 
neurite extension, in response to known stimulators. A complimentary evaluation of receptor 
activation would be examination of downstream targets of receptor activation.  
Secondly, it may be that EmtinB is not acting through LRP1 or LRP2 in this model, but through 
another member of the LDLR family. RAP is a known inhibitor of both LRP1 and LRP2, but has 
also been shown to bind strongly to the very-low-density-lipoprotein (VLDL) receptor [222] and 
Apolipoprotein2 (ApoER2) receptor [223]. The VLDL receptor is found in a wide variety of body 
tissues, including the brain, where it is found predominantly in the cortex and cerebellum 
(reviewed in [224]) and has been shown to play a role in neuronal migration and signal 
transduction [225]. ApoER2, by comparison, is found almost exclusively in the CNS and is 
expressed in the cerebellum, cortex, olfactory bulb and hippocampus, and plays a role in 
neuronal signalling (reviewed in [224]). The role of ApoER2 in the hippocampus appears to be 
of greater import than VLDLR, as ApoER2 KO mice have more pronounced hippocampal 
defects and greater deficit in hippocampal long term potentiation (LTP) than VLDLR deficient 
mice [224, 226]. These LDL family receptors may represent a viable alternative receptor for 
EmtinB action.  
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Conclusion 
Despite intensive investigation, a definitive mechanism of action for EmtinB in the in vitro 
CuAβ model of toxicity was not determined. There is evidence that dimeric EmtinB can 
undergo a metal swap with CuAβ, protect hippocampal neurons against hydrogen peroxide 
toxicity, and potentially act through members of the LRP-family of receptors to promote 
neuronal survival. As EmtinB appears to be capable of working via more than one mechanism 
against CuAβ-associated toxicity, it could be acting synergistically to address CuAβ toxicity 
through two, or more, of these mechanisms.  
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Chapter 5 – EmtinB protection in a small animal model of 
Alzheimer’s disease  
5.1 Introduction 
The ability of MT to protect against multiple mechanisms of Aβ toxicity in vitro suggests that it 
might be a potential modulator of disease progression in AD.  However, native metallothionein 
has minimal brain uptake when administered peripherally [162].  For that reason, this thesis 
has explored the potential of metallothionein-derived synthetic peptides, Emtins, to act as 
neuroprotective agents.  In previous chapters, EmtinB demonstrated significant protection 
against CuAβ-induced neurotoxicity in cell culture and, furthermore, the ability of tetrameric 
EmtinB to cross the BBB following peripheral administration in vivo has been reported [184]. 
The work reported in this chapter investigates the effect of EmtinB upon amyloid plaque 
deposition and cognitive impairment was investigated in the APPswe/PS1ΔE9 mouse model of 
AD. 
This APPswe/PS1ΔE9 mouse model is an extensively used model of AD and incorporates both 
the Swedish familial double mutation (K670N, M671L) in APP (APPswe) and the ΔE9 exon 
deletion in presenilin 1 (PS1ΔE9), both of which are associated with early onset AD [227]. The 
Swedish familial APP mutation causes altered processing of APP and, subsequently, an increase 
in Aβ1-40 and 1-42 peptide fragments [228]. Mouse models with this APP mutation show Aβ 
accumulation and amyloid pathology [228].  The ΔE9 mutation in PS1 exacerbates this by 
promoting the formation of the Aβ1-42 peptide fragment, which, in vivo, is shown to be more 
prone to aggregation than the Aβ1-40 fragment [228].  
Like other animal models of AD, the APPswe/ PS1ΔE9 mouse model does not fully recapitulate 
all of the pathological aspects of Alzheimer’s disease as there is no frank loss of neurons [229]; 
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however, they do display a variety of clinically relevant symptoms of AD [229]. In this model, 
APP levels are around two to four times higher than in non-transgenic mice [228]. Higher APP 
levels, along with mutant PS1, promote the early formation of plaques and deposition occurs 
in these mice at around six to seven months of age with abundant plaques observed in both 
the hippocampus and cortex by nine months of age [228]. Apart from early plaque deposition, 
APPswe/ PS1ΔE9 mice also exhibit memory deficits around 6 months of age, mild neuritic 
abnormalities, loss of neuronal activity related to plaque load, and activated astrocytes and 
microglia associated with plaques [229]. As such, the APPswe/ PS1ΔE9 model of AD represent 
a valuable device for testing therapeutic approaches, particularly those targeting plaques and 
inflammation [229].  
To systematically evaluate the potential beneficial effects of EmtinB in APPswe/ PS1ΔE9 mice, 
this study tested 3 key hypotheses: 
1) That EmtinB treatment will reduce the accumulation of Aβ in the APPswe/ PS1ΔE9 
mouse brain, 
2) That EmtinB will modify glial activation in the brains of APPswe/ PS1ΔE9 mice, and 
3) That EmtinB will preserve synaptic architecture, correlating with improved 
cognitive outcomes, in APPswe/ PS1ΔE9 mice.  
 
Firstly, it will be determined if EmtinB can act to decrease amyloid accumulation in the 
APPswe/PS1ΔE9 mouse brain. To determine if Aβ levels are altered in EmtinB treated mice, 
plaque load, soluble Aβ1-42 levels and APP levels will be determined in treated and control 
mice. As EmtinB and MT are known to act through LRP receptors, and LRP receptors are also 
known mediators of Aβ clearance, LRP levels will also be assessed. 
Chapter 5 – Results: EmtinB action in an animal model of AD 
Page | 158  
 
Secondly, glial activation will be investigated. Aβ is known to increase activation of both 
astrocytes and microglia. This activation is linked with inflammation. To assess if EmtinB is able 
to affect glia, IBA1 and GFAP protein will be assessed for changes in microglia and astrocytes 
respectively. 
Lastly, Aβ has been shown to interrupt long term-potentiation in culture and hippocampal 
brain slice. EmtinB has previously been shown protect LTP in the face of Aβ insult (Paul Adlard, 
Florey Institute, Vic, AUS, unpublished data). Changes in LTP have been demonstrated to 
coincide with changes in synaptic proteins. Potentially, then, EmtinB could be modulating 
synaptic changes in the hippocampus to improve memory deficits in APPswe/PS1ΔE9 mice. To 
investigate synaptic changes, both synaptophysin and PSD95 levels will be analysed in 
hippocampal enriched tissues from EmtinB treated and control APPswe/PS1ΔE9 mice.  
This chapter will explore changes in cognitive outcomes, and histological and biochemical 
characteristics, in the APPswe/PS1ΔE9 mouse model of AD in response to dimeric EmtinB 
administration.   
5.2 Methods 
5.2.1. Injection and gavage of B6 mice with EmtinB dimer 
To determine the most appropriate method of EmtinB administration for the EmtinB trial, 
aged B6 mice, between 8 and 11 months old, were either injected subcutaneously or gavaged 
with 20mg/kg biotinylated dimeric EmtinB (method 2.2.9). Three mice were used for each 
method of administration and two mice were used as an untreated control.  
5.2.2. Analysis of EmtinB in brains of injected APPswe/PS1ΔE9 mice  
Having established that EmtinB was detectable in serum after injection, it was necessary to 
determine if EmtinB could be detected in the brain after subcutaneous injection. In this 
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experiment aged APPswe/PS1ΔE9 mice between 16 and 18 months old were utilised. Four 
mice in total were used with two mice injected and two mice used as untreated controls. 
Mice were injected and euthanised as described in method 2.2.9. In addition to serum 
collection, brain tissue was also collected from these animals. The mice were terminally 
anaesthetised with sodium pentobarbitol, injected intraperitoneally (100mg/kg), then 
perfused through the heart with room temperature PBS, using a 22G needle, until the liver was 
pale and the perfusate ran clear. The brain of each mouse was then rapidly dissected out and a 
small sample of cortical tissue separated from the rest of the hemisphere. The cortical sample 
and hemisphere were then snap-frozen in liquid nitrogen for later biochemical analyses.  
5.2.3 Animal trial: Administration of dimeric EmtinB to APPswe/PS1ΔE9 
mice 
5.2.3.1 EmtinB trial: administration, cognitive assessment and tissue 
collection  
Preparation, administration, behavioural analysis and tissue collection were performed by 
Associate professor Paul Adlard et al. (The Florey Institute of Neuroscience and Mental Health, 
Parkville, Vic). All protocols for the above named sections are summarised from procedural 
notes supplied by Associate Professor Paul Adlard and herein denoted by an asterisk, *. 
5.2.3.2 Mice for EmtinB trial*  
A cohort of 44 APPswe/PS1ΔE9 mice was used to investigate the effect of EmtinB on AD 
pathogenesis in vivo. All mice were female and born on the 27/12/11. For control vs 
APPswe/PS1ΔE9 comparison in the Y-maze six B6 mice and ten APPswe/PS1ΔE9 mice were 
used. 
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5.2.3.3 Preparation of EmtinB* 
Dimeric EmtinB was reconstituted in sterile saline at 15mg/kg and administered at either 
5mg/kg or 30mg/kg, as indicated.  
5.2.3.4 Dosing protocol* 
EmtinB was administered 5 times per week, Monday-Friday, by subcutaneous injection at the 
nape of the neck. Mice were dosed daily for two months from nine months of age (19/9/12) 
until 11 months (5/12/12) of age. 
5.2.3.5 Y-maze assessment of mice* 
Treated and untreated APPswe/PS1ΔE9 mice were randomised using the randomise function 
in Microsoft Excel. Each mouse was randomly assigned a closed arm and starting arm out of 
the possible arms 1, 2 or 3. Mice were placed into the start arm of the maze with the novel 
arm closed off, and allowed to explore the open arms (called “start” and “other” arms) of the 
maze for ten minutes. Mice were removed from the maze after ten minutes and returned to 
their cage for a period of one hour. Mice were then returned to the start arm of the Y-maze 
and their movement analysed for one and five minutes using Ethovision. Raw data was 
analysed by chi-square analysis (data falling outside two standard deviations was not included 
in the analysis), and by linear regression (all data included) using PRISM software (GraphPad 
Prism, version 6, La Jolla, CA, USA). Mice were coded and EmtinB administered in a blinded 
manner. Drug administration and behavioural analyses were not carried out by the same 
researcher.  
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5.2.3.6 Tissue collection* 
Blood and serum samples were collected as per method 5.2.2. The trial mice were then 
transcardially perfused with PBS. The brains of five animals from each group were fixed in 4% 
PFA overnight then transferred to 30% sucrose/PBS. The remaining animal brains were 
dissected to remove the left-hand hemisphere cortex, hippocampus and cerebellum, while the 
right hemisphere was kept intact for whole brain analysis. These unfixed tissues were snap 
frozen in liquid nitrogen and cryogenically stored until required.  
5.2.4 Immunohistochemical (IHC) analysis of EmtinB trial brain 
5.2.4.1 Paraffin embedding of EmtinB trial brain  
Brains were prepared by excising a section of the right hand hemisphere of the brain between 
bregma -4 and bregma -0.5. Brain sections were then prepared for embedding with paraffin 
infiltration. Brain sections were put into labelled cassettes and processed as per the 
automated mouse brain protocol, in brief: 
Reagent Incubation time (minutes) Temperature (°C) 
70% ethanol 30 37 
95% ethanol 40 37 
Absolute ethanol 30 37 
Absolute ethanol 30 37 
Absolute ethanol 40 37 
Xylene 45 37 
Xylene  45 37 
Paraplast wax 60 60 
Paraplast wax 60 60 
Paraplast wax 60 60 
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Infiltrated tissue was then placed into an embedding basin with the -4 bregma oriented toward 
the bottom of the basin. The basin was then partially filled with warm paraffin and the tissue 
held steady with forceps while the paraffin was set by placing the basin onto a cold-plate. 
When this layer of paraffin was set, a plastic backing was placed over the basin and the basin 
fully filled with paraffin. The basin was then moved to a cold-plate until completely set, then 
stored at 4°C overnight. Once solid, the paraffin blocks were removed and excess paraffin 
trimmed from the blocks using a scalpel blade. Paraffin blocks were stored at room 
temperature. 
5.2.4.2 Sectioning of EmtinB trial fixed brains 
Prior to sectioning, blocks were placed in ice for five minutes to chill. Brains were then 
sectioned into 5µm sections on a microtome (Microm HM325, Thermofisher scientific, MA, 
USA). Sections were then placed into a 37°C water bath and floated onto glass slides (FLEX ICH 
microscope slides Ref #8020; Dako, Glostrup, Denmark), then dried overnight in a 37°C drying 
oven. Sections were stored at room temperature. 
5.2.4.3 Dewaxing slides  
Sections for staining were taken from approximately bregma -1.34mm to -2.3mm as per the 
work of Wright [230]. Slides were heated to 65°C for 30 minutes prior to dewaxing to assist 
with paraffin removal. The dewaxing and hydration of the sections was carried out by 
immersion in xylene twice for three minutes each, and then 100% ethanol, 95% ethanol and 
70% ethanol for two minutes each. Slides were briefly submerged in tap-water and then stored 
in PBS until required for staining. 
5.2.4.4 Antigen retrieval 
Brain sections were incubated in concentrated formic acid for eight minutes then washed six 
times for five minutes each time in immuno wash solution (method 2.1.32). 
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5.2.4.5 Immunodetection of GFAP and Aβ in trial brains 
Slides were blocked for 15 minutes at room temperature using Dako serum-free block (Dako, 
Glostrup, Denmark). EmtinB trial brains were immunostained using MOAB2 antibody (M-1586-
100, Biosensis, SA, AUS) directed against Aβ1-40 and Aβ1-42 to detect Aβ plaques.  
Primary MOAB2 antibody was diluted in immuno diluent (method 2.1.31) and applied for one 
hour at room temperature, then incubated overnight at 4°C. Slides were washed with immuno 
wash solution (method 2.1.32) three times for ten minutes each wash. Secondary antibodies 
were diluted in immuno diluent and incubated on slides in the dark for two hours at room 
temperature before being washed three times in immuno diluent for ten minutes each wash.  
Slides were rinsed in PBS (method 2.1.5), then briefly dried before coverslips were mounted 
using Dako permafluor mounting medium (Dako, Glostrup, Denmark). Slides were dried in the 
dark for two days, then the coverslips were sealed using clear nail polish (Cutex, clear; Priceline 
Pharmacy, TAS). Nail polish was dried at room temperature for four hours before the slides 
were transferred to a -20°C freezer for two days before imaging. 
5.2.4.6 Imaging of immunostained trial brain sections 
All images were taken on a spinning disk confocal Nikon TE-2000 inverted microscope with a 
Yokagawa CSU-22 confocal scanning unit and a Hamamatsu C9100-02 EMCCD camera using 
the 10x objective. 
5.2.4.7 Plaque load analysis of MOAB-2 stained trial brains 
Confocal images of MOAB-2 stained trial brain images were segmented using a custom plugin 
for the ImageJ software package [231] which used a random forest classifier, developed 
in-house by Aidan O’Mara (manuscript in preparation, Wicking Dementia Research and 
Education Centre, UTAS), to distinguish between pixels that represented Aβ pathology and 
background as described by [232]. The classifier was trained using a random selection of 
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cropped images from the data set which were annotated with examples of pathology and 
background pixels to produce a forest of 50 trees with a maximum depth of nine nodes. Each 
tree considered only a random bag of 5% of the training pixels, sampled with replacement. Aβ 
deposits in the segmented images were then counted and measured using ImageJ's "Analyze 
Particles" tool with the region of interest defined.  The region of interest was drawn for each 
image using the cortical regions of the hemispheres down to the rhinal fissure. Significance 
was determined using a one-way ANOVA with Tukey post-test and PRISM software (GraphPad 
Prism, version 6, La Jolla, CA, USA).  
5.2.5 Protein extraction from frozen trial brain whole hemispheres or 
hippocampal enriched samples 
Protein from whole hemispheres and hippocampal enriched brain tissue was extracted in RIPA 
buffer using the method described previously (method 2.2.10). 
5.2.6 ELISA analysis of soluble human Aβ1-42 (hAβ1-42) in trial brains 
ELISA analysis of soluble hAβ1-42 was carried out on whole hemisphere RIPA extracts as per 
the kit instructions. In brief, each sample was diluted at 1:1, 1:2, 1:4, and 1:8 in the provided 
diluent. Samples were then added to the ELISA plate and an equal volume (50µL) of the 
provided detection solution was added to each well. These were incubated overnight at 4°C. 
Wells were washed with the appropriate wash buffer four times for 30 seconds each time, 
then the HRP antibody (100µL) was added and incubated for 30 minutes at room temperature. 
A further four washes of 30 seconds each were performed, and the chromagen substrate 
(100µL) added. After 25 minutes incubation at room temperature, the stop solution (100µL) 
was added to each well. The absorbance of the wells was read immediately at 450nm on a 
SpectraMax M2 plate reader (Molecular Devices) running the SoftMax Pro computer program 
(v 4.8).  
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Significance was determined using a one-way ANOVA with Tukey post-test and PRISM software 
(GraphPad Prism, version 6, La Jolla, CA, USA). 
5.3 Results 
5.3.1 EmtinB is present in serum after injection but not gavage. 
To determine a reliable method of EmtinB administration, biotinylated dimeric EmtinB was 
administered to B6 mice at 20mg/kg via either subcutaneous injection or gavage. Serum was 
harvested 45 minutes after administration and biotinylated EmtinB was detected by western 
blot. As there is no antibody available for EmtinB, the peptide was detected using the biotin 
tag. An initial western blot of the samples randomised across a gel showed that serum from 
injected animals contained a biotinylated protein at low molecular weight (estimated to be 
around 4kDa), while control and gavaged animals had no bands at this molecular weight 
(Figure 5.1A). This suggests that biotinylated EmtinB is observable in serum 45 minutes after 
injection, but that dimeric EmtinB is not able to pass through the gut and into the 
bloodstream. To confirm that these low molecular weight bands were consistent with EmtinB, 
a second western blot using representative samples from each treatment group compared the 
small protein bands to a control sample of biotinylated EmtinB (Figure 5.1B). The low MW 
band observed in the EmtinB injected mouse serum was consistent with migration of the 
biotinylated EmtinB control, suggesting that EmtinB was present in serum from injected mice, 
but not in serum from control or gavaged mice.  
5.3.2 EmtinB is not detected in brain after injection 
The capacity for EmtinB to pass into the brain after injection was tested in APPswe/PS1ΔE9 
mice. Aged APPswe/PS1ΔE9 mice were injected with biotinylated dimeric EmtinB at 20mg/kg 
and the serum collected along with cortical and whole-hemisphere brain samples.
  
 
Figure 5.1 EmtinB is present in serum after subcutaneous injection but not after gavage  
Serum from B6 control untreated mice (n=2) was analysed by western blot alongside serum from mice injected (n=3) or gavaged (n=3) and with biotinylated 
EmtinB dimer (A). Low molecular weight biotinylated protein was observed in the serum of injected mice, but not gavaged or control mice. Comparison of a 
subset of these samples with monomeric biotinylated EmtinB dimer (B) shows that the low molecular weight protein observed in serum from injected mice 
is consistent in size with biotinylated EmtinB. 
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Analysis of serum samples from control untreated and EmtinB-injected mice was carried out 
by western blot. Western blot analysis shows small biotinylated protein consistent with EmtinB 
present in the serum of injected mice, but not in untreated control mice (Figure 5.2A), showing 
that EmtinB is present in the serum of the EmtinB-injected APP mice 45 minutes post 
administration. A second western blot was carried out on cortical and whole hemisphere 
extracts. No EmtinB was detected in the cortical or whole hemisphere samples (Figure 5.2B).  
5.3.3 EmtinB administration improves Y-Maze performance in 
APPswe/PS1ΔE9 mice 
The effect of EmtinB administration on cognition was examined in an EmtinB animal trial using 
APPswe/PS1ΔE9 mice.  A cohort of APPswe/PS1ΔE9 mice were treated five times per week 
with 5mg/kg EmtinB (n=14) or 30mg/kg EmtinB dimer (n=14) or sterile saline vehicle control 
(n=15). Mice were dosed with EmtinB dimer for a period of two months, from 9-11 months of 
age. At 11 months, trial APPswe/PS1ΔE9 mice were tested in a Y-maze to determine if EmtinB 
administration improved cognitive function (method 5.2.3.5). Analysis of this data was carried 
out using two statistical tests. In the first instance a chi-square test was performed, wherein 
time spent in the novel arm is compared with an expected value of 33%, which is determined 
based on the assumption that mice would spend an equal amount of time in each arm of the 
maze if they had no memory of the maze. The chi-square analysis provides information about 
whether the individual groups (SSV control and EmtinB treated  groups) mice spent more or 
less time in the novel arm than expected by random chance, which gives an of indication 
memory loss. However, a chi-square analysis does not allow for a direct comparison of EmtinB 
treated and SSV control animals.  A second analysis was carried out, using linear regression, 
where the EmtinB treatment groups were directly compared with the saline vehicle control 
group, with the dose of EmtinB (from zero to 30mg/kg) tested for its interaction with the 
dependent variable (time spent in the novel arm). To establish that APPswe/PS1∆E9 exhibit
  
 
Figure 5.2 EmtinB is detectable in serum but not in brain after subcutaneous injection  
Serum from control untreated APPswe/PS1ΔE9 mice (n=2) and APPswe/PS1ΔE9 mice injected with biotinylated dimer EmtinB (n=2) was analysed by western 
blot (A) 45 minutes after injection. EmtinB was detected in serum from injected, but not control, APPswe/PS1ΔE9 mice. Whole-hemisphere and cortex-only 
brain extracts were also analysed for EmtinB presence (B). No EmtinB was detectable in EmtinB-injected or control brain extract, in either whole hemisphere 
(Bi) or cortical (Bii) extracts.   
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an impairment that can be measured using Y-maze, an initial Y-maze trial was carried out by 
Adlard et al. (Florey Institute, VIC, AUS) to compare APPswe/PS1ΔE9 mice and B6 controls. This 
test showed that during the one minute test, APPswe/PS1ΔE9 mice spent significantly less 
time in the novel arm of the maze compared with control mice (Figure 5.3), confirming that 
APPswe/PS1ΔE9 mice exhibit impaired memory. 
5.3.3.1 Chi-square analysis  
When EmtinB treated and SSV control mice were tested in the Y-maze, chi-square analysis 
showed that untreated APPswe/PS1ΔE9 mice spent 35.51% (±5.23%) of their time in the novel 
arm of the Y-maze at one minute post entry (Figure 5.4A), which was not significantly different 
from the expected value of 33%, once again confirming cognitive impairment. Conversely, 
mice treated with EmtinB at 5mg/kg spent a significantly larger percentage of their time (62.62 
± 8.27%) in the novel arm of the maze. Mice treated with 30mg/kg also spent significantly 
longer in the novel arm (43.45 ± 11.56%), however the effect was not as pronounced as the 
5mg/kg mice.   
Chi-square analysis at five minutes post entry (Figure 5.4B), showed, that once again, 
untreated APPswe/PS1ΔE9 mice did not spend significantly longer in the novel arm of the Y-
maze (33.88 ± 3.63%) than the expected value of 33%. Mice treated with EmtinB at 5mg/kg 
again spent a larger percentage of their time (46.84 ± 3.26%) in the novel arm of the maze 
although this was not significant. Mice treated with 30mg/kg spent 39.81% (± 3.37%) of their 
time in the novel arm, however this was not statistically significant compared with the chance 
value of 33%.  
These animal studies were undertaken by A/Prof Paul Adlard (Florey Institute), and raw data 
and tissue samples (fixed and frozen brain) were subsequently analysed by the current author 
as part of this thesis. 
  
 
Figure 5.3 APPswe/PS1ΔE9 mice show reduced cognitive capacity in the Y-maze compared with control B6 mice 
12 month old APPswe/PS1ΔE9 mice and wild-type B6 controls were assessed for cognitive capacity using the Y- maze. To test cognitive capacity, mice were 
allowed to explore the two open arms (Called “start” arm and “other” arm) of the maze for ten minutes before being removed from the maze for a period of 
one hour. Mice were then returned to the Y-maze for one minute with all three arms of the maze accessible. Wild-type B6 control mice spent significantly 
longer in the novel arm of the Y-maze than their APPswe/PS1ΔE9 counterparts. Graph shows percentage of time mice spent in each of the arms. Data 
presented as mean and SEM. ANOVA with bonferroni post hoc analysis (p<0.05).   
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Figure 5.4 EmtinB treated APPswe/PS1ΔE9 mice show reduced cognitive impairment compared with sterile saline treated control mice 
APPswe/PS1ΔE9 mice treated with either EmtinB at a low dose of 5mg/kg (n=14) or a high dose of 30mg/kg (n=11), or with a control dose of Sterile Saline 
Vehicle (SSV; n= 15) were assessed for cognitive capacity using the Y- maze. Mice explored the two accessible arms of the maze for ten minutes before being 
removed from the maze for one hour. Mice were returned to the Y-maze for A) one minute and B) five minutes, with all three arms of the maze accessible 
and the time spent in the novel arm of the maze was analysed using chi-square analysis, where time spent in the novel arm was compared with an expected 
value assuming random chance (33%).  A) SSV mice did not spend significantly more time in the novel arm than the 33% expected value. Both 5mg/kg and 
30mg/kg EmtinB-treated mice spent significantly longer in the novel arm of the maze than the expected 33%, with 5mg/kg treated mice performing better 
that the 30mg/kg treated mice. B) While there was a trend for 30mg/kg -treated mice to spend longer in the novel arm of the maze than SSV, this was not 
statistically significant. Mice treated with 5mg/kg EmtinB spent significantly longer in the novel arm of the maze. p<0.05. Values are mean and SEM. 
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5.3.3.2 Linear regression analysis 
With the help of a biostatistician (Dr Karen Wills, School of Medicine, UTAS) a linear regression 
model was built in R v3.1.1 (R Core Team, 2014) to analyse the data. Linear regression of the 
data showed that at five minutes post first arm entry there was no significant difference in 
time spent in the novel arm of the maze between 30mg/kg EmtinB-treated mice and control 
SSV mice, or between 5mg/kg EmtinB-treated mice and control mice (Figure 5.5A). 
Linear regression analysis of the one minute post first arm entry data revealed a significant 
difference in the amount of time spent in the novel arm of the maze between 5mg/mL EmtinB-
treated mice (62.62 ± 30.96) compared with SSV control mice (38.80 ± 22.77). While there was 
a trend for increased time in the novel arm of the maze in 30mg/mL EmtinB-treated mice 
(43.45 ± 38.35), compared with SSV control mice, this trend was not significant (Figure 5.5B). 
5.3.4 EmtinB treatment does not alter plaque load in APPswe/PS1ΔE9 
mice  
Plaque load was assessed in the cortex of EmtinB treated (5mg/kg and 30mg/kg) and saline 
vehicle control mice. Sections were selected from the region of the brain between 
bregma -1.34mm and -2.3mm, and amyloid deposition assessed by determining the 
percentage area of the cortex containing plaque (% plaque area) and number of plaques per 
square millimetre of cortical tissue (plaque number).  There was no significant difference in % 
plaque area between SSV control mice and EmtinB treated mice (Figure 5.6A, C). There was, 
however, a trend for lower percentage plaque area in animals treated with 5mg/kg EmtinB 
(Figure 5.6A, C). Interestingly, this reflects the significant improvement in cognitive capacity 
demonstrated by the 5mg/kg EmtinB treated mice using the Y-maze, which was comparatively 
less in the 30mg/kg EmtinB dosed mice (see Figure 5.4). Similarly, there was no significant 
difference in plaque number between saline treated mice and EmtinB treated mice; however,
  
 
Figure 5.5 EmtinB treated APPswe/PS1ΔE9 mice show reduced cognitive impairment compared with sterile saline treated control mice 
APPswe/PS1ΔE9 mice treated with either EmtinB at a low dose of 5mg/kg (n=14) or a high dose of 30mg/kg (n=11), or with a control dose of Sterile Saline 
Vehicle (SSV; n= 15), were assessed for cognitive capacity using the Y-maze. Mice explored the two accessible arms of the maze for ten minutes before being 
removed from the maze for one hour. Mice were returned to the Y-maze for A) one minute and B) five minutes, with all three arms of the maze accessible 
and the time spent in the novel arm of the maze was analysed using linear regression. Linear regression analysis of the novel arm data shows that at one 
minute post first-arm entry (A) 5mg/kg treated mice spent significantly longer in the novel arm of the maze than SSV-treated mice (p<0.05) and, while there 
was a trend for 30mg/kg treated mice to spend longer in the novel arm of the maze than SSV mice, this was not statistically significant. At five minutes post 
first-arm entry (B), neither the 5mg/kg, nor 30mg/kg, EmtinB treated mice spent significantly longer in the novel arm of the maze compared to SSV mice. 
p<0.05. Values are mean and SEM. 
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Figure 5.6 EmtinB treatment at 5mg/kg or 30mg/kg does not significantly alter Aβ deposition in APPswe/PS1ΔE9 mice 
 EmtinB at 5mg/kg, EmtinB at 30mg/kg, and sterile saline vehicle (SSV) control treated mouse brains (n=5) were paraffin embedded sectioned at 5µm. Three 
sections between bregma -1.34mm and -2.3mm were selected randomly for each brain for plaque analysis. Sections were stained with MOAB2 antibody and 
imaged on a spinning disk confocal microscope. The images were segmented using a random forest segmenter before analysis for plaque area and number 
using ImageJ. Plaque load was calculated as percent area of the cortex containing plaques (A). Based on this calculation there was no significant difference in 
plaque load in the cortex of 30mg/kg or 5mg/kg EmtinB treated mice compared with SSV controls. Similarly, plaque number was calculated as plaques per 
square mm of cortex (B), and no significant differences were observed between EmtinB-treated and control mice. Interestingly there was a trend for fewer 
plaques and lower plaque numbers in 5mg/kg EmtinB treated mice; representative images in (C). One-way ANOVA, p=0.05; scale bar = 500µm. 
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once again there was a trend for lower plaque number in 5mg/kg EmtinB treated mice  
(Figure 5.6B, C). Thus, while there is a trend for lower plaque number and percentage plaque 
area in 5mg/kg EmtinB treated mice, there is no statistically significant difference in plaque 
deposition, or number, between control and EmtinB treated mice at either dose.   
5.3.5 Soluble amyloid is not altered in EmtinB treated mouse brain 
Soluble Aβ levels correlate well with cognitive decline in AD patients and AD mouse models. 
Soluble levels of human Aβ1-42 (hAβ1-42) were analysed in whole hemisphere extracts from 
APPswe/PS1ΔE9 mouse brains after treatment with EmtinB (5 or 30mg/kg) or sterile saline 
control using an ELISA (Novex by Life technologies, Thermofisher scientific, MA, USA). ELISA 
analysis showed no significant changes in soluble hAβ1-42 between EmtinB treated mice and 
saline vehicle control mice (Figure 5.7).   
5.3.6 EmtinB treatment does not affect APP levels in APPswe/PS1ΔE9 
mice  
To determine if EmtinB modulates APP in the APPswe/PS1ΔE9 mouse model of AD, a western 
blot was carried out on whole-hemisphere brain samples of EmtinB treated and control mice 
(Figure 5.8A). Quantitation of the western blot using ImageJ showed that neither 5mg/kg nor 
30mg/kg treatment with EmtinB altered brain APP levels in APPswe/PS1ΔE9 mice compared 
with saline vehicle control mice (Figure 5.8B). 
5.3.7 EmtinB does not alter LRP1 levels in APPswe/PS1ΔE9 mice 
To confirm a decrease in LRP1 in the APPswe/PS1ΔE9 model of AD, control B6 and 
APPswe/PS1ΔE9 mouse brains were analysed by western blot for LRP1. A decrease in LRP1 
levels in APPswe/PS1ΔE9 mouse brain was confirmed by western blot (Figure 5.9A) and 
subsequent western blot quantitation by ImageJ (Figure 5.9B). LRP1 levels in APPswe/PS1ΔE9  
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Figure 5.7 Soluble hAβ1-42 levels were not altered by EmtinB treatment at a dose of 5mg/kg 
or 30mg/kg 
Soluble hAβ1-42 levels in 5mg/kg and 30mg/kg EmtinB-treated mouse brain were compared 
with soluble hAβ1-42 levels in saline vehicle-treated mouse brain by Enzyme-linked 
Immunosorbent Assay (ELISA). Neither 30mg/kg (n=5) nor 5mg/kg EmtinB-treated mice (n=5) 
showed significantly altered brain hAβ1-42 levels compared with SSV control mice (n=5). One-
way ANOVA with Tukey post-test, p=0.05. Means and SEM shown.
  
 
Figure 5.8 APP is unchanged in the brains of EmtinB treated mice 
Whole brain hemisphere extracts from SSV treated mice, 5mg/kg EmtinB treated mice and 30mg/kg EmtinB treated mice were analysed for APP content by 
western blot analysis (A) and subsequent ImageJ quantitation using ImageJ (B). There was no change in APP levels in either 5mg/kg or 30mg/kg EmtinB-
treated mice compared with SSV mice. One-way ANOVA with Tukey post-test. Means and SEM shown. 
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Figure 5.9 LRP1 levels are decreased in the brain of the APPswe/PS1ΔE9 mouse model 
LRP1 levels in whole-hemisphere brain extracts from APPswe/PS1ΔE9 and wild-type B6 mice 
were analysed by western blot (A) and quantitated using ImageJ (B). LRP1 was significantly 
decreased in the brain of APPswe/PS1∆E9 mice (n=3) compared with wild-type B6 mice (n=3).  
t-test, p<0.05. Values are mean and SEM.   
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mice were found to be decreased by approximately 25% in the brain of APPswe/PS1ΔE9 mice 
compared with B6 wild-type control mice (Figure 5.9B). 
To determine if EmtinB was able to modulate LRP1 levels in APPswe/PS1ΔE9 mice, 
whole-hemisphere extracts from 5mg/kg and 30mg/kg EmtinB treated mice and SSV control 
mice were analysed by western blot. Western blotting (Figure 5.10A) and subsequent analysis 
using ImageJ (Figure 5.10B) for LRP1 in EmtinB-treated and vehicle control mice showed no 
difference in LRP1 levels, suggesting that EmtinB is not acting to modulate LRP1.  
5.3.8 EmtinB does not alter IBA1 levels in APPswe/PS1ΔE9 mice  
Microglial changes in EmtinB treated (5mg/kg or 30mg/kg) and SSV control APPswe/PS1ΔE9 
mouse brain were assessed using western blotting for IBA1 protein (Figure 5.11A). IBA-1 
protein is found in all microglia and is upregulated in activated glia [233]. IBA1 levels in whole 
hemisphere brain extracts were quantified using ImageJ (Figure 5.11B), with no significant 
difference in IBA1 found between EmtinB-treated mice at either 30mg/kg or 5mg/kg treated 
and SSV control mice.  
5.3.9 GFAP is decreased in EmtinB treated APPswe/PS1ΔE9 mice  
To confirm that GFAP levels are increased in the APPswe/PS1ΔE9 model of AD, GFAP levels in 
APPswe/PS1ΔE9 and B6 control mouse brain were assessed using western blot (Figure 5.11A). 
Quantitation of the western blot showed an increase in GFAP in APPswe/PS1ΔE9 mice 
compared with B6 control mice (Figure 5.12B), confirming increased GFAP levels in the 
APPswe/PS1ΔE9 mouse model of AD. 
To ascertain whether EmtinB is able to reduce astrogliosis in the APPswe/PS1ΔE9  mouse 
model of AD, GFAP levels were analysed in high and low dose EmtinB-treated mouse brain and 
SSV control brain by western blot (Figure 5.13 A) and quantitated using ImageJ analysis (Figure 
5.13 B). Mice treated with EmtinB at 5 or 30mg/kg had significantly lower levels of GFAP than
  
 
Figure 5.10 EmtinB does not alter LRP1 levels in APPswe/PS1ΔE9 mouse brain  
LRP1 levels in whole-hemisphere brain extracts from 30mg/kg EmtinB treated, 5mg/kg EmtinB treated, and sterile saline vehicle (SSV) treated mice were 
analysed by western blot (A) and subsequent ImageJ quantitation (B). LRP1 levels in 5mg/kg and 30mg/kg EmtinB-treated mice were not significantly different 
from SSV control animals. One-way ANOVA with Tukey post-test. Data is mean and SEM.   
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Figure 5.11 IBA1 is unchanged in the brains of EmtinB-treated mice  
Whole-hemisphere brain extracts from mice treated with 30mg/kg EmtinB, 5mg/kg EmtinB and sterile saline vehicle (SSV) were analysed by western blot (A) 
and quantitated using ImageJ (B). IBA1 was unchanged in 5mg/kg treated mice and 30mg/kg treated mice compared with SSV treated animals. One-way 
ANOVA with Tukey post-test. Values are mean and SEM.   
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Figure 5.12 GFAP levels are increased in the APPswe/PS1ΔE9 model of AD 
GFAP levels in whole brain hemisphere extracts were analysed by western blot (A) and 
quantitated using ImageJ analysis (B). APPswe/PS1∆E9 mice (n=3) had significantly higher 
GFAP levels in whole-hemisphere brain extracts compared with wild-type B6 mice (n=3). 
t-test, p<0.05; results as mean and SEM.   
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Figure 5.13 GFAP is significantly decreased in the brains of EmtinB treated APPswe/PS1ΔE9 mice 
GFAP levels in whole-hemisphere brain extracts were analysed by western blot (A) and subsequent ImageJ quantitation (B). GFAP was reduced in both 
5mg/kg and 30mg/kg compared with sterile saline vehicle control animals. One-way ANOVA with Tukey post-test; * = p < 0.05, ** = p<0.01.   
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saline vehicle-treated mice (Figure 5.13 A, B). Thus, EmtinB is able to modulate GFAP levels in 
the APPswe/PS1ΔE9 mouse brain.  
5.3.10 Neither Synaptophysin nor PSD-95 levels are altered in the 
hippocampus of APPswe/PS1ΔE9 mice after EmtinB treatment. 
Western blot analysis of synaptophysin levels in high and low dose EmtinB treated brain, and 
SSV control brain, showed no significant difference in synaptophysin with either 30mg/kg or 
5mg/kg EmtinB treatment compared to SSV control (Figure 5.14A, B).  
Similarly, neither 30mg/kg EmtinB treatment nor 5mg/kg EmtinB treatment altered PSD95 
levels in APPswe/PS1ΔE9 mouse brain compared to SSV control mouse brain, as analysed by 
western blot (Figure 5.15 A, B). Taken together, the data suggest that EmtinB does not have a 
direct impact on synapses. 
5.4 Discussion and conclusions 
The therapeutic potential of the EmtinB dimer in APPswe/PS1ΔE9 mice has been investigated. 
Subcutaneous administration of EmtinB improved cognitive outcome in 5mg/kg treated 
APPswe/PS1ΔE9 mice, but was not as efficacious in 30mg/kg treated mice. Subsequent 
analysis of Aβ accumulation in the EmtinB-treated and saline vehicle-treated control brains 
showed no changes in soluble hAβ1-42 levels. Aβ plaques were analysed by 
immunohistochemistry and, while a trend towards lower plaque load was observed for 5mg/kg 
EmtinB treated mice, this was not significant. There were no changes to levels of APP, LRP1, 
and IBA1 in whole-hemisphere brain extracts; however, there was a significant decrease in 
GFAP levels in both 5mg/kg and 30mg/kg EmtinB treated mice compared to SSV controls. 
Extracts from hippocampi of EmtinB-treated and SSV control mice showed no difference in 
synaptic markers, PSD-95 or synaptophysin.  
   
Figure 5.14 Synaptophysin levels in the hippocampus of APPswe/PS1ΔE9 mice are not altered by EmtinB treatment  
Synaptophysin levels in the hippocampus of EmtinB treated and control mice were analysed by western blot (A) and subsequent ImageJ quantitation (B). 
Neither 5mg/kg nor 30mg/kg treatment with EmtinB produced significant changes in synaptophysin levels in the hippocampus of treated animals compared 
with sterile saline vehicle control animals. One-way ANOVA with Tukey post-test.   
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Figure 5.15 EmtinB treatment does not alter PSD95 levels in the hippocampus of APPswe/PS1ΔE9 mice  
PSD95 levels in protein extracts from the hippocampus of EmtinB treated and control mice were analysed by western blot (A) and subsequent quantitation 
using ImageJ (B). No significant changes in PSD95 were detected in EmtinB treated hippocampal sections at either 5mg/kg or 30mg/kg compared with vehicle 
treated controls. One-way ANOVA with Tukey post-test.   
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5.4.1 EmtinB pharmacokinetics in the APPswe/PS1ΔE9 mouse 
5.4.1.1 EmtinB is not orally administrable   
Peptides as therapeutics have been gaining in popularity since the 1990s [234]. Currently, most 
peptide drugs (approximately 75%), are administered via injection, however alternative 
administration forms, including oral, are gaining increasing prominence [165]. Oral drug 
administration is a preferred method in terms of convenience and safety however; using this 
route, the drug is required to not only be absorbed across the intestinal wall, but also pass 
through the liver, prior to reaching its therapeutic target [234]. For peptides, this represents a 
significant obstacle as the gut’s specific function is to degrade peptides into their component 
amino acids. While emtins have not yet been tested as orally administrable peptides, there is 
some evidence to suggest that EmtinB might be orally administered. A recent study has shown 
that tetra-branched, dendrimeric peptides show decreased protease susceptibility [177]. While 
tetrameric EmtinB clearly falls into the category of tetra-branched dendrimeric peptide, it is 
unclear whether dimeric EmtinB would demonstrate similar properties in this regard. In this 
study, subcutaneous injection of EmtinB dimer into B6 mice resulted in detectable levels of 
EmtinB in serum; however, orally administered EmtinB was not detectable in serum. Recent 
advances in technology have created alternate methods of delivery for peptides including 
transdermal and intranasal, as well as methods of protecting peptides during oral delivery 
(reviewed in [165]); while these delivery methods may provide viable options for future trials, 
the only current viable method of EmtinB delivery is via injection.   
5.4.1.2 EmtinB is detectable in the serum, but not brain, of EmtinB 
injected APPswe/PS1ΔE9 mice 
In second experiment, looking at EmtinB crossing the blood-brain barrier in APPswe/PS1ΔE9 
mice showed that, while EmtinB dimer peptide was detectable in serum of injected mice, 
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EmtinB was not detectable in brain. However, a prior study has reported that EmtinB tetramer 
peptide is detectable in CSF of mice 45 minutes after subcutaneous injection [184]. There are 
two reasonable explanations for this discrepancy; either EmtinB dimer is unable to cross the 
BBB or it is crossing the BBB but is not detectable by the methods employed.  
Tetrameric EmtinB has previously been detected in the CSF of mice after subcutaneous 
injection at 20mg/kg [184]; the same dosage that EmtinB dimer was administered at in this 
current study, supporting the idea that EmtinB should be crossing the BBB in this model. Our 
study investigated the dimer and not the tetramer, and it may be that EmtinB dimer and 
tetramer possess different capacities to cross the BBB. Given that EmtinB dimer is the smaller 
of these two peptides, the possibility that the dimer is less able to cross the BBB is unlikely 
however it must be considered. While proteins often cross the blood brain barrier via 
receptor-mediated transcytosis, a second mechanism of CNS entry is also available to cationic 
proteins.  Adsorptive-mediated transcytosis is a process which allows positively charged 
proteins to cross the blood brain barrier [235, 236]. Via this mechanism, cationic proteins bind 
to the negatively charged luminal surface of ECs and are transported across the BBB in 
clatharin coated pits [236]. As both EmtinB dimer and EmtinB tetramer are estimated to have a 
positive net charge at neutral pH, +4.7 and +10.5 respectively, these proteins may be 
candidates for adsorptive-mediated transcytosis. If indeed EmtinB entry into the CNS is 
facilitated by this mode of transport, the higher cationic charge of the EmtinB tetramer (+10.5) 
as compared with the EmtinB dimer (+4.7) could represent an advantage in terms of BBB 
transcytosis.  
 One further point of difference with these peptides is the method of biotinylation. Sonn et al. 
[184] developed EmtinB with a single N-terminal biotin, while our EmtinB has an estimated 
three biotins per dimer. The effect of biotin on EmtinB action has not been fully assessed, and 
could account for a decreased capacity to cross the BBB.  
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If EmtinB dimer is crossing the BBB and is present in the brain, it may be in concentrations 
undetectable by western blot using our conditions. In this regard, it is important to note that 
Sonn et al. [184] demonstrated brain uptake of EmtinB tetramer by directly sampling the CSF, 
a technique that was not available for this project. CSF sampling presumably provides a far 
more sensitive detection of BBB penetration of emtin peptide, and future studies evaluating 
EmtinB dimer uptake into the brain should be undertaken in a similar manner. 
One of the major limitations to investigating EmtinB capacity to cross the BBB is the lack of 
EmtinB antibody. Currently, detection of EmtinB is only possible using the biotin tag. This 
poses problems such as detection of endogenous biotin in both western blot samples 
(observed by multiple bands present in western blots of the brain, presented in Figure 5.2), 
and in immunocytochemistry, where uncertain identification of the EmtinB protein, and 
possible alterations to EmtinB action could occur due to biotin labelling. To address these 
issues in future, developing an EmtinB antibody would be highly advantageous.  
5.4.2 EmtinB improves cognitive performance in the APPswe/PS1ΔE9 
mouse  
It is well documented that APPswe/PS1ΔE9 have cognitive decline from as young as six months 
of age. EmtinB administration for this animal trial was started at nine months of age, post 
symptom onset, to better reflect post-onset administration of treatment that occurs in human 
patients. Changes in the cognitive decline of the mice were assessed using a Y-maze after two 
months of EmtinB administration. Chi-square analyses showed improved outcomes for mice 
treated with 5mg/kg EmtinB in both the one and five minute tests, while mice treated with 
30mg/kg-only had significant outcomes in the one minute test. Using the more conservative 
linear regression analyses, only mice dosed at 5mg/kg EmtinB showed increased cognitive 
performance in the Y-maze at one minute, while a non-significant trend for improvement in 
5mg/kg EmtinB-treated mice was observed in the five minute test. Taken together, the data 
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suggest that while there is a clear improvement in cognitive performance in mice treated with 
5mg/kg EmtinB, the cognitive improvement in 30mg/kg treated animals is much less robust. 
Preliminary data using cultured hippocampal neurons shows that, while EmtinB concentrations 
up to 100µM are protective against CuAβ, concentrations above 100µM may cause a decrease 
in cell viability (see Figure 3.11). This suggests that EmtinB can be protective, but above 
threshold concentrations decrease the efficacy of EmtinB protection or may even be 
independently detrimental. In light of this, a key future experiment would be to determine 
optimal dosing of EmtinB in both culture and animal models. Additionally, it has not yet been 
established what effect EmtinB has on wild-type mice in terms of cognitive performance, 
however this is a key question and should be investigated in future studies to determine if 
EmtinB produces improved cognition across all animal types or acts specifically on pathological 
processes within the brain. 
 
5.4.3 Aβ accumulation is unaffected by EmtinB treatment 
Amyloid plaques are one of the main pathological hallmarks of AD. First described by Alouis 
Alzheimer in 1906 [237], the discovery of amyloid plaques and, subsequently, the identification 
of their main component as the β-amyloid peptide, led to intense investigation into the role of 
the β-amyloid peptide in AD pathogenesis [131]. These studies have confirmed the important 
role that Aβ plays in AD, with genetic studies showing that, in familial disease, AD is strongly 
associated with mutations in the amyloid precursor protein (APP) and APP processing proteins, 
such as presinilin 1 (PS1) [238]. More recently, it has been found that soluble Aβ levels 
correlate well with cognitive decline [239-243], leading to the theory that it is soluble Aβ that 
constitutes the main pathological form of Aβ. The implication of soluble and deposited Aβ in 
the pathogenesis of AD has led to amyloid pathology being the main target of a number of 
potential AD therapies and, while cognitive improvements are the gold-standard measure of 
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therapeutic efficacy, researchers commonly use hallmarks such as plaque load and soluble Aβ 
levels as correlates to cognitive data, or as indicators of therapeutic action themselves.  
In this study, both soluble Aβ and plaque load were assessed as indicators of EmtinB action. 
Investigation of amyloid plaque deposition by immunohistochemistry of insoluble deposits 
showed no changes in amyloid plaque levels after EmtinB treatment at 5 or 30mg/kg. This lack 
of change was reflected in the soluble Aβ levels by ELISA analysis of soluble hAβ1-42, which 
similarly showed no changes in soluble Aβ levels in EmtinB treated APPswe/PS1ΔE9 mouse 
brains. Taken together, the data suggests that EmtinB does not modulate Aβ accumulation in 
the APPswe/PS1ΔE9 mouse brain.  
5.4.3 EmtinB does not alter Aβ production or clearance in the 
APPswe/PS1ΔE9 mouse model of AD 
Changes in Aβ accumulation, such as a decreased plaque load or reduced soluble Aβ load, 
would have indicated changes in either in Aβ production, for example by APP modulation to 
reduce Aβ production, or improvement in Aβ clearance, such as improved transport across the 
blood-brain barrier by LRP1.  
APP is the parent protein for the Aβ peptide, and the APPswe/PS1ΔE9 mouse model of AD 
overexpresses APP as part of its generation of pathological amyloid and subsequent 
deposition. There is some evidence that modulation of APP can be used to reduce Aβ. Asuni et 
al. [244] found that using a compound called 2-PMAP, they could bring about a decrease in 
APP in an APP-overexpressing mouse model of AD via an inhibition of RNA translation to 
protein. Subsequently, these mice demonstrated improved memory performance and 
reduction in Aβ deposition in the brain. Other studies have shown that modulation of this 
overexpressed APP can have positive benefits in cognition and amyloid accumulation in the 
mouse model brain [245-247].  
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LRP1 is a key player in Aβ clearance from the brain, facilitating both clearance of Aβ from the 
brain by transportation across the BBB, and cellular uptake of Aβ for subsequent lysosomal 
degradation [248]. Interestingly, brain levels of LRP have been shown to be decreased in both 
AD brain and aged human brain [249], as well as in aged rat brain [250]. Given the pivotal role 
of LRP1 in Aβ clearance and the decline in LRP levels during disease and aging, LRPs have 
garnered interest as a therapeutic target for the treatment of AD and other diseases [251, 
252]. 
As decreases in LRP1 are potentially an exacerbating factor in the pathogenic progression in 
APPswe/PS1ΔE9 mice, it is possible that EmtinB-induced cognitive improvements in 
APPswe/PS1ΔE9 mice could be a result of modulation of LRP1 levels in the brain. 
Both APP and LRP1 levels were assessed by western blot and neither of these proteins were 
found to be altered in response to EmtinB treatment compared to control APPswe/PS1ΔE9 
mice.  As neither APP nor LRP1 levels were altered in the EmtinB-treated mice, EmtinB-induced 
improvement in cognitive outcomes in these mice is not likely due to reduction in Aβ 
pathology.  
The inability of EmtinB to alter amyloid accumulation is consistent with the western blot data 
that shows EmtinB is not able to alter APP or LRP1 levels in the APPswe/PS1ΔE9 mouse model 
of AD.  
5.4.4 EmtinB modulates astroglial but not microglial activation in 
APPswe/PS1ΔE9 mice 
Gliosis is a key pathological event in the AD brain and is believed to not only be a symptom of 
AD, but a contributor to disease pathogenesis [253]. The Aβ peptide has been shown to 
activate both microglia and astrocytes and, under various circumstances, metallothioneins 
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have been shown to reverse this gliosis [75, 76, 83, 84], raising the possibility that EmtinB may 
act to decrease gliosis in the APPswe/PS1ΔE9 mouse model of AD. 
5.4.4.1 EmtinB does not alter levels of microglial marker IBA1 
Microglia are the immune cells of the brain and become activated in response to insult or 
injury. Activation of microglia induces rapid proliferation, as well as alterations, in microglial 
marker expression and morphology compared with quiescent microglia.  
In the AD brain, changes in both molecular and morphological characteristics of microglia are 
observed [254].  Microglia that are in the vicinity of plaques proliferate and accumulate around 
plaques [255, 256] and undergo morphological changes consistent with activated microglial 
morphology [257]. While the activation of microglia under some circumstances has been 
shown to be beneficial [255, 258], there is increasing evidence that microglial activation 
contributes to AD pathogenesis by initiating and/or maintaining inflammation, with plaque-
associated activated microglia found to express pro-inflammatory cytokines such as 
interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α) [255, 257]. Indeed, in vitro studies 
have shown that Aβ peptide can induce microglial activation [259-261] and this microglial 
activated subsequently potentiates neuronal cell death [259]. This evidence indicates that 
decreasing microglial activation could prevent Aβ-mediated damage to neurons. 
Interestingly, MT2 has been shown to decrease microglial activation in rat [83] and mouse [84] 
models of traumatic brain injury (TBI). Further evidence for MT regulation of microglial 
activation comes from studies of MT-overexpressing mice and MTKO mice, wherein mice that 
overexpress MT show less microglial activation, and subsequent neuronal loss, after TBI [76], 
while increased  microglial activation is observed in MTKO mice after cryolesion [75]. Given 
that MT2 is able to effect a change in microglial activation, it seems plausible that EmtinB 
might also be capable of modulating microglial activation in response to Aβ.  
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In this study the activation of microglia was examined by western blot analysis of IBA1 levels in 
whole-hemisphere brain extracts from EmtinB trial mice. Interestingly, EmtinB was not able to 
affect microglial activation, as measured by unaltered IBA1 protein level, suggesting that, 
unlike MT2, EmtinB does not modulate microglial activation state.  
IBA1 expression is a commonly used marker of microglia and is upregulated during activation. 
Theoretically, IBA1 should reflect changes in microglial activation as microglia undergo rapid 
proliferation in response to insult or injury.  However, IBA1 is not able to distinguish between 
the specific activation states of microglia. Microglia can exist in two phenotypically discrete 
activation states, termed M1 (classical activation) and M2 (alternate activation). Microglia can 
produce either cytotoxic or protective effects depending on the whether they are of M1 or M2 
phenotype [262]. In AD, classically activated microglia are associated with plaques and are 
responsible for the pro-inflammatory environment of the AD brain [263]. Future directions for 
this work should include an investigation into which microglial activation state is predominant 
in the APPswe/PS1ΔE9 mouse brain, and whether EmtinB is able to alter this to a more 
favourable microglial activation phenotype. It would also be important to histologically 
investigate the morphology and neurochemical signature of activated microglia surrounding 
amyloid plaques. 
5.4.4.1 EmtinB decreases GFAP levels in APPswe/PS1ΔE9 mice 
Astrocytes are specialized glial cells which carry out supportive and protective roles within the 
central nervous system [264, 265].  As with microglia, astrocytes become reactive in response 
to illness or injury, and this activation induces changes in protein expression and morphology; 
this response is termed reactive astrogliosis [264, 265]. 
Astrogliosis is a common feature of AD [264], with reactive astrocytes associated with plaques 
in the brain parenchyma of both animal models of AD [266, 267] and human AD patients [266, 
268, 269]. Much like microglia, astrocyte activation can be protective against a range of CNS 
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insults (reviewed in [264]), however reactive astrocytes can release pro- and anti-inflammatory 
cytokines [270] and thus can have beneficial or detrimental effects depending on context 
[264]. There is evidence that astrogliosis plays a detrimental role in AD disease progression 
[271] and contributes to the impairment of synaptic transmission and memory loss in the aging 
process [272]. A recent study by Garwood et al. [273] demonstrated that Aβ induced 
morphological changes, and inflammatory cytokine release, in primary astrocyte cultures. 
Furthermore, Aβ-treated astrocytes promoted neuronal cell death [273]. Modulation of 
astrogliosis has been propositioned as a therapeutic target for AD. GFAP expression is the 
prototypical marker for astrocyte identification. GFAP is highly expressed in activated 
astrocytes but is often not detectable in astrocytes in healthy CNS tissue [264]. As such, GFAP 
is regarded as a sensitive method for detecting activated astrocytes. GFAP has been found to 
be increased in temporal tissue from AD patient brains compared to control [274], and is 
increased in APPswe/PS1ΔE9 mice compared with wild-type control (see Figure 5.12). 
EmtinB has been shown in this study to reduce GFAP levels compared with saline vehicle-
treated APPswe/PS1ΔE9 mice, suggesting that EmtinB is reducing astrogliosis and decreasing 
GFAP levels back toward wild-type levels.  Interestingly, GFAP levels were reduced in both 
30mg/kg and 5mg/kg EmtinB dosed animals equally, while cognitive improvements were 
observed predominantly in 5mg/kg treated animals.  
The ability of EmtinB to specifically modify astroglial activity correlates with reported 
observations that native metallothionein modulates astrocyte function. Metallothionein 
administered exogenously induces a regenerative reactive astrocyte phenotype [82] and, 
furthermore, reactive astrocytes have been shown to produce MT2 and promote regeneration 
in injured neurons [275]. To investigate the capacity of EmtinB to directly interact with 
astrocytes, it would be essential to look at the EmtinB/astrocyte interaction in vitro in primary 
cultured astrocytes.  Preliminary investigation into the effect of EmtinB on primary cultured 
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astrocytes showed that treatment of astrocytes with EmtinB increased MT expression, 
suggesting that EmtinB can directly interact with astrocytes (data not shown). Thus, 
potentially, EmtinB is able to directly modify astrogliosis. 
5.4.5 EmtinB does not alter synaptic markers  
Loss of synapses is a hallmark of AD and is one of the strongest correlates of cognitive 
impairment [276]. Synaptophysin and PSD95 are widely used markers of synapses. 
Synaptophysin levels are decreased in the hippocampus of AD patients [277] and in transgenic 
AD mouse brain [278, 279]. Similarly, PSD95 levels have been found to be decreased in the 
hippocampus of subjects with mild cognitive impairment, in the cortex [280] and grey matter 
[281] of AD patients and in the hippocampus of 5xFAD transgenic mice [282]. In APP695/PS1ΔE9 
mice, both synaptophysin and PSD95 are markedly reduced the hippocampus and cortex at 12 
months of age [283], suggesting that excitatory synapses have been lost. This is reflected in the 
APPswe/ PS1ΔE9 mouse model, with Mitew et al. [284] demonstrating decreased 
synaptophysin levels in the brains of APPswe/PS1ΔE9 at 12 months of age compared to 
wild-type aged-matched controls. 
To determine if synaptic marker changes were observable in the hippocampus of EmtinB 
treated mice, compared with saline control mice, both Synaptophysin and PSD95 levels were 
assessed by western blot.  
PSD95 and synaptophysin levels were not altered in EmtinB treated APPswe/PS1ΔE9 mice 
compared with control, suggesting that cognitive improvements in these mice were not a 
result of altered synaptic density in the hippocampus. However, changes to cognitive 
outcomes can be observed in the absence of synaptic changes.  
Defects in a proximal area of the brain, the entorhinal cortex (ERC), have also been implicated 
in AD [285]. In the AD brain, the hippocampus and the ERC show the largest degree of 
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pathological change [286] and are among the first areas to develop plaques [285, 287]. 
Decosahexanoic acid (DHA) has been shown to improve cognitive outcomes in 3xTG AD mice, 
as measured by object recognition, with no effect on PSD95 or synaptophysin levels [285]. This 
improved cognition was linked to the direct effect of DHA on neuronal function, with DHA 
rescuing AD-related electrophysiological defects in the neurons. As changes in the entorhinal 
cortex pre-empt changes in the hippocampus, it is possible that EmtinB is eliciting changes in 
the ERC in this trial.  Furthermore, while total levels of these synaptic proteins were unaltered 
by EmtinB treatment, this does not necessarily indicate that there has been no change in the 
number of functional synapses. Functional synapses can be assessed using 
immunohistochemistry to determine synapses where both presynaptic and postsynaptic 
markers co-locate. Future studies should evaluate the distribution of synaptic proteins to 
determine if there are differences in the colocation of pre- and post-synaptic markers in 
EmtinB treated mice compared with saline vehicle-treated mice. 
5.4.6 Alternate theory of EmtinB action  
As this work was unable to conclusively prove the presence of EmtinB in the brain, the 
possibility that EmtinB dimer was unable to cross the BBB must be considered. Given that the 
EmtinB had a significant impact on animal behaviour, it is possible the emtins may be exerting 
an effect on processes within the brain by a mechanism external to the CNS.  An explanation of 
this mechanism may come from the work of Pankhurst [288]. Pankhurst observed that 
metallothionein plays a protective role after cryolesion brain injury as evidenced by prolonged 
neuronal death in MTKO mice compared to wild-type mice [288]. However, Pankhurst also 
noted that at least part of this action was related to peripheral effects of MT rather than direct 
CNS effects [288].  T cells are an important part of the immune response and when activated 
can infiltrate the CNS [289]. Interestingly, evidence suggests that T cells may be a contributor 
to the pathology of diseases such as multiple sclerosis and experimental autoimmune 
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encephalopathy (EAE) [290, 291] which might suggest that T cells would also contribute to the 
pathology of brain injury.  In experiments performed by Pankhurst, the number of T cells 
infiltrating the cryolesion injury site was significantly higher 7 days post-injury in MTKO mice 
compared with wild-type mice, suggesting that immune system function is altered in the 
absence of MT [288]. 
Additionally, Pankhurst noted that MT2 was upregulated in the liver of wild-type mice that has 
been subjected to cryolesion as part of the acute phase response, which is the early defense 
system activated by stimuli such as infection or injury [288]. This response was predictably 
absent in MTKO mice and Pankhurst postulates that, as zinc availability affects the function of 
the immune system, it is possible that metallothionein modulates some aspects of immune 
response via zinc homeostasis [288]. 
If indeed MT is able to modulate the immune system response to brain injury to promote a 
more positive outcome in the CNS, then as an MT-mimetic it follows that emtins may also have 
this capacity. 
5.4.7 Conclusion 
EmtinB improved some features of cognitive performance in the APPswe/PS1ΔE9 AD mouse 
compared with SSV APPswe/PS1ΔE9 controls, as measured by the Y-maze. EmtinB was not 
found to alter either soluble or deposited Aβ levels, and, additionally, neither APP nor LRP1 
levels were altered in whole-hemisphere extracts, suggesting that EmtinB does not influence 
either production or clearance in the APPswe/PS1ΔE9 mouse.  No synaptic changes were 
detected on the hippocampus of EmtinB treated mice, with no significant changes found in 
either synaptophysin or PSD95 levels. Interestingly, while EmtinB did not alter microglial 
activation, as measured by IBA1, GFAP levels were significantly reduced, suggesting that 
EmtinB was able to modulate astrogliosis. The data show that EmtinB is able to positively 
modulate astrogliosis and improve cognitive outcomes in the APPswe/PS1ΔE9 model of AD.
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Chapter 6 – Final discussion 
Findings of this work 
This thesis has investigated the potential of emtins to protect cultured neurons against CuAβ 
toxicity, the mechanism of EmtinB action in culture, and attempted to determine if EmtinB has 
beneficial effects in the APPswe/PS1ΔE9 model of AD.    
Aim 1: Efficacy of emtin protection in the CuAβ model of Aβ insult 
This work has shown that both EmtinAc and EmtinB, in tetrameric form, are capable of 
protecting hippocampal neuron cultures from CuAβ-mediated toxicity. In these experiments, 
EmtinB appeared to be more efficacious. Tetrameric EmtinB was shown to be as efficacious as 
parent protein MT2 in the CuAβ model of toxicity. A comparison of EmtinB tetrameric and 
dimeric forms showed that EmtinB dimer was significantly more efficacious in protecting 
cultured hippocampal neurons against CuAβ-mediated toxicity. Taken together, these data 
suggest that EmtinB dimer is the most promising potential therapeutic tested in this work. 
Interestingly, pre-treatment of hippocampal neurons with EmtinB dimer had no protective 
effect, suggesting that EmtinB needs to be present at the time of insult.    
Aim 2: Mechanism of dimeric EmtinB protection in the CuAβ model of 
toxicity 
While a mechanism of action was not unequivocally determined, this work has identified the 
capacity of EmtinB to bind both copper and zinc and to use bound zinc to undergo a metal 
swap with CuAβ1-42. Apo-EmtinB was unable to affect CuAβ aggregation and, as EmtinB is 
added to cultures in Apo form, for metal swap to be the mechanism of EmtinB action in the 
CuAβ model of Aβ toxicity, the EmtinB must be scavenging metals from the experimental 
cultures. The current study was unable to confirm that EmtinB scavenges metals from cultures, 
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with no metals found to be associated with EmtinB after incubation with either fresh tissue 
culture media or tissue culture media conditioned by cortical neurons; thus other mechanisms 
of action were considered. 
The action of emtin peptides in previous studies have been linked to their ability to act through 
the LRP family of receptors [94, 185]. Consistent with this, EmtinB protective action against 
CuAβ toxicity could be effectively blocked when neurons were pre-incubated with RAP, 
indicating that EmtinB was unable to protect cells when LRP receptors were inaccessible to 
ligands. Receptor knockdown using siRNA against LRP1 and LRP2 was unable to block EmtinB 
action indicating that either, LRP1 and LRP2 are not involved in EmtinB action, or that the 
siRNA knockdown was insufficient to mute their activity.  
EmtinB was additionally shown to protect cultured hippocampal neurons against H2O2 toxicity, 
a characteristic which has not been observed with its parent protein, MT2. Whether this was a 
direct result of radical scavenging or via a receptor mediated protective action has not yet 
been investigated.          
Aim 3: EmtinB protective action in the APPswe/PS1ΔE9 model of AD 
EmtinB administration to APPswe/PS1ΔE9 mice from 9-11 months of age improved cognitive 
outcomes in the AD model as assessed by the Y-maze. Analysis of soluble and deposited Aβ 
showed no changes in Aβ levels as a result of EmtinB treatment and, furthermore, no changes 
to APP or LRP1 were observed, suggesting that EmtinB does not modulate Aβ production or 
clearance. 
No changes were observed in post or pre synaptic markers PSD95 and Synaptophysin in the 
hippocampus of EmtinB-treated mice, indicating that EmtinB is not altering synapses in the 
hippocampus to induce cognitive changes. 
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Interestingly, EmtinB altered astrogliosis in APPswe/PS1ΔE9 mice. While microglial activation 
did not appear to be altered, as per IBA1 levels, astrocyte activation was decreased in EmtinB 
treated mice as indicated by a significant reduction in GFAP levels. While astrocyte activation 
was decreased in EmtinB mice, it remains to be elucidated whether this is a direct effect of 
EmtinB on astrocytes or whether EmtinB affects other disease related factors and decreased 
glial activation is a secondary aspect of EmtinB action.        
Future directions 
To advance our understanding of EmtinB, as a potential therapeutic, future studies will be 
required to fully elucidate the mechanism of action of EmtinB. Confirmation of a mechanism of 
action would allow a more directed analysis of EmtinB action in the APPswe/PS1ΔE9 model of 
AD.  
The current animal study offers scope for further investigation. Both sectioned tissue and 
frozen brain are available for further analysis. Analysis of these samples for other LRP family 
receptors or alternate receptors, markers of gliosis and synaptic dysfunction, or distribution of 
certain cell types may shape our understanding of the molecular mechanism of EmtinB. 
Additionally, given the reduction in GFAP observed in EmtinB-treated APPswe/PS1ΔE9 mice, 
determining the capacity of EmtinB to directly modulate astrogliosis should be a key aim of 
future studies.  
Future animal studies looking at the EmtinB action in APPswe/PS1ΔE9 mice should encompass 
both temporal and dosage aspects of optimisation. Additionally, the inclusion of EmtinB 
treated and untreated control B6 mice would allow a more rigorous assessment of the effects 
of EmtinB in the APPswe/PS1ΔE9 cohort.         
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Final conclusion 
This work has demonstrated that emtins are able to protect hippocampal neurons from CuAβ- 
induced toxicity in primary culture. Dimeric EmtinB was shown to be the most efficacious of 
the tested emtins. Comparison of tetrameric EmtinB and MT2 show that tetrameric EmtinB 
has a similar efficacy to MT2 and a further comparison of tetrameric and dimeric EmtinB 
suggest that dimeric EmtinB is the more efficacious peptide. These data suggest that the 
dimeric EmtinB peptide may represent a more effective therapeutic than the parent protein, 
MT2. While the exact mechanism of EmtinB protection is yet to be elucidated, the metal-swap 
mechanism, free radical scavenging and LRP-receptor mediated responses have all been 
implicated, raising the possibility that emtins could act synergistically via two or more 
mechanisms EmtinB has also elicited cognitive improvements and reduced astrogliosis, key 
clinical and pathological components of AD, in the APPswe/PS1ΔE9 mouse model of AD. 
Excitingly, these changes in clinical and pathological outcomes in the APPswe/PS1ΔE9 imply 
that EmtinB may be crossing the BBB and promoting beneficial outcomes in this mouse model 
of AD. Notably, these beneficial outcomes were observed in aged animals where treatment 
was administered post symptom onset. Given the lack of any prevention therapy currently 
available, emtins represent an exciting new modality to treat AD. Taken together, the data 
indicate that EmtinB could represent a novel therapeutic for the treatment of AD.    
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Figure A1. Knockdown of LRP1 and LRP2 using siRNA perturbs MT2-induced growth cone 
chemoattraction 
MT2 is a chemoattractant and induces growth cone turning of DRG neurons towards the MT2 
concentration gradient. siRNA targeted to LRP1 and LRP2 abolished the response of growth 
cones to MT2. Reproduced from [202, 203] with permission. 
 
